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INTRODUCTION
Fever is a common symptom in Indonesian patients and often a sign of an 
ongoing infectious disease. Several studies analyzed the etiology of fever in 
Indonesia over time: the first was conducted by Anderson in 1971-72 in Jakarta 
[1], followed by Olson in Klaten, Central Java in 1978 [2], Suharti in Semarang 
in 1995 [3], Tjitra in Sumba in 1998 [4] and Vollaard in Jakarta in 2002-2003 [5]. 
The latest study was carried out by Gasem in Semarang in 2005 and 2006 [6]. 
Most studies were designed to determine specific etiologies and only in one 
study was a thorough search on different etiologies conducted. Consequently, 
these different studies produced a variety of results and do not provide a 
comprehensive picture on the prevalence of infectious diseases in Indonesia. 
According to these studies, dengue was one of the most common etiologies of 
fever in Indonesia.
Dengue virus is a positive strand RNA virus belonging to the Flaviviridae family 
[7]. Four antigenically different serotypes of dengue virus have been identified: 
DENV-1, DENV-2, DENV-3 and DENV-4. Dengue virus is transmitted by Aedes 
aegypti and Aedes albopictus mosquitoes, and this virus is therefore also grouped 
into the arthropod-borne (arbo) viruses [7]. Infections with dengue virus are in 
the majority of cases asymptomatic, but may manifest with clinical symptoms 
as well, ranging from a mild febrile illness (dengue fever/DF) to severe disease 
(dengue hemorrhagic fever/DHF or dengue shock syndrome/DSS) [8]. Outbreaks 
of dengue fever are now globally documented, but epidemics of DHF/DSS were 
largely unknown until after the end of World War II, when outbreaks were noticed 
in Southeast Asia in 1950s. Currently, it is estimated that 50-100 million dengue 
infections occur each year among the 2.5 billion people that live in tropical and 
subtropical countries, causing 2000 deaths annually [9].
In Indonesia, dengue was first diagnosed in 58 patients in Surabaya and Jakarta 
in 1968. Over time, the incidence rate (IR) increased to 70/100 000 in 2007, and 
cases have been reported in 33 Indonesian provinces [10]. The number of cases 
fluctuates over time (the IR was only 27.6/100 000 in 2011 [11]), and peaks occur 
every four or five years. Overall, the mortality rate has gradually declined from 
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41.4% in 1968 [10] to 0.91% in 2011, although in several provinces it remains 
high (2-8%) [11]. Since these statistics are mostly based on hospitalized cases, 
it can be expected that the true IR would be higher. It is however difficult to 
estimate the accurate IR as dengue is generally undifferentiated from other 
febrile illnesses, particularly during the acute phase. In addition, no simple, rapid, 
cheap and reliable diagnostic tests are available that can be used under field 
conditions to confirm the etiology of fever, including dengue.
Clinically, severe dengue cases may be differentiated from other infectious 
diseases: plasma leakage and a bleeding tendency that develops during 
defervescence are typical clinical manifestations of a dengue virus infection 
that are rarely caused by other pathogens [12]. Despite extensive studies, the 
underlying pathogenesis of severe dengue disease remains unclear. Several 
theories are proposed, including: the virulence of strains or serotypes; the 
sequence of infecting serotypes in individuals with multiple dengue infections; 
heterologous neutralizing antibodies from previous infections that may enhance 
current viral infections (antibody dependent enhancement (ADE)); a cytokine 
storm affecting the permeability of vascular endothelial cells; and genetic factors 
[13]. 
Apart from the pathogenesis, preventive strategies have been extensively 
studied, including a dengue vaccine. The main challenge of vaccine development 
is the existence of four antigenically distinct but related serotypes, whereby 
infection with one serotype will not protect that individual from subsequent 
infections with other serotypes. On the contrary, it is suspected that secondary 
dengue infections are associated with more severe dengue because of the ADE 
phenomenon [13]. So far, the main prevention method remains the limitation of 
mosquito bites on an individual and/or community level, as the results from the 
first phase III vaccine trial revealed only part protection [14].
Although various scientific reports have addressed dengue virus infections 
in Indonesia, many issues still need further clarification. Several studies were 
therefore carried out between 2000 and 2009, including a prospective cohort 
study for DF/DHF in Indonesian adults, as well as an intensive community 
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observation and a hospital study. The results from these studies are presented 
in this thesis.
The epidemiology, virology and pathophysiology/clinical aspects of dengue 
infections in a prospective cohort study lasting 79 months that included 4380 
adults in Bandung, West Java, is described in chapter 2. The lack of an animal 
model means a prospective cohort study is the most suitable approach to 
determine various aspects of natural dengue infections. Traditionally, dengue 
is seen as a disease that mostly occurs in children, and cohort studies therefore 
often do not focus on adults. However, dengue is now frequently reported in 
adults, and in Brazil severe illness is mostly noticed in adults [10,15-17]. The 
study described in chapter 2 therefore focuses on an adult population. As well-
documented previous dengue infections may be determined in such a cohort, 
this study also provides a population of adults with a well-characterized dengue 
immune status which may be precious for vaccine studies. While chapter 2 
provides data on natural dengue infections in an endemic setting, chapter 3 
reports epidemiological, clinical and virological data obtained from ten large 
hospitals within the capital city of Jakarta during a dengue outbreak in 2004. This 
is one of the periodic large outbreaks of dengue that have emerged in Indonesia 
since 1968, with 50 000 cases and 603 deaths reported.
West Java is a hyper-endemic region for dengue where all four seroytpes are 
circulating. According to the ADE theory, repeated infections predispose the 
populations to more severe disease. In chapter 4 we analyzed and elaborated 
the details of the presence of three heterologous sequential dengue infections 
in an adult cohort, including data on neutralizing antibodies before and during 
each dengue episode.
The differential diagnosis of dengue is broad, while the laboratory confirmation 
has its limitations. In addition to neutralizing antibody assays, a hemagglutination 
inhibition (HI) test is also recommended by the WHO [18] to diagnose and/or 
distinguish primary from secondary infections. The latter is important as it is 
associated with dengue pathogenesis of mild or severe illnesses. The HI test is 
broadly recognized as the conventional method and in chapter 5, HI is compared 
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with IgG ELISA antibody assay, using the plaque reduction neutralization antibody 
test (PRNT) as the gold standard to evaluate performance in distinguishing 
primary or secondary infections. Serological dengue assays are prone to cross-
reactivity from other Flaviviruses and usually need paired specimens, limiting 
their applicability for daily practise in the field. Nevertheless, gold standards such 
as virus culture and isolation assays are technically difficult and time consuming. 
On the other hand, molecular techniques such as RT-PCR are promising as results 
are provided within several hours. However, molecular tests are generally limited 
by high costs and high technical requirements and are therefore presently only 
available in large hospitals, universities or research institutes. The limitations of 
the current tests challenged scientists to produce a rapid and accurate diagnostic 
test during acute illness so that early treatment can be provided, and the signal 
can be given to the family and the community to take the necessary precautions 
[19]. Currently, the NS1 antigen test is produced to fulfill this need. In chapter 6, 
the diagnostic and predictive values of NS1 antigen assay and factors associated 
with its performance were evaluated. The importance of developing an accurate 
dengue diagnostic tool is important as the prevention, control and treatment of 
dengue may differ from other febrile illnesses. Chapters 7, 8, 9 and 10 focus on 
four important pathogens that are often considered in the differential diagnosis 
of febrile patients in Indonesia. Chapter 7 reports on chikungunya infections 
among febrile patients in the adult cohort during a six year observation period. 
Chapter 8 reports on Indonesian national influenza surveillance, including in 
Bandung and five other sites in West Java from 2003-2007. Chapter 9 discusses 
a case report of a hantavirus infection that was identified during a hospital-
based hantavirus surveillance study, followed by rodent investigations in the 
index case community as well as in a control population. Chapter 10 describes 
the first discovery of West Nile virus in Indonesia from a hospitalized patient 
with thrombocytopenia, indicating the need for further study to determine the 
importance of this disease as the cause of unknown etiologies of fever and/or 
neurological symptoms.
Finally, as a safe and effective vaccine for dengue is not yet available, prevention 
efforts should increase the awareness and knowledge of the population, as 
discussed in chapter 11. Knowledge about dengue was tested during enrollment 
in the study, while education was undertaken during participation in the study. 
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Finally, one and half years after enrollment, knowledge was tested again. 
This chapter reports pre- and post-test results from the volunteers. Increased 
understanding of transmission patterns can also add to better prevention 
strategies and therefore a cluster study was conducted in West Jakarta from 2002 
to 2003. In the community of 53 index cases, a cluster of 15 family members and 
close neighbors were assessed for previous and acute dengue infections and 
monitored daily for two weeks to anticipate the occurrence of dengue episodes 
(chapter 12). Finally, in chapter 13 the main findings are summarized and future 
options for research are discussed. 
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ABSTRACT
Dengue has emerged as one of the most important infectious diseases in 
the last five decades. Evidence indicates the expansion of dengue endemic 
areas and consequently the exponentially increase of dengue virus infections. 
Furthermore, the clinical manifestations are now well-recognized, including the 
serious complications, which may occur in children as well as in adults. Clinical 
aspects and management of this disease in adults have been reported from 
outbreak investigations and prospective hospital based studies. Here, we report 
the results from a prospective cohort study where 4380 adults participated in 
West Java, Indonesia, from 2000-2004 and 2006-2009. A total of 2167 febrile 
episodes were documented whereby dengue infections were confirmed 
in 268 cases (12.4%). This proportion ranged from 7.6-41.8% each year. The 
incidence rate was 17.3 cases/1,000 person years which is 43 times higher than 
previously reported national or provincial rate. Asymptomatic infections were 
2.6 times more frequent than symptomatic infections. According to WHO 1997 
classifications, there were 210 dengue fever cases, 53 dengue hemorrhagic fever 
(DHF) cases (32 DHF grade I, 20 DHF grade II, one dengue shock syndrome), 
and five unclassified cases. Evidence for sequential dengue infections was seen 
in seven subjects. All four dengue serotypes circulated every year with DENV-3 
infections were associated with a more severe illness. Asymptomatic infections 
were associated with DENV-4 infections. Sequence analysis suggested that the 
envelope of isolates from all serotypes were strictly conserved and clustered in 
genotypes that are commonly found in Indonesia.
INTRODUCTION
Dengue is caused by infection with one of the four dengue viruses: dengue virus 
1 (DENV-1), DENV-2, DENV-3 and DENV-4 [1]. Infection with any of these viruses 
may result in asymptomatic infection, dengue fever (DF), or the more severe 
forms dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DHF 
and DSS were recognized in Southeast Asia soon after multiple serotypes began 
to circulate in the 1950s [2,3]. Since then the burden of dengue has increased 
rapidly with the number of annual cases worldwide rising from 908 in the 1950s 
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to 925,896 in the 2000s [4]. The number of dengue-endemic countries has also 
expanded from nine to over than 110 countries nowadays [4,5]. Cases of DHF and 
DSS have also been increasingly recognized in other regions including South 
Asia, Latin America and the Pacific [6-9]. Finally, in recent years, DF and DHF/
DSS have been observed to become more common in adults [10-12]. Because of 
the spreading of the virus and the impact of the infection, dengue is nowadays 
widely recognized as the most important arboviral infection worldwide.
Many clinical and epidemiological studies on dengue have relied on outbreak 
investigations and hospital based studies [13-23]. These studies provide a wealth 
of data regarding clinical manifestations, laboratory parameters, pathology, and 
management of the disease. However, they also have some limitations. Hospital 
studies, for instance, mostly represent severe cases and do not cover the wide 
spectrum of the clinical picture of dengue infections in adults. Furthermore, pre-
illness sera to determine well-characterized previous dengue and early illness sera 
to measure circulating predictors of disease severity are not collected. Therefore, 
there is a need for prospective population-based studies to complement the 
hospital-based investigations [24]. This form of study is considered the best 
method to determine the epidemiology of dengue infections in a given 
geographical area. To study the epidemiology of dengue in Bandung, West Java, 
Indonesia, we conducted a prospective study in a cohort of adults from August 
2000 to June 2004 and from September 2006 to April 2009. The aims of this 
study were to: 
1. determine the incidence rate of symptomatic and asymptomatic infections; 
2. determine temporal distribution of dengue serotypes ; 
3. characterize the clinical manifestations of dengue disease in adults and; 
4. determine whether there is a correlation between severity of disease, 
infecting virus serotypes, pre-illness immune status and sequence of 
infections. 
Preliminary results of the first two years were published previously [25]. Here, 
we report a complete observation of the study, covering the epidemiology, 
virology, immunology and clinical pictures of dengue infections.
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MATERIALS AND METHODS
Ethical considerations
The study protocol was reviewed and approved by the Institutional Review 
Boards at the Naval Medical Research Unit No. 2 and the National Institute of 
Health Research and Development, Ministry of Health, Indonesia (DoD 30855, 
KS.02.01.2.1.2181 and N2.2006.0001, KS.02.01.2.1.2776) in compliance with all 
U.S. Federal Regulations governing the protection of human subjects. Each 
volunteer read and signed a consent form upon enrolment.
Study design
The study was conducted in two phases: from August 2000 to June 2004 and 
from September 2006 to April 2009. The first phase was carried out in factories 
A and B and the second phase in Factories A and C. A cohort of 2978 adult 
volunteers was prospectively followed during the first phase and 2726 during 
the second phase. Among these volunteers, 1324 participated in both phases. 
Details of the study design and procedures are illustrated in Figure 1 and are also 
described by Porter et al [25]. Briefly, blood was collected during enrolment and 
every three to four months thereafter. Volunteers who experienced fever were 
evaluated at the factory clinics for clinical assessment and blood was collected 
when indicated by study clinicians or nurses. A complete blood count (CBC) 
and dengue diagnostic tests as described below, were performed. Patients were 
advised to be hospitalized if their platelet count was less than 150,000/mm3 or 
at the discretion of the clinic attending physicians. 
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Dengue diagnostic assays 
To diagnose dengue infection, virus isolation and RT-PCR were performed on 
blood specimens collected during the acute phase of illness. Dengue IgM, IgG 
antibody ELISA (Focus technology), and hemagglutination inhibition (HI) assays 
were performed on acute and convalescent specimens. A plaque reduction 
neutralization test (PRNT) was performed on pre-illness, acute and convalescent 
specimens from confirmed dengue patients. PRNT was also used on paired 
serosurvey specimens from suspected asymptomatic dengue infection study 
volunteers. Details of the laboratory procedures have been previously described 
[25]. 
Figure 1. Overall study design
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Asymptomatic dengue infections
To estimate the incidence of asymptomatic dengue infections, we randomly 
selected 675 volunteers, representing 25% of the total volunteer population 
from September 2006 to February 2008. During this period, serum samples were 
collected every three to four months from each volunteer up to a total of six 
serum samples. In order to be able to test thousands of samples for which the HI 
test is too cumbersome, we developed a new method to identify asymptomatic 
dengue infections utilizing dengue IgG ELISA (Focus Technology) assays for 
screening followed by PRNT for confirmation. First, we established an IgG index 
ratio (IR) that could be used to identify potential asymptomatic infection cases 
from serial serosurvey samples. In order to do this, we tested 43 paired serosurvey 
sera, collected before and after confirmed symptomatic dengue episodes, along 
with 38 paired sera from confirmed non-dengue febrile episodes. A post-/pre-
illness IgG index ratio (IR) was calculated in dengue and non-dengue episodes 
and receiver operating characteristic (ROC) analysis was used to determine the 
IgG cut-off ratio to identify dengue infections. As samples identified through 
this screening process were to be further tested by PRNT, a conservative cut-off 
ratio was chosen in order to ensure that no cases were missed. We chose the 
lower IR between the lowest IR in the dengue group and the highest IR in non-
dengue group as the cut-off value for screening. This resulted in an IR of 1.2. The 
diagram for these steps is shown in Figure 2A. Upon determining the cut-off IgG 
IR, six serial serosurvey specimens from 675 volunteers were tested. Specimens 
with IgG IRs higher than 1.2 between two consecutive serosurvey samples were 
further tested by PRNT (Figure 2B). The serosurvey samples from each volunteer 
were tested simultaneously according to the manufacturer’s instructions, using 
the same lot of the kit. 
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Figure 2A. Method to determine the IgG Index Ratio cut-off between post –illness to pre-illness sera
Figure 2B. Method for volunteer randomization, screening and confirmation of asymptomatic dengue 
infections.
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Genotyping/Sequencing analysis
The envelope genes from eight DENV-1, one DENV-2, three DENV-3 and five 
DENV-4 isolates were sequenced. Viral genome sequencing was conducted 
based on the methods and primer sets previously described [26-28]. In brief, viral 
RNA was extracted from virus isolates using Qiamp Viral RNA mini kit (Qiagen, 
Germany). RNA was used as a template for three RT-PCR assays using different 
primers set to amplify three overlapping DNA fragments covering the Envelope-
NS1 genes (approximately 2700 bases). Specific primer sets were utilized for each 
serotype. Amplicons were purified using X and the BigDye cycle sequencing 
kit was used for sequencing reactions (Applied Biosystem, USA) using specific 
sequencing primers. Sequencing analysis was conducted on a 3130 XL Genetic 
Analyzer (Applied Biosystems) and sequence outputs were assembled using 
Sequencher software (Genecodes, USA). Phylogenetic trees were generated 
using the Neighbor Joining method with bootstrapping in MEGA 4 [29]N.I.H.
Definitions
The following definitions were used in this study:
1. Dengue infection: a recent dengue infection was confirmed when DEN 
virus was isolated, or the RNA was detected in an acute sample, and/or IgM 
seroconversion, and/or a four-fold or greater increase in HI antibody titers 
between acute and convalescent specimens was observed.
2. Primary dengue infection: a confirmed dengue infection in which dengue 
IgG antibodies were not detected in the acute sample and an HI titer of 
≤ 80 in the convalescent specimen was observed. In cases indeterminate 
by IgG and HI, cases were also classified as primary infections when PRNT50 
seroconversion to at least one serotype was detected between acute and 
convalescent specimens.
3. Secondary dengue infection: a confirmed dengue infection in which 
dengue IgG antibodies or HI antibodies were detected in acute specimens 
or increased to ≥1280 in convalescent specimens. In cases indeterminate by 
IgG and HI, cases were classified as secondary infections when the presence 
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of neutralization antibodies to any serotype in the acute specimens was 
detected.
4. Clinical category: clinical data were analyzed using WHO 1997 criteria. 
Cases with evidence of plasma leakage but no thrombocytopenia 
<100,000/mm3 were categorized as unclassified. 
5. Asymptomatic dengue infection: An asymptomatic dengue infection was 
confirmed when a four-fold or greater increase of PRNT50 titer in any serotype 
between two serosurvey specimens whose IgG IR ≥ 1.2 was observed. 
6. Naïve population: a subset of study participants whose serosurvey 
specimens did not show antibodies to dengue as verified by IgG index <1. 
7. Pre-illness neutralizing Antibody: pre-illness neutralizing antibodies, 
as measured by PRNT, were present when the titer >10 and considered 
protective when the titer was >100 [30].
Data analysis
Incidence of symptomatic and asymptomatic DEN virus infection was expressed 
as the number of infections occurring among the cohort per 1,000 person years 
of follow-up. Volunteers that dropped out from the study were accounted for in 
the denominator (total person-years) by including only the length of time they 
were available for follow-up. For comparison between two proportions, the chi-
square test was used using STATA 9 software (Texas).
RESULTS
Study population
A total of 4380 volunteers were enrolled in the study, 1324 volunteers participated 
during the entire duration of the study, 1654 only participated in the first phase 
of the study (August 2000- June 2004) and 1402 only participated in the second 
phase of the study (September 2006 to April 2009). The mean (SD) age and age 
range of volunteers at enrolment were 35.6+/-7.7 and 18 to 66 years. A higher 
proportion of the study population was male (ratio 1.87: 1). Characteristics of the 
study population aggregated by factory are shown in Table 1.
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Epidemiology of dengue infections 
1. Seroprevalence and asymptomatic dengue infections
The presence of asymptomatic infections was determined in 675 randomly 
chosen subjects. No evidence of a previous dengue infection was found 
in 21 (3.1%) of these subjects. Serological evidence of a previous dengue 
infection was found in 86.3% of subjects aged 18-27 years, in 96.5% aged 28-
37 years, in 96.9% aged 38-47 years, and in all subjects above ≥48 years old. 
The occurrence of IgG IRs greater than 1.2 between two consecutive 
serosurvey samples was found in 35 of 675 volunteers. After being re-tested 
with PRNT, seven were excluded as no four-fold increase in any serotype 
was observed (of note: all of the excluded cases had low IgG IRs). Three 
of the 28 asymptomatic cases were primary infections, two were due to 
DENV-4 and one was due to DENV-1. We evaluated pre-illness PRNT titers in 
25 secondary infection cases. In four cases, the highest antibody titers, all to 
DENV-3, were lower than the level of the suggested protective neutralizing 
titer (≥100) [30]. In nine cases, protective neutralizing titers to one serotype 
were detected, five to DENV-3, two to DENV-1 and one each to DENV-2 and 
DENV-4. In eight cases, protective neutralizing titers were detected to two 
serotypes (six to DENV-1 and 3, one to DENV-1 and 2, and one to DENV-2 
and 3. Protective neutralizing titers to DENV-1, 2 and 3 were identified in 
Factory A Factory B Factory C Total
Duration Aug 00-
June 04
Aug 06-
April 09
Both
periods
Aug 02-
June 04
Aug 06-
April 09
Volunteers:
Males
Females
451
251
67
35
844
480
438
514
1055
245
2855
1525
Age at enrolment
Mean (range)
38.4
(18-64)
35.8
(20-53)
36.2
(18-49)
31.9
(18-66)
36.2
(19-55)
35.6
(18-66)
Table 1.  The Characteristics of Volunteers
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four cases. In all the secondary cases, pre-illness neutralizing antibodies to 
DENV-4 were detected in protective titer in 1 case, low titers in 11 and not 
detected in 13 (76%) cases. During the same time period, 43 symptomatic 
dengue infections occurred in the cohort resulting in an asymptomatic to 
symptomatic dengue ratio of 2.6:1. 
2. Symptomatic dengue infections
A total number of 2,167 febrile episodes occurred during the course of the 
study, which encompassed a total of 15,454.5 person months of observation. 
DENV infections were confirmed in 268 episodes, giving an overall proportion 
of dengue disease among fever patients of 12.4%. This proportion was less 
than 10% in 2002, 2004, 2006 to 2007, while the highest proportions were 
observed in 2000 (41.2%) and 2009 (26.6%). The overall incidence rate in 
the cohort was 17.3/1,000 person years. The annual incidence rate was the 
lowest in 2006 with 6.3/1,000 person years and the highest in 2009 with 
37.8/1,000 person years (Figure 3A). In general, cases started to increase 
during the rainy season in January, peaked in the first half of the year and 
then slowly decreased in the second half (Figure 3B).
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Figure 3A. The proportion of dengue infections among febrile episodes by years with the number of 
cases at the bottom (blue bars), the incidence rate of dengue infections in the population 
(red), the national incidence rate (yellow) and provincial incidence rate (green)
Figure 3B.  The monthly distribution of dengue cases, break down by serotypes. No surveillance from 
July 2004 until August 2006.
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Diagnosis and virological findings
Of 268 dengue cases, 92 were confirmed by virus isolation, RT-PCR and serology, 
104 by RT-PCR and serology, and 72 only by serological assays. According to HI, 
IgG ELISA and PRNT antibodies, primary infections were ascertained in 21 (7.8%) 
and secondary infections in 247 (92.5%) cases. All serotypes were identified 
in Bandung every year, except DENV-2 which was absent for 18 months from 
December 2001 until June 2003. DENV-1 and DENV-2 were not detected for 
nine months from September 2006 to June 2007 and DENV-2 was absent from 
August 2007 to November 2008. DENV-3 and DENV-4, conversely, were more 
evenly distributed throughout the year. From a total of 196 cases where the 
serotype was identified, DENV-4 was the most frequent (28.6%), followed by 
DENV-3 (26.5%), DENV-2 (22.4%) and DENV-1 (22.4%). The only month that all 
serotypes were detected to be circulating simultaneously was in March 2009 
when concurred with the highest amount of dengue during the study period 
(Figure 3B).
In confirmed cases, IgM antibodies were positive only in 7.9% (7/89) of subjects 
who came to the clinics on day two, increased to 20.2% (18/89) on day three, 
36.7% (18/49) on day four and 51.3% (20/39) on day five or more. In 16.4% 
(42/256) of the cases, IgM antibodies were never detected not even on the 
convalescent specimens. All of these cases were secondary infections.
Sequencing of envelope genes and genotype analysis
The similarity of envelope gene DENV-1 sequences within isolates from this study 
and compared to other Indonesian isolates were between 98-99% and 94-98% 
to 98%, respectively. The similarity of amino acid sequence within this study and 
other Indonesian isolates was 98-99%, and grouped to genotype IV following 
classification by Goncalvez 2002. The similarity with Indonesian isolates 2007 
(gb/EU448401) was only 97%, resulting in different genotypes. The similarity 
of envelope gene DENV-2 sequences with Indonesian isolates from 1976 to 
2010 was between 97-98% and the similarity of amino acid sequences was 
99%. Genotype analysis grouped this isolate into the Cosmopolitan genotype. 
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Three DENV-3 sequences in the study have similarity of around 96.8-98% with 
most Indonesian isolates. The similarity in amino acid sequence was 99% and 
grouped to genotype I. However the sequence similarity with two Indonesian 
isolates 1998 (AY912454, AY912455) was only 94.5% and the similarity in amino 
acid sequence was 98%, resulting in a different genotype. Genotype analysis of 
five DENV-4 isolates placed them in genotype II, together with other Indonesia 
isolates from 1973 to 2010.
Clinical categories, signs and symptoms 
The majority of cases were DF (78.4%), followed by DHF grade I (11.9%), DHF 
grade II (7.5%), unclassified (1.9%) and DSS (0.4%). Since patients were advised 
to come early when they experienced fever, the mean days from fever onset 
was 3.2 (±1.2) day, ranging from day two to day eight. Symptoms and signs that 
were frequently reported included myalgia (91.3%), headache (90.9%), arthralgia 
(63.8%), nausea (59.6%), and a positive tourniquet test (30.9%). Leukopenia 
(<4000/mm3) and thrombocytopenia (<150,000/mm3) were detected in 12.4% 
and 17.8% patients, respectively who came to the clinics on day two of illness, 
21.3% and 32.6% on day three, 46.2% and 40% on day four and 66.7% and 69.4% 
on day five or later. 
Sequential dengue infections
Seven patients experienced multiple confirmed dengue febrile illnesses during 
their participation in this study. Four of them have been reported elsewhere 
[31]. For the remaining three, two volunteers had evidence of three sequential 
dengue infections and one had evidence of two dengue infections. The first 
was a 36 year old male with a probable DENV-3 infection prior to enrolment, 
followed by unknown serotype, and DENV-1 infections during his participation 
in the study. The second case was a 33 year old male with evidence of a previous 
DENV-4 infection, followed by DENV-1 infection and a DENV-3 infection five 
and half years later. In both cases, the clinical diagnosis was DF. The third case 
was a 28 year old male with a DENV-2 infection followed by a DENV-3 infection 
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two years later. Clinically, both episodes manifested as DF with hemorrhagic 
manifestations that required hospitalization. 
Associations of clinical severity and risk factors
1. Clinical severity and serotypes
As described above, 53 (19.8%) cases were classified as the severe form of 
illness, DHF I, II and DSS. The proportion of DHF/DSS cases among all cases 
per serotype revealed that DENV-3 tended to be associated with more 
severe disease (18/52=34.6%), compared to DENV-1 (8/44=18.2%, p=0.07), 
DENV-2 (8/44=18.2%,p=0.07), and DENV-4 (12/56=21.4%, p=0.12), and to 
total other serotypes (28/144=19.4%, p=0.03). The significance remained 
when primary cases were excluded in the analysis. Clinical diagnoses and 
the infecting serotypes are described in Table 2.
2. Clinical outcomes and pre-existing immune status 
The severe forms of illness (DHF and DSS) were more frequent in secondary 
(96.2%) than primary infections (3.8%). The proportion of DHF and DSS 
among primary cases tended to be lower than secondary cases (9.5% vs 
20.6%, p value=0.21). Details of clinical categories and types of infections are 
summarized in Table 2. 
3. Clinical outcomes and sequence of infections 
There were 27 cases in which the serotype of the second infecting virus 
was determined by RT-PCR and the serotype of the previous dengue virus 
infection could be determined through pre-illness neutralizing antibody 
titers. Previous infections with DENV-1 were identified in five cases, DENV-2 
in 19 cases, DENV-3 in one case and DENV-4 in two cases. Following a DENV-
2 infection, infections with DENV-3 or DENV-4 resulted in more severe illness 
than DENV-1 (40%, 28.6%, and 14.3%, respectively). Two DHF cases occurred 
when DENV-1 was the first infecting virus (2/5), each followed by DENV-2 
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or DENV-3, and five cases when DENV-2 was the first infecting virus (4/19), 
two followed by DENV-3, two DENV-4 and one DENV-1. The details were 
described in Table 3.
Table 2.  The distribution of clinical severity, type of infections and infecting serotypes
Serotypes
DENV-1 
(44)
DENV-2 
(44)
DENV-3 
(52)
DENV-4 
(56)
Unknown 
(72)
Primary infections 
(21) 9 7 4 1 0
DF(+HM) 6(1) 6(1) 1(2) 1 0
DHF I 0 0 0 0 0
DHF II 1 0 1 0 0
Unclassified 1 0 0 0 0
Secondary infections 
(247)
35 37 48 55 72
DF(+HM) 25(1) 27(2) 26(5) 39(3) 59(5)
DHF I 5 5 10 8 4
DHF II 2 3 7 4 2
DSS 0 0 0 0 1
Unclassified 2 0 0 1 1
Table 3.  Clinical severity in cases with evidence of previous and current infecting serotypes
First infecting 
serotype (27)
DENV-1 (5) DENV-2 (19) DENV-3 (1) DENV-4 (2)
Followed by DENV-2
1 DF, 1 DHF
DENV-1
6 DF, 1 DHF
DENV-1 DENV-1
1 DF
Followed by DENV-3
1 DHF
DENV-3
3 DF, 2 DHF
DENV-2 DENV-2
1 DF
Followed by DENV-4
1 DF, 1 DF+HM
DENV-4
4 DF, 2 DHF,
 1 unclassified
DENV-4
1 DF
DENV-3
The epidemiology, virology and clinical findings of Dengue Infections in a large cohort 
of Indonesian adults
37
2
Figure 4.  Phylogenetic tree of circulating DENV-1 (top left), DENV-2 (top right), DENV-3 (bottom left) 
and DENV-4 (bottom right)
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DISCUSSION
Our long-term prospective cohort study provides several important findings 
on the epidemiology of dengue infections in adults living in endemic areas. 
First, dengue is a major etiology of febrile illness (12.4%) in adults in Bandung, 
West Java, Indonesia. Second, the average incidence rate from 2000-2004 and 
2006-2009 was 43 times higher than the national or provincial rate [32]. Lastly, 
asymptomatic infections, which provide more accurate information on dengue 
transmission, were 2.6 times more frequent than symptomatic infections. 
The proportion of dengue infections among acute febrile patients in the 
outpatient setting has rarely been reported in Indonesia. A previous study from 
1976, which was a bacteriological and serological survey among febrile patients 
admitted to hospitals in Jakarta, revealed a similar proportion of dengue 
infections. [33]. Studies from Malaysia, Myanmar and Thailand report proportions 
ranging between 5.7 to7%, suggesting dengue is more prevalent in Indonesia 
[34-36]. The incidence rate in our prospective cohort was calculated from the 
number of dengue cases that were identified in outpatient clinics, representing 
both mild and severe cases of dengue illness, whereas previously reported 
provincial and national incidence rates from Indonesia were based on the 
hospitalized cases, representing more severe cases. This explains why we found 
a 43 times higher incidence rate, compared to provincial and national figures.
Furthermore, our study revealed a better estimate of asymptomatic infections, as 
we monitored a representative proportion of volunteers for one and half years 
and evaluated the occurrence of dengue infections every quarter of the year. This 
more detailed information, compared to data derived from yearly serosurvey, 
gives a better insight into prevalence of dengue and as such transmission rates. 
The high rate of dengue transmission in this region was in line with our finding 
that almost all our volunteers have been infected by DENV (96.9%).
Our study revealed that dengue infections in adults were mostly mild (78.4%). 
This finding is different to previous reports that demonstrate severe cases are 
more predominant [16,17]. One of the reasons was that our febrile patients came 
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mostly from outpatients clinics whereas other studies were patients who were 
indicated to be hospitalized (usually platelet <100,000/mm3). Also, we may under-
estimate DHF because we relied heavily on serial hematocrit results which may 
be influenced by fluid therapy, and we used a strict 20% hematocrit increase to 
confirm hemoconcentration. Although we also performed ultrasonography, at a 
maximum of once a day it is probably not sufficient as plasma leakage is transient. 
It was not possible to classify five cases as the clinical manifestations did not fit 
with any of the categories. All showed plasma leakage but no thrombocytopenia 
was noticed. Besides the classical signs and symptoms such as fever, headache 
and myalgia, we found that leukopenia and thrombocytopenia only supported 
the dengue diagnosis if tested on day five or more of illness. Furthermore, the 
development of leukopenia and thrombocytopenia concurred with a sensitivity 
of DENV IgM antibodies above 50%. 
The DHF cases were predominantly secondary infections (96.2%). Furthermore, 
the proportion of DHF cases as part of a secondary infection was higher than in 
primary infections, but the difference was not significant. In addition, we also 
identified tertiary infections in six patients, all presenting with DF. This indicates 
that a previous infection with two dengue serotypes does not protect an 
individual against future clinical dengue infections.
Our study demonstrated that no serotype was significantly more predominant 
and almost all serotypes circulated all years in Bandung, except for DENV-1 and 
DENV-2 for a certain period. The fact that certain serotypes were not detected 
for some time is probably not caused by the disappearance of these serotypes 
but may be due to the limited seize of the study population in comparison with 
the total population of Bandung (approximately 1.5 million). This is supported by 
the observation that only during the most intensive transmission period (March 
2009) all serotypes could be identified. Similar findings were reported during 
other outbreaks in Indonesia [16,17]. 
Although any DENV serotypes can cause DHF/DSS, our data revealed that DENV-
3 serotype is significantly more frequently associated with severe disease than 
all other serotypes combined. The higher pathogenicity of DENV-3 was first 
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discovered in the Philippines and later globally [14,37-41]. Also, in Indonesia, 
DENV-3 has persistently been reported to cause severe DHF/DSS and to be the 
predominant serotype in large outbreaks [14,16,17,42,43]. However, the DENV-3 
genotypes I and II that are identified in Indonesia [44] are different than genotype 
III that commonly causes severe disease in other parts of the world. [41]. DENV-3 
genotype II, which was identified in Taiwanese citizens returning to Taiwan from 
Indonesia in 1998, has never been observed since [45]. 
Apart from serotypes, the sequence of infecting serotypes has also been 
associated with disease severity [46,47]. We found that most cases with well-
characterized sequence serotypes had DENV-2 as the previous infecting 
serotype. Furthermore DHF more frequently occurred when DENV-3 (40%) was 
the infecting serotype for the second infection compared to DENV-4 or DENV-1, 
although this difference was not significant. Our data do not support previous 
findings from Thailand and Cuba that a DENV-2 infection after DENV-1 is a risk 
factor to develop a severe dengue [46,47]. The conclusion cannot be drawn 
regarding other sequences, as the number of cases was too limited. 
We suspect that the majority of asymptomatic infections were caused by DENV-
4 infections, for the following reasons. First, two of the three primary infections 
were caused by DENV-4. Second, all pre-illness sera from 24 of 25 secondary 
asymptomatic infections revealed no or very low neutralizing antibodies to 
DENV-4. Third DENV-4, along with DENV-3, were the predominant serotypes 
(39.4% and 42.4%, respectively) that were identified as symptomatic cases during 
the same period in the same cohort. Asymptomatic or mild form resulting from 
DENV-4 infections have been reported before from Indonesia [48] and thought 
to be the reason for the scarcity of DENV-4 hospitalized cases [30]. 
Finally, our study shows that there are dynamic changes in the various genotypes 
of the circulating DENV in Indonesia. DENV-1 genotype IV that was detected in 
our study in 2003, 2005 and 2008 was first detected in 1968 and since then has 
been endemic in various area in Indonesia [44,45,49]. Regarding other genotypes, 
DENV-1 genotype I was first reported in Indonesia in 2007 (gb:EU448401) and 
2010 in Surabaya [49] and became the predominant genotype in Semarang in 
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2012, while DENV-1 genotype II has begun to be detected again after the last 
identification in 1964 in Thailand [50]. Monitoring the dynamic change is very 
important as it may relate to clinical severity and thus may have public health 
impact. For example, despite the high homology of DENV-1 isolates from our 
study with the strain from the 1998 Sumatera outbreak isolates, no significant 
rise in cases was reported during our study. A plausible explanation based on the 
genotype analysis was that the 1998 outbreak was caused by the introduction 
of DENV-1 genotype IV, but from a different clade. Contrasted with the dynamic 
changes of DENV-1 genotypes, the circulating DENV-2 isolates in Indonesia from 
1976 to 2012 that are available in the gene bank, and the isolates from our study, 
were only grouped into the Cosmopolitan genotype [45,50]. This Cosmopolitan 
genotype has previously been associated with severe disease [51]. Similarly, 
the genotype I of DENV-3 in our study is the common genotype in Indonesia 
and has remained endemic since 1973. However, during the1998 outbreak, the 
circulating DENV-3 was from genotype II. Our study was one of only a few studies 
in Indonesia that have successfully detected and isolated DENV-4 [50]. All DENV-
4 isolates were similar to the Indonesia isolates from 1973-2010, belonging to 
genotype II, which were different to the dominant circulating strain in Thailand 
(genotype I) [26]: and cause mostly mild illness [52].
In conclusion, as our study was a population-based cohort study carried out 
in large factories in West Java Indonesia with intense monitoring during nearly 
six years, we were able to identify dengue infections also at an early stage and 
presenting with minimal symptoms and thus provided accurate epidemiological 
data regarding the spectrum of dengue disease in adults. In addition, it also 
provided virological data regarding the serotypes and genotypes circulating 
and dominating in the region, enable us to make association between clinical 
severity and pre-illness immune status, infecting serotypes), and/or the sequence 
of infecting serotypes. Furthermore, this study has identified a population 
of adults with well-characterized histories of dengue infections, providing 
preconditions for vaccine-related studies. As dengue continues to be the threat 
to public health, effective preventive measures have not yet been found and 
pathogenesis of severe illness is still unclear, further surveillance and studies still 
need to be conducted.
Chapter 2
42
ACKNOWLEDGEMENTS
We would like to acknowledge all the volunteers, our research team at Padjadjaran 
University, Hasan Sadikin Hospital, NAMRU#2 and NIHRD, Ministry of Health, RI, 
for a long mutual collaboration. In particular, we thank Dr Ardini Raksanagara 
and Hodijah Satriyo. who were the key leads at the factory, Ratna Irsiana Tan 
who dedicated most of her time for dengue research, Kendra Chittenden from 
USAID, Jakarta and INA-RESPOND for their assistance and support during the 
preparation of this manuscript. 
The epidemiology, virology and clinical findings of Dengue Infections in a large cohort 
of Indonesian adults
43
2
References
1. Henchal EA, Putnak JR (1990) The dengue viruses. Clin Microbiol Rev 3: 376-396.
2. Kuno G (2009) Emergence of the severe syndrome and mortality associated 
with dengue and dengue-like illness: historical records (1890 to 1950) and their 
compatibility with current hypotheses on the shift of disease manifestation. Clin 
Microbiol Rev 22: 186-201, Table of Contents.
3. Halstead SB, Yamarat C (1965) Recent Epidemics of Hemorrhagic Fever in Thailand. 
Observations Related to Pathogenesis of a “New” Dengue Disease. Am J Public Health 
Nations Health 55: 1386-1395.
4. WHO (2009) Dengue guidelines for diagnosis, treatment, prevention and control.
5. Guha-Sapir D, Schimmer B (2005) Dengue fever: new paradigms for a changing 
epidemiology. Emerg Themes Epidemiol 2: 1.
6. Gupta N, Srivastava S, Jain A, Chaturvedi UC (2012) Dengue in India. Indian J Med Res 
136: 373-390.
7. Humayoun MA, Waseem T, Jawa AA, Hashmi MS, Akram J (2010) Multiple dengue 
serotypes and high frequency of dengue hemorrhagic fever at two tertiary care 
hospitals in Lahore during the 2008 dengue virus outbreak in Punjab, Pakistan. Int J 
Infect Dis 14 Suppl 3: e54-59.
8. Tapia-Conyer R, Mendez-Galvan JF, Gallardo-Rincon H (2009) The growing burden of 
dengue in Latin America. J Clin Virol 46 Suppl 2: S3-6.
9. Bouldouyre MA, Baumann F, Berlioz-Arthaud A, Chungue E, Lacassin F (2006) Factors 
of severity at admission during an epidemic of dengue 1 in New Caledonia (South 
Pacific) in 2003. Scand J Infect Dis 38: 675-681.
10. George R, Lam SK (1997) Dengue virus infection--the Malaysian experience. Ann 
Acad Med Singapore 26: 815-819.
11. Teixeira MG, Costa MC, Coelho G, Barreto ML (2008) Recent shift in age pattern of 
dengue hemorrhagic fever, Brazil. Emerg Infect Dis 14: 1663.
12. Ibrahim NM, Cheong I (1995) Adult dengue haemorrhagic fever at Kuala Lumpur 
Hospital: retrospective study of 102 cases. Br J Clin Pract 49: 189-191.
13. Srichaikul T, Punyagupta S, Nitiyanant P, Alkarawong K (1975) Disseminated 
intravascular coagulation in adult Dengue haemorrhagic fever: Report of three cases. 
Southeast Asian J Trop Med Public Health 6: 106-114.
14. Sumarmo, Wulur H, Jahja E, Gubler DJ, Suharyono W, et al. (1983) Clinical observations 
on virologically confirmed fatal dengue infections in Jakarta, Indonesia. Bull World 
Health Organ 61: 693-701.
15. Gubler DJ, Suharyono W, Lubis I, Eram S, Sulianti Saroso J (1979) Epidemic dengue 
Chapter 2
44
hemorrhagic fever in rural Indonesia. I. Virological and epidemiological studies. Am J 
Trop Med Hyg 28: 701-710.
16. Corwin AL, Larasati RP, Bangs MJ, Wuryadi S, Arjoso S, et al. (2001) Epidemic dengue 
transmission in southern Sumatra, Indonesia. Trans R Soc Trop Med Hyg 95: 257-265.
17. Suwandono A, Kosasih H, Nurhayati, Kusriastuti R, Harun S, et al. (2006) Four dengue 
virus serotypes found circulating during an outbreak of dengue fever and dengue 
haemorrhagic fever in Jakarta, Indonesia, during 2004. Trans R Soc Trop Med Hyg 
100: 855-862.
18. Pang J, Salim A, Lee VJ, Hibberd ML, Chia KS, et al. (2012) Diabetes with hypertension 
as risk factors for adult dengue hemorrhagic fever in a predominantly dengue 
serotype 2 epidemic: a case control study. PLoS Negl Trop Dis 6: e1641.
19. Leo YS, Thein TL, Fisher DA, Low JG, Oh HM, et al. (2011) Confirmed adult dengue 
deaths in Singapore: 5-year multi-center retrospective study. BMC Infect Dis 11: 123.
20. Thomas L, Brouste Y, Najioullah F, Hochedez P, Hatchuel Y, et al. (2010) Prospective and 
descriptive study of adult dengue cases in an emergency department, in Martinique. 
Med Mal Infect 40: 480-489.
21. Hanafusa S, Chanyasanha C, Sujirarat D, Khuankhunsathid I, Yaguchi A, et al. (2008) 
Clinical features and differences between child and adult dengue infections in 
Rayong Province, southeast Thailand. Southeast Asian J Trop Med Public Health 39: 
252-259.
22. Chan KP, Lau GK, Doraisingham S, Chan YC (1995) Adult dengue deaths in Singapore. 
Clin Diagn Virol 4: 213-222.
23. Tripathi BK, Gupta B, Sinha RS, Prasad S, Sharma DK (1998) Experience in adult 
population in dengue outbreak in Delhi. J Assoc Physicians India 46: 273-276.
24. Endy TP, Yoon IK, Mammen MP (2010) Prospective cohort studies of dengue viral 
transmission and severity of disease. Curr Top Microbiol Immunol 338: 1-13.
25. Porter KR, Beckett CG, Kosasih H, Tan RI, Alisjahbana B, et al. (2005) Epidemiology of 
dengue and dengue hemorrhagic fever in a cohort of adults living in Bandung, West 
Java, Indonesia. Am J Trop Med Hyg 72: 60-66.
26. Klungthong C, Zhang C, Mammen MP, Jr., Ubol S, Holmes EC (2004) The molecular 
epidemiology of dengue virus serotype 4 in Bangkok, Thailand. Virology 329: 168-
179.
27. Zhang C, Mammen MP, Jr., Chinnawirotpisan P, Klungthong C, Rodpradit P, et al. 
(2005) Clade replacements in dengue virus serotypes 1 and 3 are associated with 
changing serotype prevalence. J Virol 79: 15123-15130.
28. Zhang C, Mammen MP, Jr., Chinnawirotpisan P, Klungthong C, Rodpradit P, et al. 
The epidemiology, virology and clinical findings of Dengue Infections in a large cohort 
of Indonesian adults
45
2
(2006) Structure and age of genetic diversity of dengue virus type 2 in Thailand. J 
Gen Virol 87: 873-883.
29. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics 
Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
30. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, et al. (2004) Relationship 
of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity 
of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189: 
990-1000.
31. Kosasih HY, H. Sudjana, P. Alisjahbana, B. Wuryadi, S. Akterono. Tan, RI. Yuwono, D. 
Beckett, C. Porter, KR. Blair, PJ. (2006) Report of Four Volunteers with Primary, Secondary 
and Tertiary Dengue Infections during a Prospective Cohort Study. Dengue Bulletin 
30: 87-92.
32. Pusdatin (2010) Buletin jendela epidemiologi. Departemen Kesehatan Republik 
Indonesia. pp. 1-4.
33. Anderson KE, Joseph SW, Nasution R, Sunoto, Butler T, et al. (1976) Febrile illnesses 
resulting in hospital admission: a bacteriological and serological study in Jakarta, 
Indonesia. Am J Trop Med Hyg 25: 116-121.
34. Leelarasamee A, Chupaprawan C, Chenchittikul M, Udompanthurat S (2004) 
Etiologies of acute undifferentiated febrile illness in Thailand. J Med Assoc Thai 87: 
464-472.
35. Ellis RD, Fukuda MM, McDaniel P, Welch K, Nisalak A, et al. (2006) Causes of fever in 
adults on the Thai-Myanmar border. Am J Trop Med Hyg 74: 108-113.
36. Brown GW, Shirai A, Jegathesan M, Burke DS, Twartz JC, et al. (1984) Febrile illness in 
Malaysia--an analysis of 1,629 hospitalized patients. Am J Trop Med Hyg 33: 311-315.
37. Hammon WM, Rudnick A, Sather GE (1960) Viruses associated with epidemic 
hemorrhagic fevers of the Philippines and Thailand. Science 131: 1102-1103.
38. Chungue E, Glaziou P, Spiegel A, Martin PM, Roux JF (1992) Estimation of dengue 
infection attack rate in a cohort of children during a dengue 3 outbreak in Tahiti 
(1989-1990). Southeast Asian J Trop Med Public Health 23: 157-158.
39. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM (2003) Emergence and 
global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 9: 800-809.
40. Kanakaratne N, Wahala WM, Messer WB, Tissera HA, Shahani A, et al. (2009) Severe 
dengue epidemics in Sri Lanka, 2003-2006. Emerg Infect Dis 15: 192-199.
41. de Araujo JM, Bello G, Romero H, Nogueira RM (2012) Origin and evolution of dengue 
virus type 3 in Brazil. PLoS Negl Trop Dis 6: e1784.
42. Richards AL, Bagus R, Baso SM, Follows GA, Tan R, et al. (1997) The first reported 
Chapter 2
46
outbreak of dengue hemorrhagic fever in Irian Jaya, Indonesia. Am J Trop Med Hyg 
57: 49-55.
43. Sukri NC, Laras K, Wandra T, Didi S, Larasati RP, et al. (2003) Transmission of epidemic 
dengue hemorrhagic fever in easternmost Indonesia. Am J Trop Med Hyg 68: 529-
535.
44. Raekiansyah M, Pramesyanti A, Bela B, Kosasih H, Ma’roef CN, et al. (2005) Genetic 
variations and relationship among dengue virus type 3 strains isolated from patients 
with mild or severe form of dengue disease in Indonesia and Thailand. Southeast 
Asian J Trop Med Public Health 36: 1187-1197.
45. Ong SH, Yip JT, Chen YL, Liu W, Harun S, et al. (2008) Periodic re-emergence of 
endemic strains with strong epidemic potential-a proposed explanation for the 2004 
Indonesian dengue epidemic. Infect Genet Evol 8: 191-204.
46. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, et al. 
(1984) Risk factors in dengue shock syndrome: a prospective epidemiologic study in 
Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653-669.
47. Guzman MG, Deubel V, Pelegrino JL, Rosario D, Marrero M, et al. (1995) Partial 
nucleotide and amino acid sequences of the envelope and the envelope/
nonstructural protein-1 gene junction of four dengue-2 virus strains isolated during 
the 1981 Cuban epidemic. Am J Trop Med Hyg 52: 241-246.
48. Beckett CG, Kosasih H, Faisal I, Nurhayati, Tan R, et al. (2005) Early detection of dengue 
infections using cluster sampling around index cases. Am J Trop Med Hyg 72: 777-
782.
49. Sjatha F, Takizawa Y, Yamanaka A, Konishi E (2012) Phylogenetic analysis of dengue 
virus types 1 and 3 isolated in Jakarta, Indonesia in 1988. Infect Genet Evol 12: 1938-
1943.
50. Fahri S, Yohan B, Trimarsanto H, Sayono S, Hadisaputro S, et al. (2013) Molecular 
surveillance of dengue in Semarang, Indonesia revealed the circulation of an old 
genotype of dengue virus serotype-1. PLoS Negl Trop Dis 7: e2354.
51. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, et al. (1999) Dengue virus 
structural differences that correlate with pathogenesis. J Virol 73: 4738-4747.
52. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, et al. (2003) 
Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand 
from 1973 to 1999. Am J Trop Med Hyg 68: 191-202.
The epidemiology, virology and clinical findings of Dengue Infections in a large cohort 
of Indonesian adults
47
2

Chapter 3
Four dengue virus serotypes found 
circulating during an outbreak of dengue 
fever and dengue haemorrhagic fever in 
Jakarta, Indonesia, during 2004
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006 
Agus Suwandono 1, Herman Kosasih 2, Nurhayati 2, Rita Kusriastuti 3, 
Syahrial Harun 1, Chairin Ma’roef 2, Suharyono Wuryadi2, Bambang Herianto1, 
Djoko Yuwono1, Kevin R. Porter4, Charmagne G. Beckett 4, Patrick J. Blair 2
1 National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia
2 Viral Diseases Program, U.S. Naval Medical Research Unit #2, Jakarta, Indonesia
3 Arbovirus Sub-directorate, Communicable Disease Center, Ministry of Health, Jakarta, Indonesia
4 Naval Medical Research Center, Silver Spring, MD, USA
Chapter 3
50
SUMMARY
Periodic outbreaks of dengue have emerged in Indonesia since 1968, with the 
severity of resulting disease increasing in subsequent years. In early 2004, a 
purported dengue outbreak erupted across the archipelago, with over 50,000 
cases and 603 deaths reported. To confirm the disease aetiology and to provide 
an epidemiological framework of this epidemic, an investigation was conducted 
in ten hospitals within the capital city of Jakarta. Clinical and laboratory findings 
were determined from a cohort of 272 hospitalized patients. Exposure to 
dengue virus was determined in 180 (66.2%) patients. When clinically assessed, 
100 (55.6%) of the 180 patients were classified as having dengue fever (DF), 
31 (17.2%) as DF with haemorrhagic manifestations and 49 (27.2%) as dengue 
haemorrhagic fever (DHF). Evidence from haemagglutination inhibition assays 
suggested that 33/40 (82.5%) of those with DHF from which laboratory evidence 
was available suffered from a secondary dengue infection. All four dengue viruses 
were identified upon viral isolation, with DEN-3 being the most predominant 
serotype recovered, followed by DEN-4, DEN-2 and DEN-1. In summary, the 2004 
outbreak of dengue in Jakarta, Indonesia, was characterized by the circulation 
of multiple virus serotypes and resulted in a relatively high percentage of a 
representative population of hospitalized patients developing DHF.
INTRODUCTION
The dengue virus occurs as four antigenically distinct serotypes (DEN-1, -2, 
-3 and -4) that have emerged or re-emerged throughout the world since the 
17th century [1]. Infection from one or more dengue virus serotypes continues 
to increase in tropical and subtropical regions, spurred on by an explosion of 
population growth, urbanization and the spread of the primary vector of disease, 
the mosquito Aedes aegypti. Now recognized in over 100 countries, these viruses 
are the causative agents of dengue disease and are a threat to almost 40% (2.5 
billion) of the world’s population. Whilst the majority of dengue infections are 
asymptomatic, or cause a moderate-to-mild self-limiting febrile illness (dengue 
fever (DF), sequential heterotypic infections can lead to dengue haemorrhagic 
fever (DHF) and the more severe dengue shock syndrome (DSS). Infection with 
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one dengue serotype confers lifelong immunity to that virus. However, previous 
exposure to a single virus does not provide immunity against subsequent 
infection with other serotypes. Those living in dengue-endemic areas are often 
infected with two or more serotypes and are therefore prone to developing 
severe disease. 
Modern times have seen a resurgence of dengue disease in Asia. The first 
recognized outbreaks of DHF occurred in this region during the 1950s [2,3]. 
Initial cases in Indonesia were reported in the cities of Surabaya and Jakarta in 
1968 [4]. Since then, outbreaks have emerged both in rural and major urban 
areas of the island chain [5-8]. Over time, an increase in the number of reported 
dengue cases has become apparent, with a three-fold rise evident in the city 
of Palembang, South Sumatra, between January and April 1998 relative to 
historical records [9]. Notwithstanding, the island of Java, where almost 60% 
of 226 million Indonesians live, has been the region most severely afflicted by 
periodic outbreaks. 
In early 2004, an outbreak of dengue began to spread throughout Indonesia. 
On 16 February 2004, the Indonesian Ministry of Health declared a national DF/
DHF epidemic. Jakarta, the capital city with approximately 16 million inhabitants, 
was the most affected area [10]. To confirm the aetiology of the outbreak and to 
define the clinical presentation of the afflicted subjects, the Directorate General, 
Centers of Disease Control and National Institute of Health Research and 
Development of the Indonesian Ministry of Health, and the U.S. Naval Medical 
Research Unit #2 (NAMRU-2) collaborated to conduct an investigation in ten 
hospitals (Figure 1) across Jakarta from 26 February to 28 March 2004. Results 
from this study confirmed the circulation of all four dengue virus serotypes and a 
high incidence of DHF among a cohort of 272 hospitalized patients, the majority 
of these with laboratory evidence (33/40; 82.5%) occurring in patients who had 
previously been exposed to dengue.
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MATERIALS AND METHODS
STUDY SITES
Located on the western end of the island of Java, Jakarta is the capital of 
Indonesia with a population of 16 million people living in a temperate zone with 
little seasonal variation in weather and mean temperatures ranging between 
230C and 330C. The average annual rainfall in Jakarta is 2000mm3 with a peak 
falling between December and February. The province of Jakarta has five 
municipalities: West, North, Central, South and East Jakarta. Each has a similar 
population (1.3-2.8 million) with a density of approximately 5000 inhabitants/
Figure 1.  Map showing the position of jakarta, indonesia (inlaid), over a city map with the location of 
ten hospitals surveyed during the outbreak investigation.
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km2. During the conduct of this investigation, two major hospitals from each 
municipality were chosen for participation: Sumber Waras and Cengkareng from 
West Jakarta; Infectious Disease Sulianti Saroso and Kodja from North Jakarta; 
Tarakan and St Carolus from Central Jakarta; Fatmawati and Tebet from South 
Jakarta; and Budi Asih and Persahabatan from East Jakarta.
SURVEILLANCE OF FEBRILE PATIENTS
Patients who presented with an undifferentiated febrile illness denoted by 
abrupt fever of 2-7 days in the absence of an identifiable focus of infection 
were surveyed. Enrollees were recruited from within all regions of the city and 
encompassed a wide socioeconomic range. This study was characterized as part 
of an outbreak investigation and, therefore, whilst studied by the Institutional 
Review Board (IRB) of both primary institutes, was declared exempt from formal 
IRB submission and review. 
During an initial visit, clinical histories were gathered and physical examinations 
were performed on each patient. Signs and symptoms were recorded using a 
standardized clinical form developed by the Ministry of Health team conducting 
the investigation. Blood was drawn upon presentation and again just prior to 
discharge. Results from patients with incomplete records were not included in 
this review.
HAEMAGGLUTINATION INHIBITION (HI) ASSAYS
Serum samples were tested at serial two-fold dilutions, between 1:10 and 1:5120 
by HI assay as escribed previously [11]. A greater than four-fold rise in HI titre in 
paired samples, or a titre ≥1280 in an acute sample, was considered evidence 
of dengue infection [12]. Sera with titres <1280 were tested by ELISA to detect 
anti-dengue IgM antibodies. Primary dengue infections were determined when 
acute titres were <10 and convalescent titres were ≤80. Subsequently, secondary 
infection was determined in samples with acute or convalescent titres ≥1280.
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ANTI-DENGUE ELISA
A commercially available antibody capture ELISA previously optimised within our 
laboratory was used to test for IgM dengue antibodies [13]. Briefly, 1:100 dilutions 
of patient sera were tested in 96-microwell plates (Dynatech Laboratories Inc., 
Chantilly, VA, USA) containing passively adsorbed antigen. Samples were allowed 
to incubate for 1 hour at 370C, then plates were washed and 100 µl of horseradish 
peroxidase-conjugated goat anti-human IgM was added per well for 1 hour at 
370C. Microwells were washed and paramethylbenzidine/ hydrogen peroxide 
(TMB/H2O2) was added. Chromogenic change was indicative of the presence 
of anti-dengue IgM antibodies in the experimental samples. After 30 minutes, 
absorbance was measured at 450nm by microplate reader (Dynex Laboratories, 
Inc.). A positive serum sample was determined as one that exceeded the cutoff 
calculated for each test as specified by the manufacturer.
VIRUS ISOLATION AND CHARACTERISATION
Isolation of dengue virus was attempted on acute sera from serologically positive 
individuals. Approximately 0.2 ml of 1:10 diluted patient serum was inoculated 
onto a confluent monolayer of C6/36 cells and allowed to adsorb at 350C. 
Cultures were monitored daily for the appearance of cytopathic effects. Upon 
development of cytopathic effects, or at day 14, cells were scraped from the 
plates and stained for the presence of virus by standard immunofluorescence 
using the flavivirus genus reactive monoclonal antibody 4G2. Samples reactive 
against 4G2 were subtyped with serotype-specific monoclonal antibodies. 
QIAamp Viral RNA Mini Kits (Qiagen Inc., Valencia, CA, USA) were used to prepare 
RNA from 140 µl of sera and nested dengue virus reverse transcriptase (RT)-PCR 
was conducted to confirm the serotype of the isolates [14].
CLINICAL DIAGNOSIS
The incubation period following dengue exposure varies from 3 to 14 days 
[15]. DF typically presents with an abrupt fever of 2-7 days and two of the 
following signs/symptoms, including: retro-orbital pain, headache, myalgias/ 
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arthralgias and haemorrhagic manifestations (i.e. a positive tourniquet test, 
epistaxis) [16]. An intense erythematous rash occasionally occurs as temperature 
spikes. Petechiae appear in some patients as fever declines at the conclusion 
of illness. DF is a rarely fatal, self-limiting disease that afflicts mostly younger 
children. In contrast, DHF occurs mostly in older children or adults, but has been 
seen in younger children in countries where multiple viruses are endemic. It is 
characterized by a sudden onset of fever and an acute phase that lasts 2-6 days. 
The acute phase of DHF is not remarkable and is often difficult to distinguish 
from DF or other tropical illnesses. Signs of DHF include those of DF in addition 
to cerebral oedema, pleural effusion, haemoconcentration, haematuria and 
thrombocytopenia (platelet count ≤100,000/mm3) [17]. These symptoms are 
often followed by a sudden deterioration of haemodynamics in the patient. A 
tourniquet test may suggest increased capillary fragility to attending physicians. 
During defervescence, plasma leakage can rapidly lead to a haemorrhagic 
syndrome if not treated promptly. Extensive plasma leakage throughout the 
body may result in shock and subsequent death. 
The 272 patients in the study were considered probable infections when they 
demonstrated HI titres of ≥1280 on the acute sample or a four-fold titre increase 
while hospitalized as defined by established WHO criteria [12]. Additionally, 
primary infections were determined only when acute titres were <10 and 
convalescent titres were ≤80, and secondary infection was determined when 
acute or convalescent titres were ≥1280. Serotypes were confirmed by RTPCR 
or viral isolation. Laboratory-confirmed cases were also classified according to 
the WHO guidelines. Those cases with haemorrhagic tendencies that could not 
meet other criteria for DHF (platelet count <100 000/mm3 or plasma leakage) 
were classified as DF with haemorrhagic tendencies grade I. Patients yielding 
evidence of a positive tourniquet test, thrombocytopenia and evidence of plasma 
leakage were grouped as DHF grade I, whilst those cases with spontaneous 
bleeding manifestations (petechiae, ecchymoses, purpura, mucosal bleeding, 
haematemesis or melena) were classified as DHF grade II.
Chapter 3
56
THEORY
Since emerging in Southeast Asia in the 1950s, subsequent epidemics of dengue 
have infected more people and occurred with greater frequency. With one of the 
highest populations in the region, the disease burden has been particularly harsh 
in Indonesia where the first well characterized outbreak occurred in 1973 with 
10,189 cases, followed 15 years later by an epidemic that resulted in 47,573 cases. 
The most severe epidemic to strike the country appeared in 1998 when over 
72,133 individuals were infected and 1414 deaths were reported (R. Kusriastuti, 
unpublished data). The intensity of dengue transmission has been of utmost 
public health concern on the island of Java since the early 1980s [4]. In 1982, 71% 
of all Indonesian cases occurred in Java, rising to 84% in 1983 and 91% in 1984 
[8]. Whilst the influence of increased prevalence on severe disease can only be 
determined by the conduct of focused cohort-based studies, it is probable that 
the spread of dengue viruses across the archipelago and the increase in total 
population also contribute to increased DHF rates across Indonesia.
RESULTS
Between January and February 2004, the Indonesian Ministry of Health reported 
cases of DF in 30 of 32 providences within the archipelago. In the capital city of 
Jakarta, a total of 20,503 cases were recorded, with an epidemic peak between 
March and April (Figure 2). To characterize the outbreak better, hospitalized 
patients were followed in ten hospitals located throughout the municipality. 
Patient observations coincided with the epidemic curve seen in Jakarta (Figure 
2). Acute and secondary sera were collected from a total of 272 febrile patients 
surveyed both within paediatric (age 1-14 years) and internal medicine (age >14 
years) Wards in the five municipalities of Jakarta: West, 103; Central, 24; North, 47; 
East, 56; and South, 42 (Table 1). The male to female ratio in the cohort was 1.08 
and the age ranged from 1 to 72 years, with a mean of 23.4 years. The majority of 
cases were over 15 years of age, with 37.9% between 15 and 25 years and 37.5% 
>25 years old. Just fewer than 5% (13 cases; 4.8%) were 3 years of age or younger 
and 19.9% were between the ages of 4 and 14 years. 
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Figure 2.  Number of reported dengue cases in jakarta (white bars) or cases surveyed (black bars) 
over an epidemic week. Each bar represents a week. Data span the time September 2003 
to june 2004.
Table 1.  Age and sex of patients per hospital site
Hospital No. of patients
0-3 years 4-14 years 15-25 years >25 years
Male Female Male Female Male Female Male Female
West Jakarta 103
RSSW 87 2 5 9 13 6 22 18 12
Cengkareng 16 0 0 0 0 6 4 2 4
North Jakarta 47
RSPI 23 2 0 3 4 5 5 3 1
Kodja 24 1 0 7 3 2 6 4 1
Central Jakarta 24
St. Carolus 13 0 0 1 1 3 3 4 1
Tarakan 11 0 0 0 1 0 5 4 1
East Jakarta 56
Persahabatan 36 0 0 1 0 10 6 9 10
Budi Asih 20 2 1 2 3 2 1 9 0
South Jakarta 42
Fatmawati 37 0 0 1 5 11 5 8 7
Tebet 5 0 0 0 0 0 1 4 0
Total (%) 272 13 (4.8%) 54 (19.9%) 103 (37.9%) 102 (37.5%)
RSSW : Sumber Waras; RSPI: Infectious Diseases Sulianti Saroso
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Dengue infections were confirmed in 180 (66.2%) of the 272 patients. Of these, 
137 (76.1%) were termed probable infection upon a four-fold rise in HI titres 
of DEN antibodies, 35 (19.4%) by HI titres ≥1280 and 8 (4.4%) by positive anti-
dengue IgM (data not shown). When clinically assessed, 100 (55.6%) patients 
were classified as having DF, 31 (17.2%) as DF with haemorrhagic manifestations 
(DF + HM) and 49 (27.2%) with DHF. The remaining 92 febrile cases showed no 
evidence of dengue infection, although those tested who were negative by 
IgM ELISA (60 cases) when tested prior to day five were deemed inconclusive. 
Signs, symptoms and common laboratory findings in the reported dengue cases 
included fever (99.4%), headache (92.2%), thrombocytopenia (78.9%) and nausea 
(67.2%) (Table 2). Symptoms found more frequently in the group of dengue 
cases included spontaneous bleeding, haemoconcentration, thrombocytopenia 
(<100,000/mm3) and leukopenia. Several findings, such as headache, myalgia 
and positive tourniquet tests, were more common in adults, whereas vomiting, 
thrombocytopenia and spontaneous bleeding were more common in patients 
1-14 years of age.
Table 2.  Clinical categorization and age among patients
symptoms 1-14 years 15-25 years >25 years
Confirmed 
dengue
Non-dengue
Fever 43/43 (100%) 72/72 (100%) 64/65 (98.5%) 179/180 (99.4%) 32/32 (100%)
Headache 38/43 (88.4%) 66/72 (91.7%) 62/65 (95.4%) 166/180 (92.2%) 23/32 (71.9%)
Retro-orbital pain 9/43 (20.9%) 21/72 (29.2%) 20/65 (30.8%) 50/180 (27.8%) 6/32 (18.8%)
Myalgia 11/43 (25.6%) 32/72 (44.4%) 34/65 (52.3%) 77/180 (42.8%) 12/32 (37.5%)
Sore throat 8/43 (18.6%) 9/72 (12.5%) 4/65 (6.2%) 21/180 (11.7%) 4/32 (12.5%)
Nausea 27/43 (62.8%) 53/72 (73.6%) 41/65 (63.1%) 121/180 (67.2%) 20/32 (62.5%)
Vomiting 22/43 (51.2%) 38/72 (52.8%) 23/65 (35.4%) 83/180 (46.1%) 15/32 (46.9%)
Abdominal pain 13/42 (31%) 29/72 (40.3%) 22/65 (33.8%) 64/179 (35.8%) 8/32 (25%)
Positive tourniquet test 6/16 (37.5%) 13/25 (52%) 16/26 (61.5%) 35/67 (52.2%) 9/19 (47.4%)
Spontaneous haemorrhage a 17/43(39.5%) 19/72 (26.4%) 12/65 (18.5%) 48/180 (26.7%) 1/32 (3.1%)
Haemoconcentration a 12/43 (27.9%) 28/72 (38.9%) 18/65 (27.7%) 58/180 (32.2%) 1/30 (3.3%)
Leukopenia a 19/41 (46.3%) 40/64 (62.5%) 27/65 (41.5%) 86/170 (50.6%) 4/25 (16%)
Thrompocytopenia a 36/43 (83.7%) 61/72 (84.7%) 45/65 (69.2%) 142/180 (78.9%) 17/32 (53.1%)
a significantly different(p-value <0.05) between dengue and non-dengue cases.
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Disease severity was evaluated in 147 of the 180 laboratory-confirmed dengue 
cases (Table 3). Primary and secondary infections were categorised based 
on HI titres. Thirty-three patients were excluded from this analysis as results 
were unclear. Primary infection was identified in 28 (19%) of the cases, whilst 
secondary infections occurred in 119 (81%) of the 147 confirmed individuals. 
Sixteen (57.1%) primary infections were characterized as DF, five (17.9%) as DF + 
HM, whilst seven (25%) were in DHF grades I or II. Of the 119 secondary infections 
analysed, 64 (53.8%) were categorised as DF, 22 (18.5%) as DF + HM, 25 (21%) as 
DHF grade I and 8 (6.7%) as DHF grade II. The majority of the primary infections 
were seen among children 1-14 years old and in (32.1%) younger adults 15-25 
years old (46.4%). 
Secondary infections occurred predominantly in those aged 15-25 years and 
>25 years (39.5% and 35.3%, respectively). Overall, a high incidence of DHF 
(33/40; 82.5%) occurred in patients determined as having a secondary infection. 
The distribution of DF/DHF cases in those aged 1-14 years was 22 DF, 6 DF + 
Table 3.  Diseases severity and primary versus secondary infection
Infection type and age
Disease severity
DF DF+HM DHF I DHF II
Primary
1-14 years 4 2 3 0
15-25 years 8 2 3 0
>25 years 4 1 0 1
Total (%) 16 (57.1) 5 (17.9) 6 (21.4) 1 (3.6)
Combined DHF 7(25)
Secondary
1-14 years 18 4 7 1
15-25 years 24 8 10 5
>25 years 22 10 8 2
Total (%) 64 (53.8) 22 (18.5) 25 (21) 8 (6.7)
Combined DHF 33 (27.7)
Overall total (%) a 80 (54.4) 27 (18.4) 31 (21.1) 9 (6.1)
Overall DHF 40 (27.2)
DF: dengue fever; DF+HM with haemorrhagic manifestations; DHF: dengue haemorrhagic fever.
a refers to those in both the primary and secondary category
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HM, 10 DHF grade I and 1 DHF grade II. In those patients older than 14 years, 
the distribution was 58 DF, 21 DF + HM, 21 DHF grade I and 8 DHF grade II. No 
mortalities occurred among the patients observed. 
The infecting dengue serotype was confirmed either by RT-PCR or isolation in 28 
acute sera (Table 4). The predominant serotype found in the 2004 outbreak was 
DEN-3 (18; 64.3%), followed by DEN-4 (4; 14.3%), DEN-2 (4; 14.3%) and DEN-1 (2; 
7.1%); there was a single co-infection with DEN-3 and DEN-4. Ten isolates were 
recovered from 72 serologically confirmed dengue sera, giving an isolation rate 
of 13.9% overall. DEN-3 was both predominant and widespread, having been 
found in all five municipalities. Molecular characterization and sequencing of 
the DEN-3 isolates revealed similarities to previous viruses isolated in Indonesia 
during a 1998 outbreak (unpublished data). 
Disease severity was correlated with the infecting virus in 28 patients from 
whom the virus was identified (Table 4). Two cases infected with DEN-1 were 
either DF + HM or DHF grade I, whilst three cases of DEN-2 were DF and one was 
DHF grade I. Of 18 persons infected with DEN-3, 7 had DF, 4 had DF + HM, 5 had 
DHF grade I and 2 had DHF grade II. Four cases were infected with DEN-4, which 
included one DF + HM and three DHF grade I.
Table 4.  Infecting virus versus disease severity
Disease severity
Infecting virus
Total
DEN-1 DEN-2 DEN-3 DEN-4
DF (%) a 0 3 (30) 7 (70) 0 10
DF+HM (%) 1 (17) 0 4 (67) 1 (17) 6
DHF grade I (%) b 1 (10) 1 (10) 5 (50) 3 (30) 10
DHF grade II (%) 0 0 2 (100) 0 2
Total (%) c 2 (7.1) 4 (14.3) 18 (64.3) 4 (14.3)
DF: dengue fever; DF+HM: DF with haemorrhagic manifestations; DHF; dengue haemorrhagic fever.
a Percentage based upon specific disease category.
b A single DHF grade I patient was co-infected with both DEN-3 and DEN-4.
c Percentage based upon specific dengue serotype.
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DISCUSSION
Beginning in the early months of 2004, Indonesia was stricken by a significant 
outbreak of dengue. Similar to 1998, this epidemic affected all districts 
and subdistricts in Jakarta, transitioning urban and rural areas and across 
socioeconomic boundaries. By its end, tens of thousands of cases of the disease 
had been recorded in the capital city of Jakarta alone, resulting in 603 deaths 
[10]. Of note, whilst the magnitude and severity of cases have increased in 
Indonesia with each subsequent outbreak, over the last decade the case fatality 
rate has declined as a consequence of the ability of local clinicians to recognise 
and manage DHF patients.
To confirm disease aetiology and to provide a framework for the 2004 epidemic, 
an opportunistic hospital-based study was conducted. At the height of the 
epidemic in Jakarta, evidence for dengue exposure was examined in a cohort of 
272 hospitalised patients recruited from ten geographically disparate healthcare 
centres. Case definition was based upon criteria that included abrupt fever 
and common signs of dengue infection. An age-based assessment of infection 
demonstrated that cases were distributed to a greater extent among those 15 
years of age or older, whilst it was more limited in younger individuals. This is in 
contrast to earlier studies in Southeast Asia that showed that dengue infections 
primarily afflicted paediatric populations, for example a study from Thailand 
exhibiting a modal age of hospitalised patients of 4-6 years [18]. Indeed, the 
population often at greatest risk for DHF has been children, although a marked 
increase in the number of DHF cases in subjects over 15 years old was observed 
more recently in the Philippines and Malaysia [19]. Follow-up among the 
patients did not demonstrate a bias towards adults when hospitalisation was 
considered. Indeed, care has been extended to patients of all ages as, during 
times of national emergency, the government of Indonesia has provided for the 
costs incurred by patients.
Clinical symptoms such as fever, headache, nausea, myalgia and vomiting were 
commonly exhibited by patients seen during the investigation. However, the 
percentage of patients reporting these symptoms was not significantly different 
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from those recorded in the non-dengue group. Further, a positive tourniquet 
test did not discern between those patients with proven dengue and those with 
a non dengue infection (52.2% and 47.4%, respectively). Signs more frequently 
correlated with dengue infection within our cohort were spontaneous 
bleeding, haemoconcentration, leukopenia and thrombocytopenia. These 
observations are in contrast to a study conducted in Bangladesh that suggested 
an association between dengue infection and myalgia or vomiting but not 
thrombocytopenia [20]. Several symptoms, such as headache, retroorbital pain, 
myalgia and abdominal pain, were less frequently observed in the younger 
patients than in older age groups. However, thrombocytopenia, spontaneous 
bleeding and vomiting were more predominantly reported in children.These 
findings parallel a study conducted in Mumbai in paediatric patients where 
bleeding manifestations were observed in 54% and thrombocytopenia in 92% 
of the cohort [21]. 
Although dengue infections are often asymptomatic, the incidence of DHF 
increases in parallel with an elevation in heterotypic dengue infections [3,22,23]. 
As shown in earlier work in Asia [23], our study demonstrated a clear link 
between morbidity and secondary infection. When clinically assessed, 54.4% 
of the patients infected with dengue were classified as DF, whilst 45.6% were 
segregated into either DF + HM or DHF. Evidence from HI suggested that 33/40 
(82.5%) of those who developed DHF suffered a secondary infection. Also, the 
percentage of DHF cases seen in our study during the epidemic was notably 
higher than that seen in non-outbreak settings on Java. For instance, in a dengue 
pathogenesis study recruited around an index dengue case, only 1 of 17 dengue 
infections progressed to DHF, whilst in a disease incidence study among an adult 
cohort only 5 DHF cases were observed among 90 individuals with documented 
dengue infection [24]. 
The pathogenesis of DHF is not well characterised. Among a multitude of 
contributing factors is the infecting virus serotype. The emergence of a new 
dengue serotype in a dengue-endemic area often results in an epidemic, as was 
the case in Myanmar in 2001 [25]. Some data have pointed to an association 
between dengue serotype, genotypes and disease pathogenesis. For instance, 
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clinically monotypic infection with the American genotype DEN-2 virus results 
in an asymptomatic disease. The genetic sequence of the American DEN-2 
virus differs from the Asian genotype viruses by approximately 10%. A single 
change in domain III of E (amino acid 390) is suspected as being associated with 
decreased virulence of the American virus [26]º. However, little is known about 
the evolution of virulence among dengue viruses and the pressure of many 
factors, including passive serotype immunity, likely contribute to disease severity 
[27]. 
In this investigation, all four dengue viruses were isolated from patients, although 
DEN-3 was the predominant serotype. Furthermore, DEN-3 viruses were more 
prominently associated with DF + HM and DHF. As the DEN-3 viruses in Southeast 
Asia evolve, it is conceivable that their virulence could be altered. For example, a 
DEN-3 outbreak in Central Java in 1978 was associated with mild disease and low 
viraemia [28]. However, recent epidemics attributed to the DEN-3 virus in Asia 
demonstrate a higher incidence of symptomatic disease [29,30]. Whole genome 
phylogenic analysis of the DEN-3 virus isolated in our current study (unpublished 
data) reveals its strong similarity to the DEN-3 strain that emerged and wrecked 
havoc in 1998. These isolates appear to result in an increase in symptomatic 
disease, although a correlation between specific base pair changes and viraemia 
remains circumstantial. 
In conclusion, this investigation confirmed the aetiology and provided the 
epidemiological framework for an outbreak of DF and DHF that emerged in 
Indonesia in the early months of 2004. Whilst such epidemics have become 
increasingly more common throughout Southeast Asia in recent times, this 
one was particularly alarming given the relatively high number of individuals 
infected and the percentage of adults who developed DHF. Progress in 
controlling morbidity and mortality from dengue will be gained only when 
an understanding of the molecular fingerprint of the infecting virus is realised 
and the confounding role of previous heterotypic infections understood. In the 
absence of these, public health initiatives involving education and vector control 
remain at the forefront of dengue control.
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ABSTRACT
A prospective study of dengue fever (DF) and dengue haemorrhagic fever (DHF) 
in adults was conducted at two factories in Bandung, Indonesia, between August 
2000 and July 2004. A total of 2978 employees were followed for the development 
of fever and clinical signs of DF/DHF. Among 1431 patients reporting a febrile 
illness, dengue infections were detected in 177 individuals. Four enrollees with 
evidence of previous dengue exposure experienced two consecutive episodes 
of dengue infection. Analysis of pre illness sera revealed that one patient 
had neutralizing antibodies (nAbs) to DENV-1, two had nAbs to DENV-2, and 
another had nAbs to DENV-2, 3 and 4. The individual with pre-illness neutralizing 
antibodies to DENV-1 experienced a DENV-3 secondary infection, followed by 
a third infection with an unknown serotype. One of the two individuals with 
pre-illness neutralizing antibodies to DENV-2 experienced a DENV-3 and then 
a DENV-1 infection. The other DENV-2 immune patient experienced sequential 
infections with DENV-4 and DENV-3 viruses. Finally, the individual with pre-illness 
neutralizing antibodies against three dengue viruses had a subsequent infection 
with DENV-4, followed one year later by DENV-3. In this instance, the patient 
acquired grade II DHF (WHO criteria) from the subsequent DENV-4 infection. 
These data provide confirmatory evidence that humans can experience three 
sequential heterologous dengue infections. Importantly, the occurrence of 
a second and third infection in individuals with pre-illness antibodies against 
multiple dengue serotypes indicates that neutralizing antibodies are cross-
reactive in vitro but not cross-protective in vivo.
INTRODUCTION
Dengue fever (DF) and dengue haemorrhagic fever (DHF) are endemic diseases 
that occur with regularity across Indonesia. The first recognized outbreak of DHF 
occurred during the 1960s. Since then, outbreaks have occurred both in rural and 
major urban areas across the archipelago. In recent years, an increase in dengue 
cases among individuals ≥15 years old had been reported [1,2] but the clinical 
manifestations of dengue disease progression are poorly understood in adults. 
To further evaluate the epidemiology of DF and DHF in an adult population, a 
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prospective dengue cohort study was initiated in adult workers at two textile 
factories in Bandung, West Java, Indonesia [3]. During the course of this study, 
enrollees were actively followed up for the development of the disease over a 
four-year study period.
METHODS
After obtaining informed consent, 2978 workers were enrolled and medical 
history questionnaires and demographic data forms completed. The enrollees 
underwent physical examination and their blood samples were taken. Baseline 
neutralizing antibody titers to assess their previous dengue exposure in 
addition to routine laboratory blood counts and chemistries were measured. 
When a volunteer experienced a febrile illness, a medical evaluation was 
conducted and blood samples were taken for complete blood counts (CBC), 
DENV isolation, reverse-transcriptase polymerase chain reaction (RT-PCR) and 
serology (anti-DENV IgM, haemagglutinationinhibition/HI, and neutralizing 
antibodies). Volunteers with thrombocoytopenia (platelet count ≤100 000/
mm3) or those appraised as severely ill, were hospitalized. During their hospital 
stay, haematocrit and platelet counts were evaluated daily, while chest and 
abdominal sonograms were performed to detect plasma leakage. Convalescent 
sera were collected from hospitalized and nonhospitalized patients on day 10 
through day 14. Serosurveys were conducted every three months to obtain 
peripheral blood mononuclear cells (PBMCs) and plasma for the evaluation of 
dengue immune status. Fifty per cent plaque reduction neutralizing antibody 
titers were determined by probit analysis. Titers below a dilution of 1:20 on a 
PRNT were considered negative.
An enrollee was considered to have a DENV infection if he or she had a 
compatible clinical illness and laboratory evidence of DENV, which included 
either identification of the infecting virus by RT-PCR or virus isolation, the 
presence of IgM antibodies, or a four-fold increase in HI antibody titer. World 
Health Organization (WHO) criteria were used to categorize disease status [4].
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RESULTS AND DISCUSSION
From August 2000 until July 2004, 1431 febrile illnesses were evaluated, which 
resulted in the confirmation of 177 acute dengue infections. Among these, four 
dengue-immune enrollees experienced two separate (consecutive) episodes of 
dengue infection.
The first instance of multiple dengue infection occurred in a 42-year-old male 
who presented to the hospital with fever, headache, myalgia, coryza, nausea and 
vomiting (Table 1). Analysis of pre-illness serum obtained 2 months prior to his 
second dengue infection revealed the presence of neutralizing antibodies to 
DENV-1 (PRNT50 titer: 187). The neutralizing antibody profile of the subsequent 
convalescent serum indicated that the infecting serotype was DENV-3. Five 
months later, the study volunteer demonstrated anti-DENV IgM antibodies and 
a four-fold increase in HI antibody titers suggesting a third dengue infection 
(Table 2). However, in this instance, the infecting serotype was not determined. 
While both episodes required hospitalization, the first episode was slightly more 
severe with the onset of thrombocytopenia. Clinically, both episodes were 
diagnosed as DF.
The second example of consecutive dengue infection was observed in a 29-year 
old female. In this instance, analysis of neutralizing antibody activity two months 
prior to the second infection revealed a PRNT50 titer of 359 against DENV-2. The 
infecting serotype was later confirmed as DENV-3 by RT-PCR. Eighteen months 
after the second infection, a third infection with DENV-1 was suspected based 
on the development of nAbs. Only the second DENV-3 infection resulted in the 
hospitalization of the subject. Non-specific symptoms such as fever, headache, 
retro-orbital pain, myalgia, sore throat, nausea and vomiting were recorded.
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The study volunteer also exhibited a positive tourniquet test, haemorrhagic 
tendencies and thrombocytopenia. Since there was neither plasma leakage nor 
circulatory failure the final diagnosis was DF (Table 1). The third infection with 
DENV-1 was milder and consequently no hospitalization was required as the 
patient was managed in the outpatient clinic.
A third subject, a 38-year-old male had neutralizing antibodies to DENV-2 
(PRNT50 titer:215) a month prior to his second infection with DENV-4 (confirmed 
by RT-PCR, virus isolation and neutralizing antibody profile). Eighteen months 
later, this individual experienced a DENV-3 infection as identified by RT-PCR. Both 
the DENV-4 and DENV-3 infections resulted in a clinically mild disease (DF). The 
symptoms reported were fever, headache, retro-orbital pain, myalgia, nausea 
and sore throat (Tables 1 and 2).
The fourth study volunteer, a 30-year-old female, demonstrated neutralizing 
antibodies against DENV-2 and DENV-3 and a lower titer against DENV-4 two 
months prior to a DENV-4 infection that was documented by the recovery of 
the virus from the acute serum sample. Eleven months later, the volunteer 
was infected by a DENV-3 virus as evidenced by RT-PCR and virus isolation. 
The neutralizing antibody profile in these two episodes was in accordance 
with the infecting serotypes. Clinical symptoms, haemorrhagic tendencies and 
thrombocytopenia were reported in both episodes; however, plasma leakage, as 
noted by pleural effusion, ascites and hypoproteinemia, was only detected after 
the second infection. In this patient, the second infection was diagnosed as DHF 
grade II and the third as DF (Tables 1 and 2).
Previously, sequential dengue infections were recorded in 1971 in an individual 
from India [5]. In this instance, the first infection was in 1960 by a DENV-4 
virus, followed by DENV-1 one year later and DENV-2 in 1969. All the infections 
manifested as a mild disease without haemorrhagic tendencies. However, dengue 
immune status prior to each episode of illness was unknown. Furthermore, the 
interval between the second and third infections was very long (8 years), which 
may suggest that cross-immunity to DENV-2 had disappeared.
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Heterologous secondary dengue infection is often associated with more severe 
manifestations (DHF including dengue shock syndrome-DSS). In our case series, 
one of the four secondary infections resulted in DHF grade II. The enrollee 
was infected by DENV-4 despite having low-level neutralizing antibody to 
this serotype (PRNT50 titer 29). In the other three cases, pre-illness neutralizing 
antibodies to the infecting serotypes were not detected. All tertiary dengue 
infections resulted in milder diseases. Pre-illness neutralizing antibodies to the 
infecting serotypes ranged from 36 to 99.
Pre-illness, acute and convalescent PRNT data from episodes with confirmed 
infecting serotypes (by RT-PCR or virus isolation) also showed that the highest 
neutralizing titers among convalescent sera may indicate that the previous 
infecting serotypes and the current infecting serotypes resulted in the second 
highest neutralizing titers in the convalescent sera. Our work supports the 
original antigenic sin theory first proposed by Halstead [6].
These data support early studies that imply that the presence of neutralizing 
antibodies against additional dengue viruses clearly does not protect against 
subsequent dengue infections.
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ABSTRACT
Secondary dengue infection by a heterotypic serotypes is associated with severe 
manifestations of disease, i.e. dengue hemorrhagic fever (DHF) and dengue 
shock syndrome (DSS). The World Health Organization (WHO) has recommended 
criteria based on the hemagglutination inhibition (HI) assay to distinguish 
between primary and secondary dengue infections. Since the HI assay has 
practical limitations and disadvantages, we compared the WHO HI criteria with 
criteria based on an IgG enzyme-linked immunosorbent assay (ELISA) assay, 
using a plaque reduction neutralization test (PRNT) as the gold standard. Both 
HI and IgG ELISA criteria performed strongly (16/16) in determining primary 
infection. However, to determine secondary infections, the IgG ELISA criteria 
performed better (72/73) compared to the WHO HI criteria (23/73).
INTRODUCTION
Dengue virus is a global concern, with increasing incidence especially in endemic 
areas like Southeast Asia, South America and the Pacific. Recent analysis based 
on the geographical distribution of the disease, estimates 250-500 million 
infections annually, which is three times higher than the estimation of the World 
Health Organization [1-3]. 
Dengue virus (DENV) belongs to the family Flaviviridae, genus Flavivirus, 
which consists of four antigenically distinct serotypes (DENV-1, -2, -3 and -4). 
Infection with any one of the four serotypes can be asymptomatic or result in 
a wide range of clinical manifestations from dengue fever (DF), mild to severe 
dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS) which is 
often fatal. Besides viral virulence and host background (immune, genetic and 
nutritional), severe dengue is often associated with secondary infection [4]. 
Secondary infections, which are common in endemic areas such as Indonesia 
[5-8], comprised approximately 80-90% of the DHF/DSS cases. It is therefore 
important to distinguish between primary and secondary infection. The 1997 
World Health Organization (WHO) guidelines on dengue suggested criteria 
based on hemagglutination inhibition (HI) titers to distinguish between primary 
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and secondary infection. While the accuracy of the HI criteria in distinguishing 
between primary and secondary infections has been questioned [9-14], this 
criteria is still used in studies that would like to analyze the relationship between 
primary or secondary infections with the severity of disease as well as studies 
conducted to develop other serological methods [9,10,15-17]. Several methods 
based on enzyme-linked immunosorbent assay (ELISA), which is easier and 
faster to perform, have been proposed as alternative methods to distinguish 
primary and secondary infections, for example, by measuring IgG antibodies; the 
avidity titer of IgG; calculating the ratio of IgM/IgG; or the absence of IgG in acute 
specimens [11,12,14,18,19]. However, none of these studies utilized another 
serological assay as the gold standard. In this study, we compared the utility of 
the HI test and IgG ELISA in discriminating primary and secondary infections 
using acute and convalescent specimens that had been tested by a plaque 
reduction neutralization test (PRNT). In addition, we also propose modified HI 
criteria to distinguish between primary and secondary infections.
MATERIALS AND METHOD
Sample collection
A total of 178 acute and convalescent sera from 89 confirmed dengue cases were 
used in this study. These sera were collected as a part of two dengue studies 
in Bandung. These studies were approved by the Institutional Review Board of 
United Stated Navy Medical Research Unit (US-NAMRU)#2 (N2.2006.0001 and 
N2.2004.0010, respectively) in compliance with all U.S. Federal Regulations 
governing the protection of human subjects and at the National Institute of Health 
Research and Development, Ministry of Health, Indonesia (KS.02.01.2.1.2776 and 
KS.02.01.2.1.3461, respectively). Acute sera were taken when study participants 
came to health centers or hospitals, while convalescent sera were obtained 
at least seven days later or when the participants were discharged from the 
hospitals.
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Dengue diagnosis
A dengue infection was confirmed when : 1). DENV was isolated from tissue 
culture or DENV RNA was detected by the reverse-transcriptase polymerase 
chain reaction or 2). when the acute sample was positive for IgM and paired sera 
demonstrated increasing IgG titers and/or a four-fold rise in HI titers. 
The HI test was performed as previously described [20]. A preliminary experiment 
comparing the performance of all four dengue antigens in the HI test did not show 
any difference in their ability to determine recent infection or in differentiating 
primary and secondary infections (data not shown). Hence, only dengue-3 
antigen was used for HI tests throughout the rest of this study. Specimens with 
detectable HI antibodies at 1:10 or higher dilutions were confirmed as positive. 
If no antibody was detected at the lowest dilution (1:10), the specimen was 
confirmed as negative. Any case with a convalescent HI antibody titer higher 
than 1280 was classified as a secondary infection [21].
IgG ELISA was performed using a commercial dengue IgG ELISA kit (Dengue IgG 
ELISA, Focus Technologies, Cypress, CA, USA) according to the manufacturer’s 
instructions. The index value was calculated by dividing the sample optical 
density (OD) with the mean of calibrator OD. Specimens with an IgG index value 
<1 were confirmed as negative and those with an IgG index value >1 were 
confirmed as positive. When IgG was negative in the acute specimen the case 
was classified as a primary infection.
PRNT was performed using the following reference strains: DENV-1 (16001), 
DENV-2 (16682), DENV-3 (16562), and DENV-4 (1036). In brief, 500 plaque forming 
units per milliliter of dengue virus were incubated with serial 4-fold diluted 
serum from 1:10 to 1:10,240. A suspension of the baby hamster kidney (BHK) cells 
was used to detect the virus reduction following previously described methods 
[22]. The PRNT50 titer was calculated using a log probit regression analysis by 
SPSS (SPSS Inc., Chicago, IL). A sample was confirmed as negative for neutralizing 
antibodies when the PRNT50 values were lower than 10 against all dengue 
serotypes. A sample was confirmed as positive for neutralizing antibodies when 
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PRNT50 titers were 10 or greater for at least one dengue serotype. Any case with 
seroconversion of neutralizing antibodies was classified as a primary infection. 
Any case with detectable neutralizing antibodies in the acute specimen was 
confirmed as a secondary infection.
Statistical analysis
Statistical analysis was performed using STATA version 9 (STATA Corporation, TX). 
Comparison between two assays was analyzed using McNemar’s test.
RESULTS
Subject demographics and specimen characteristics categorized by primary 
and secondary infection according to PRNT results are presented in Table 1. 
Subjects with primary infections were slightly younger that those subjects with 
secondary infections, but there was no difference in the gender distribution, 
acute sample collection day, convalescent sample collection day, or the interval 
between acute and convalescent sample collection.
Table1.  Subject and Sample characteristics
Subjects Samples
Age
(years)
Sex
(Male, %)
Acute
(days of 
onset)
Convalescent
(days of onset)
A-C interval
(days)
Primary
26±9
(7-42)
13 (65)
2.5±1.7
(1-7)
18.5±5.9
(9-32)
15.9±5.6
(7-30)
Secondary
36±8
(9-53)
47(65)
2.1±1.3
(1-7)
15.3±4.4
(6-28)
13.2±3.9
(4-26)
Total
34±9
(7-53)
60 (65)
2.2±1.4
(1-7)
15.9±4.8
(6-32)
13.7±4.4
(4-30)
* Mean +/- SD (range)
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HI and IgG ELISA performances compared to PRNT
First, we sought to examine the sensitivity and specificity of the IgG ELISA and HI 
assays in comparison to the PRNT. Based on PRNT results, 162 of 178 specimens 
were positive for dengue neutralizing antibodies and 16 specimens (all acute) 
were negative. Among the 162 positive samples, IgG ELISA results were positive 
for 161 (99.4%) samples and HI results were positive for 153 (94.4%) samples. 
Among the 16 specimens negative by PRNT, IgG ELISA results were also negative 
for these samples whereas HI antibodies results were negative in only 10 
(62.5%) samples. Thus, while the sensitivities between ELISA and HI were similar 
compared to PRNT, the IgG ELISA was significantly more specific than the HI 
assay (p<0.01). 
Distinguishing between primary and secondary infections
We next aimed to determine the performance of the IgG ELISA and HI assays 
in distinguishing between primary and secondary infections using PRNT results 
as the gold standard. According to the PRNT results, of the 89 dengue cases 
included in this study, 16 cases were categorized as primary infections and 73 
cases were categorized as secondary infections. Of 16 cases classified as primary 
infections, classification by HI and IgG ELISA concurred in all of these cases. IgG 
ELISA also identified 72 of 73 (98.6%) secondary cases, whereas HI was only able 
to detect 23 of the 73 (31.5%) secondary cases. The difference between the two 
was significant (p<0.01). When convalescent HI titers were compared to PRNT 
classification 11 cases with HI titers ≤80 were primary infections, 46 cases with 
HI titers ≥1280 were secondary, 32 cases with HI convalescent titers between 
160 and 640, PRNT results only confirmed primary infections in five (15.6%) cases 
(Table 2).
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To determine if we could better categorize the cases with convalescent HI titers 
between 160 and 640, we considered HI results from the acute samples of these 
cases. For this analysis, cases with convalescent HI titers between 160 and 640 and 
negative acute sample HI results were considered primary cases and cases with 
convalescent HI titers between 160 and 640 and positive acute sample HI results 
were considered secondary cases. Using this classification algorithm, 24 of 32 
(75%) cases with convalescent HI titers between 160 and 640 were classified in 
concordance with PRNT results. We also considered using only acute sample HI 
results for classification by defining cases with no acute HI antibodies as primary 
infections. Using this criteria, 64/73 secondary cases and 10/16 primary cases 
were classified in concordance with PRNT results. 
Table 3 summarizes the percentage of cases classified in concordance with PRNT 
results as primary or secondary infections using all of the criteria examined in 
this study. Cases classified according to an acute sample IgG ELISA results had 
the highest concordance with PRNT based classification while criteria that took 
into account convalescent and acute HI results had the next best concordance 
with PRNT classification.
Table 2.  Comparison of HI test and PRNT on Convalescent-phase samples
HI Titer Cases
PRNT
Primary infections Secondary infections
Cases Percentage Cases Percentage
≤80 11 11 100 0 0
160 4 1 25 3 75
320 14 3 21.4 11 78.6
640 14 1 7.1 13 92.9
1280 23 0 0 23 100
≥2560 23 0 0 23 100
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DISCUSSION
Serology assays are the most applicable and affordable confirmatory test for 
dengue infections in third world countries where dengue is commonly endemic. 
In addition, WHO has recommended IgM Antibody Capture (MAC) ELISA, HI 
and PRNT to determine primary and secondary infections [21]. Compared 
with MAC ELISA and PRNT, HI has long been the most widely used serology 
assay. However, similar to previous reports, we showed that HI underestimated 
secondary infections when the WHO recommended cut-off was applied [13,14]. 
By applying modified cut-off criteria and both convalescent and acute sample HI 
results, the accuracy in determining secondary infection increased from 31.5% 
to 93.2%, while the accuracy in determining primary infections decreased from 
100% to 81.3% (13/16). 
Nevertheless, compared to the HI test, the commercially available ELISA kit is 
simpler and faster than the HI test. It is also easier to obtain than HI antigens in 
some countries such as Indonesia. Although several kinds of ELISA evaluation 
Table 3.  Percent concordance with PRNT case classification using ELISA IgG, HI (WHO 1997) or 
modified HI criteria
Criteria to determine primary infection//secondary infections:
a 1st infection if HI Abs negative in acute specimens
b 1st infection if convalescent HI Abs ≤ 80, or if convalescent HI Abs are 160, 320, or 640 and HI Abs negative 
in acute specimen
1,2,3,4,5,6 statistically significant
1st infection
IgG ELISA HI (WHO 1997) Modified HI-1a Modified HI-2b
16/16 (100)1 16/16(100)2 10/16(62.5)1,2 13/16(81.3)
2nd infection 72/73(98.6)3,4 23/73(31.5)3,5,6 64/73(87.7)4,5 68/73(93.2)6
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(avidity, ratio IgM/IgG) have been compared with HI and have been determined 
to be more reliable than HI tests, these studies did not use a third assay as a 
reference [12,14,18,19]. By using PRNT as the gold standard, our study has 
confirmed results from previous studies that ELISA is superior to HI in determining 
primary and secondary infections. 
Our study was similar to de Souza et al. 2007 in regards to the IgG ELISA kit 
used (Focus Diagnostics) and the simple criteria for determining primary 
infection or secondary infection - the absence or presence of IgG antibodies in 
the acute specimens. As other IgG ELISA kits may have different sensitivities and 
specificities, this criteria should only be used after the sensitivity and specificity 
of these kits are assessed. Compared to other methods that used IgG ELISA 
and showed similar performance, such as IgM/IgG ratio and avidity index, our 
method is simpler and more cost-effective. 
In conclusion, considering the limitation of HI criteria in discriminating primary 
and secondary infections, we recommend the use of the absence or presence of 
IgG antibodies in acute specimens as measured by IgG ELISA as the criteria. HI 
may still be used, however, the criteria for interpretation should be revised. We 
propose that HI convalescent titers ≤80 should be classified as primary infections, 
HI convalescent titers ≥1280 should be classified as secondary infections and for 
cases with convalescent HI titers between 160 and 640, the acute samples should 
be evaluated. If the acute sample does not have any detectable HI antibodies, 
the case should be classified as a primary infection. If the acute sample does have 
detectable HI antibodies, the case should be classified as a secondary infection. 
The performance of acute IgG ELISA criteria and the proposed HI criteria are 
equally good.
ACKNOWLEDGEMENT
We would like to thank all the volunteers, dengue research teams at the factories 
and Hasan Sadikin Hospital, National Institute Health Research and Development, 
Ministry of Health and NAMRU#2 for their dedication in dengue research, and 
Chapter 5
88
to Kendra Chittenden from the USAID and INA-RESPOND for their support and 
assistance.
The views expressed in this article are those of the authors and do not 
necessarily reflect the official policy or position of the Department of the 
Navy, Department of Defense, nor the U.S. Government. Some of the authors 
are military service members or employees of the U.S. Government. This work 
was prepared as part of their official duties. Title 17 U.S.C. §105 provides that 
‘Copyright protection under this title is not available for any work of the United 
States Government.’ Title 17 U.S.C. §101 defines a U.S. Government work as a work 
prepared by a military service member or employee of the U.S. Government as 
part of that person’s official duties.
The comparison of hemagglutination inhibition test and IgG ELISA in diagnosing primary and 
secondary dengue infections based on plaque reduction neutralization test
89
5
References
1. WHO (2012) Dengue and Severe Dengue. World Health Organization.
2. Egger JR, Coleman PG (2007) Age and clinical dengue illness. Emerg Infect Dis 13: 
924-925.
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, et al. (2013) The global 
distribution and burden of dengue. Nature 496: 504-507.
4. Guy B, Almond JW (2008) Towards a dengue vaccine: progress to date and remaining 
challenges. Comp Immunol Microbiol Infect Dis 31: 239-252.
5. Suwandono A, Kosasih H, Kusriastuti R, Harun S, Ma’roef C, et al. (2006) Four dengue 
virus serotypes found circulating during an outbreak of dengue fever and dengue 
haemorrhagic fever in Jakarta, Indonesia, during 2004. Trans R Soc Trop Med Hyg 
100: 855-862.
6. Sam SS, Omar SFS, Teoh B-T, Abd-Jamil J, AbuBakar S (2013) Review of Dengue 
Hemorrhagic Fever Fatal Cases Seen Among Adults: A Retrospective Study. PLoS 
Negl Trop Dis 7: e2194.
7. Ngwe TM, Thant KZ, Inoue S, Kurosawa Y, Lwin YY, et al. (2013) Serological 
characterization of dengue virus infections observed among dengue hemorrhagic 
fever/dengue shock syndrome cases in Upper Myanmar. J Med Virol 85: 1258-1266.
8. Sharp TM, Hunsperger E, Santiago GA, Munoz-Jordan JL, Santiago LM, et al. (2013) 
Virus-specific differences in rates of disease during the 2010 Dengue epidemic in 
Puerto Rico. PLoS Negl Trop Dis 7: e2159.
9. Miagostovich MP, Nogueira RM, dos Santos FB, Schatzmayr HG, Araujo ES, et al. (1999) 
Evaluation of an IgG enzyme-linked immunosorbent assay for dengue diagnosis. J 
Clin Virol 14: 183-189.
10. Shu PY, Chen LK, Chang SF, Yueh YY, Chow L, et al. (2003) Comparison of capture 
immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assay (ELISA) and 
nonstructural protein NS1 serotype-specific IgG ELISA for differentiation of primary 
and secondary dengue virus infections. Clin Diagn Lab Immunol 10: 622-630.
11. Matheus S, Deparis X, Labeau B, Lelarge. J, Morvan J (2005) Use of four dengue 
virus antigens for determination of dengue immune status by enzyme-linked 
immunosorbent assay of immunoglobulin G avidity. J Clin Microbiol 43: 5784-5786.
12. Matheus S, Deparis X, Labeau B, Lelarge J, Morvan J, et al. (2005) Discrimination 
between primary and secondary dengue virus infection by an immunoglobulin G 
avidity test using a single acute-phase serum sample. Journal of clinical microbiology 
43: 2793-2797.
13. Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, et al. (1999) A prospective 
Chapter 5
90
seroepidemiologic study on dengue in children four to nine years of age in 
Yogyakarta, Indonesia I. studies in 1995-1996. Am J Trop Med Hyg 61: 412-419.
14. A-nuegoonpipat A, Prakong S, Sa-ngasang A, Chanama S, Sawanpanyalert P, et 
al. (2006) Comparison between Haemagglutination Inhibition (HI) Test and IgM 
and IgG-capture ELISA in Determination of Primary and Secondary Dengue Virus 
Infections. Dengue Bulletin 30: 141-145.
15. Lam SK, Devine PL (1998) Evaluation of capture ELISA and rapid 
immunochromatographic test for the determination of IgM and IgG antibodies 
produced during dengue infection. Clin Diagn Virol 10: 75-81.
16. Becerra A, Warke RV, de Bosch N, Rothman AL, Bosch I (2008) Elevated levels of 
soluble ST2 protein in dengue virus infected patients. Cytokine 41: 114-120.
17. Sriprom M, Pongsumpun P, Yoksan S, Barbazan P, Gonzalez J, et al. (2003) Dengue 
haemorrhagic fever in Thailand, 1998-2003: primary or secondary Infection. Dengue 
Bulletin 27: 39-45.
18. Vaughn DW, Nisalah A, Solomon T, Kalayanarooj S, Nguyen MD (1999) Rapid 
serologic diagnosis of dengue virus infection using a commercial capture ELISA that 
distinguishes primary and secondary infections. Am J Trop Med Hyg 60: 693-698.
19. de Souza VA, Tateno AF, Oliveira RR, Domingues RB, Araujo ES, et al. (2007) Sensitivity 
and specificity of three ELISA-based assays for discriminating primary from secondary 
acute dengue virus infection. J Clin Virol 39: 230-233.
20. Clarke DH, Casal J (1958) Technique for Hemagglunation and Hemagglunation 
Inhibition with Arthropod Borne Virus. Am J Trop Med Hyg 7: 561-567.
21. WHO (1997) Dengue haemorrhagic fever: diagnosis, treatment, prevention, and 
control. Genevea, Switzerland: World Health Organization.
22. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N (1985) Simplified 
plaque reduction neutralization assay for dengue viruses by semimicro methods in 
BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction 
neutralization. J Clin Microbiol 22: 250-254.
The comparison of hemagglutination inhibition test and IgG ELISA in diagnosing primary and 
secondary dengue infections based on plaque reduction neutralization test
91
5

Chapter 6
The diagnostic and prognostic value 
of dengue non-structural 1 antigen 
detection in a hyper-endemic region in 
Indonesia
PLoS One, 2013
Herman Kosasih1,3, Bachti Alisjahbana1, 2, Susana Widjaja3, Nurhayati3, 
Quirijn de Mast4, Ida Parwati5, Patrick J. Blair3, Timothy H. Burgess3, 
Andre van der Ven4, Maya Williams3
1 Health Research Unit, Faculty of Medicine, Padjadjaran University, Bandung, Indonesia
2 Viral Diseases Program, U.S. Naval Medical Research Unit Two, Jakarta, Indonesia
3 Internal Medicine Department, Hasan Sadikin Hospital, Bandung, Indonesia
4 Department of Internal Medicine, Radboud University Nijmegen Medical Centre, the Netherlands
5 Clinical Pathology Department, Hasan Sadikin Hospital, Faculty of Medicine, Padjadjaran University 
Bandung, Indonesia
Chapter 6
94
ABSTRACT
As dengue fever is undifferentiated from other febrile illnesses in the tropics 
and the clinical course is unpredictable, early diagnosis is important. Several 
commercial assays to detect dengue NS1 antigen have been developed; 
however, their performances vary and data is lacking from hyper-endemic 
areas where all four serotypes of dengue are equally represented. To assess the 
sensitivity of the Bio-Rad Platelia Dengue NS1 antigen assay according to virus 
serotype, immune status, gender, and parameters of severe disease, acute sera 
from 220 individuals with confirmed dengue and 55 individuals with a non-
dengue febrile illness were tested using the Bio-Rad Platelia Dengue NS1 antigen 
assay. The overall sensitivity of the NS1 ELISA was 46.8% and the specificity 
was 100%. The sensitivity in primary infections was significantly higher than in 
secondary infections (100% vs. 35.7%). In secondary infections, the sensitivity 
of NS1 detection was highest in DENV-3 (47.1%), followed by DENV-1 (40.9%), 
DENV-2 (30%) and DENV-4 (27%) infections. NS1 was less frequently detected in 
sera with high titers of HI antibodies or in acute samples from patients whose 
pre-illness sera showed neutralizing antibodies to more than one serotype. The 
detection of NS1 was higher in females, severe cases, and individuals with lower 
platelet counts (<100,000/mm3). While the overall sensitivity of this NS1 ELISA is 
poor, our data suggest that in secondary infections, detection may be predictive 
of a more severe illness.
INTRODUCTION
Dengue fever (DF) is a major public health problem with 50 million annual cases 
worldwide. It has been reported in more than 100 countries and continues to 
spread to previously unaffected regions [1]. DF is caused by dengue viruses 
(DENV), which consist of four serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. 
Infection with any serotype usually results in asymptomatic infection or mild 
non-specific febrile illness, but in a subset of patients, severe disease develops, 
characterized by a transient capillary leakage syndrome (dengue hemorrhagic 
fever/ DHF) [2]. This unpredictable disease course and the need to differentiate 
The diagnostic and prognostic value of dengue non-structural 1 antigen detection 
in a hyper-endemic region in Indonesia
95
6
DF from other causes of fever make an early and sensitive diagnosis of acute 
dengue virus infection important. 
Non-structural 1 protein (NS1) is encoded by the virus and secreted in a soluble 
form [3]. Several commercial assays to detect dengue NS1 have been developed 
recently [4]. Advantages of NS1 tests are: NS1 is detected early in disease, several 
days prior to the appearance of anti-dengue IgM antibodies [5], and the test is 
inexpensive, easy, and fast. Moreover, NS1 levels early in dengue disease have 
been correlated with disease severity [6], suggesting that NS1 tests may also 
have prognostic value. 
Previous studies evaluating the diagnostic value of NS1 antigen assays have had 
varying results [4,7] (Table S1). Several factors may account for this : proportion of 
primary vs. secondary infections [4,8-11], timing of sample collection [4,7,8,12,13], 
infecting serotype [4,7,8,13,14], viremia levels [6,13,15,16] and severity of illness 
[6,7,15]. A low sensitivity has been reported in secondary infections possibly due 
to immune-complex formation of NS1 and pre-existing antibodies [17]. This may 
especially be important as the proportion of secondary infections is expected to 
rise worldwide [18]. Although studies evaluating the NS1 assays were conducted 
in hyper-endemic areas of Southeast Asia or South America, in several studies, all 
four dengue serotypes were not represented equally [4,7,8,10,13,15,16,19,20] or 
evaluated [11,21]. In others, the percentage of primary infections was too high 
to represent the situation in hyper-endemic areas [9,11,12,15,20]. Additionally, 
only a few studies evaluated the association between NS1 detection and clinical 
severity [4,6,7,15,21]. The objectives of the study were: 1) Determine diagnostic 
performance of the Bio-Rad Platelia Dengue NS1 antigen assay in a region 
where all dengue serotypes circulate year round and clinical severity could be 
evaluated 2) Assess the sensitivity of this assay in secondary cases according to 
pre-illness and acute dengue immune status 3) Determine the sensitivity of this 
assay according to clinical severity. 
Chapter 6
96
MATERIALS AND METHODS
Ethics Statement
All samples were obtained after written informed consent through studies 
approved by the Institutional Review Board of NAMRU#2 (N2.2006.0001, 
N2.2004.0010, N2.2004.0008) and at the National Institute of Health Research and 
Development, Ministry of Health, Indonesia (KS.02.01.2.1.2776, KS.02.01.2.1.3461 
and KS.02.01.2.1.2336) in compliance with all U.S. Federal Regulations governing 
the protection of human subjects.
Sample characteristics
Acute sera from archived and fresh samples of 220 confirmed dengue cases and 
55 non-dengue febrile illness cases were used. Samples were from previously 
published studies [22,23]. Study one was a prospective dengue cohort study of 
~3,000 factory workers in two factories in Bandung, Indonesia from 2000-2004 
and 2006-2009. Volunteers participated in serosurveys every three months and 
visited factory clinics when they experienced fever. Study two was a community 
dengue study where 15-20 people living near a confirmed dengue case were 
observed for two weeks when a dengue case was confirmed at the study 
hospital. Volunteers in study one and two were hospitalized when dengue 
infection was confirmed. Study three was a hantavirus surveillance study at two 
hospitals in Bandung, Indonesia. As clinical manifestations between dengue and 
hantavirus are indistinguishable, samples were screened for evidence of dengue 
infection. In all studies, acute sera were collected when volunteers presented at 
clinics or hospitals, and convalescent samples were collected during hospital 
discharge or 7-10 days after acute sample collection. Paired samples were 
tested for evidence of dengue infection as described below. Complete blood 
counts to detect thrombocytopenia and hematocrit measurements to look for 
hemoconcentration as one indicator of plasma leakage were taken daily for 
hospitalized patients and upon indication for outpatients. Ultrasonography to 
detect plasma leakage was performed on hospitalized patients in study one and 
two.
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Case Definitions
A dengue infection was confirmed when 1. DENV RNA was detected by RT-
PCR or 2. For RT-PCR negative cases, when all of the following criteria were 
met: IgM positive, increasing IgG titers and a four-fold rise in hemagglutination 
inhibition (HI) titers. A primary or secondary dengue infection was determined 
by the absence or presence of IgG antibodies in the acute sample [24]. Non-
dengue infection was confirmed when dengue RT-PCR was negative, and no 
IgM antibodies, increase in IgG titers or four-fold increase of HI antibody titers 
was detected. Infecting serotypes were determined by RT-PCR and neutralizing 
antibodies to each serotype in pre-illness sera were measured by plaque 
reduction neutralization test (PRNT). Dengue cases were classified as DF, DHF, 
and dengue shock syndrome (DSS) according to 1999 WHO guidelines [25]. 
Cases of DF with hemorrhagic manifestations formed a separate group (DF+HM).
Laboratory tests
Acute serum samples were assayed for DEN virus RNA by RT-PCR [26]. Acute and 
convalescent sera were tested for dengue IgM, IgG and HI antibodies. Dengue 
IgM and IgG were detected by capture and indirect ELISA respectively according 
to the manufacturer’s instructions (FOCUS Technologies, CA, USA). HI tests were 
performed as previously described [27]. Acute samples were tested with the 
NS1 Platelia antigen capture ELISA according to the manufacturer’s instructions 
(BioRad, CA, USA). PRNT was conducted on pre-illness sera collected during the 
serosurvey in study one from 2000-2004. Three 10-fold serum dilutions were 
made starting at 1:10 and diluted samples were assayed as described previously 
[28]. The dilution that produced an 80% reduction in plaque count compared 
with the negative control sample was determined by probit analysis using SPSS 
(SPSS, Chicago, IL). The virus strains used in the assays were isolated from DEN 
patients in Thailand (16001 DENV-1, 16682 DENV-2, and 16562 DENV-3) and 
Indonesia (1036 DENV-4).
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Statistical analysis
Data were entered into Microsoft Access. Statistical analysis was performed 
using STATA version 9 (STATA Corporation, TX). Categorical variables between 
two groups were compared with a chi-square test. A p value of less than 0.05 
was considered significant.
RESULTS
Overall and serotype specific sensitivity of the NS1 test
Samples from 275 volunteers were used, 220 confirmed dengue cases and 55 
non-dengue cases. Dengue infection was confirmed by both virological and 
serological evidence in 195 (88.6%) cases and by serological evidence alone in 
25 (11.4%) cases. Table 1 summarizes the characteristics, WHO clinical category, 
virological and serological data for these cases. The overall sensitivity of the assay 
was 46.8% (95% CI: 40.2-53.3) and the specificity was 100% (55/55) (Table 2). 
The sensitivity was 50.3% (95% CI: 43.3-57.3) in samples positive by RT-PCR, and 
20% (95% CI: 4.3-53.7) in samples negative by RT-PCR. The sensitivity was 100% 
(34/34) in primary infections and 35.7% (95% CI: 28.7-42.7) in secondary infections 
(p=0.00). In secondary infections, no significant (p=0.38) difference was found 
between fresh and archived specimens (38.9%, 95%CI: 28.8-49 vs.32.6%, 95%CI: 
23-42.2); however, the sensitivity by serotype varied. The highest sensitivity was 
observed for DENV-3 (47.1%, 95% CI: 35.2-58.9), followed by DENV-1 (40.9%, 95% 
CI: 20.4-61.4), DENV-2 (30%, 95% CI: 13.6-46.4) and DENV-4 (27%, 95% CI: 12.7-
41.3). This difference in sensitivity was significant when comparing DENV-3 to 
DENV-4 (p=0.045.).
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Table 1.  Specimen characteristics
Source of Specimens Study 1 Study 2 Study 3 Total
Non-dengue 51 4 0 55
Acute dengue 125 27 68 220
Mean age in years (range)
Sex Ratio (male:female)
36.5 (21-53)
3.3:1
19.5 (4-47)
1:1.1
24.4 (12-50)
1.4:1
30.7 (4-53)
2.1:1
Outpatients
Inpatients
Mean day after illness onset (range)
72
53
2.7 (1-7)
8
19
2 (1-7)
0
68
5.1 (2-7)
80
140
3.5 (1-7)
Clinical diagnosis (%)
dengue fever (DF)
DF with hemorrhagic manifestations
dengue hemorrhagic fever grade I
dengue hemorrhagic fever grade II
dengue shock syndrome
84
8
18
15
0
9
2
6
8
2
33
22
5
8
0
126 (57.3)
32 (14.5)
29 (13.2)
31 (14.1)
2 (1)
Infecting serotype (%)
DENV-1
DENV-2
DENV-3
DENV-4
Unknown
23
19
35
32
16
6
5
6
1
9
6
18
40
4
0
35 (15.9)
42 (19.1)
81 (36.8)
37 (16.8)
25 (11.4)
Type of infection (%)
Primary
Secondary
Unknown
16
109
0
5
22
0
13
51
4
34 (15.4)
182 (82.7)
4 (1.8)
Table 2.  Sensitivity of the NS1 antigen test according to infection status
Type of 
infection
Infecting serotypes
TOTAL
DENV-1 DENV-2 DENV-3 DENV-4 Unknown*
Primary 13/13(100) 11/11(100) 10/10(100) 0/0(0) 0/0(0) 34/34(100)1
Secondary 9/22 (40.9) 9/30 (30) 32/68(47.1)2 10/37(27)2 5/25(20) 65/182(35.7)1
Unknown# 0/0(0) 1/1(100) 3/3(100) 0/0(0) 0/0(0) 4/4(100)
Total 22/35(62.9) 21/42(50) 45/81(55.6) 10/37(27)  5/25(20) 103/220(46.8)
*PCR negative, #IgG results not available,
1statistically significant difference (p=0,00)
2statistically significant difference (p=0.04)
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NS1 sensitivity according to dengue immune status 
To determine if the sensitivity of the NS1 test varied by dengue immune status, 
dengue HI titers were determined on all acute samples and PRNTs were performed 
on pre-illness (one to two months prior to dengue infection) sera from the 47 
patients enrolled in the first phase of study one. The sensitivity was significantly 
(p<0.05) lower in acute samples with high HI titers (≥1280) compared to samples 
with lower or undetectable titers (Table 3A). Among the 47 samples tested by 
PRNT, neutralizing antibodies to more than one serotype were detected in 32 
cases and NS1 was only positive in one acute specimen, giving a sensitivity of 
3.1%. In contrast, in patients with pre-illness neutralizing antibodies to only one 
serotype, the sensitivity of the NS1 test was 60% (9/15) (Table 3B). Among these 
nine NS1 positive cases, eight had pre-illness neutralizing antibodies to DENV-2 
and one to DENV-1, whereas among the six negative cases, four had neutralizing 
antibodies to DENV-1, one to DENV-3 and one to DENV-2. The infecting serotypes 
in eight of the nine positive cases were DENV-1 (2), DENV-3 (2) and DENV-4 (4).
A. Acute specimen HI titer (n=179)
HI titer Sensitivity
< 10 26/32(81.3%)1
10 – 80 29/72 (40.3%)
160 – 640 18/40 (45%)
≥1280 7/35 (22%)1
B. Presence of pre-illness neutralizing antibodies* (n=47)
Number of serotypes Sensitivity
1 9/154 (60%)
more than 1 1/324 (3.1)
Table 3.  Sensitivity of the NS1 antigen test according to dengue immune status
1significantly different from the other groups
*plaque reduction neutralizing antibodies (80%)
4significantly different from each other
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NS1 sensitivity according to disease severity and gender
As the sensitivity of the NS1 assay was 100% in primary infections, only 
secondary infections were included in this analysis. The sensitivity among DF 
cases (25%, 95% CI: 16.7-33.3) was significantly lower compared to DF+HM 
cases (55%, 95% CI: 33.2-76.8) and DHF I and DHF II cases (50%, CI: 36.9-63.1). 
Additionally, the sensitivity was higher in patients with platelet counts below 
100,000/mm3 at presentation (48% vs. 27.1%, p=0.00) or at time of platelet 
nadir (50% vs.16.2%, p=0.00). A higher sensitivity was also found in cases with 
spontaneous hemorrhagic manifestations, hemoconcentration or effusion, but 
these differences were not significant (Figure 1).
Figure 1.  Sensitivity of the NS1 antigen test according to diagnosis category and clinical variables in 
secondary dengue cases.
Data from a subset of patients enrolled in study one and two in which patients 
were identified early, revealed that the mean and range interval between the 
detection of NS1 and thrombocytopenia among 28 patients was 1.8 (0-5) days, 
whereas the time between the detection of NS1 and evidence of plasma leakage 
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among 17 DHF patients was 3.3 (1-5) days. The sensitivity of the NS1 assay was 
significantly higher in females than males with values of 49.1% (95% CI: 36.1-
62.1) and 29.6% (95% CI: 21.6-37.6) respectively (p=0.01). This gender difference 
remained present when analysis was restricted to those with manifestations of 
more severe disease (Figure 2).
Figure 2.  The sensitivity of the NS1 antigen test according to gender and clinical variables in 
secondary infections.
DISCUSSION
NS1 tests are increasingly being used as a rapid and inexpensive diagnostic 
tool for acute DF. We found that its sensitivity in a dengue hyper-endemic 
area (Indonesia) where most infections are secondary was low with an overall 
sensitivity of 46.8%. In samples from primary infections, the sensitivity was 100% 
indicating that it is a good diagnostic tool for patients from non-endemic areas, 
such as in travelers [29]. Our findings are also in line with reports from other 
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countries that found a low sensitivity in secondary infections [4,13,20]. Apart 
from primary or secondary infection status, our data also suggest that sensitivity 
was affected by dengue immune status, infecting dengue serotype, gender and 
severity of illness.
Our data demonstrated poor performance of the NS1 test in acute sera with high 
titers of HI dengue antibodies. Further analysis showed that NS1 antigen was 
undetectable in nearly all acute sera from patients with pre-illness neutralizing 
antibodies to more than one serotype, but was detectable in more than half 
of those with only one serotype. These findings are in line with the hypothesis 
that immune-complexes are formed in secondary infections and high levels 
of antibodies capture and bind soluble NS1 (sNS1) resulting in a reduction 
of circulating NS1 [17]. Therefore, the use of a NS1 assay in areas where post-
secondary dengue infection is common [30,31] has limited value. The serotype of 
a previous dengue infection may also influence the sensitivity of NS1 detection in 
secondary infections as we found the sensitivity was significantly higher in acute 
samples from patients with pre-illness neutralizing antibodies to DENV-2 (88.9%) 
compared to DENV-1 (11.1%). It has been reported that in comparison to DENV-1 
and DENV-3, DENV-2 infections result in much lower concentrations of sNS1 [32]. 
Thus, during primary DENV-2 infections, the amount of sNS1 produced may be 
unable to generate sufficient NS1 antibodies to form immune-complexes with 
sNS1 in secondary infections. The influence of pre-existing antibodies to other 
flaviviruses that may circulate in the region such as Japanese encephalitis as a 
result of natural infection or vaccination may also affect the sensitivity of NS1 
and should be considered. The data presented here are consistent with previous 
studies that report a higher sensitivity of the NS1 test in DENV-3 and DENV-1 
infections compared to DENV-2 and DENV-4 infections [12,14]. As the specimens 
used in this study included all DENV serotypes, the overall sensitivity was not 
affected by a predominating serotype as has been reported elsewhere [7]. 
Our study also demonstrated that in secondary cases, the sensitivity is better in 
patients with more severe illness. The sensitivity of the test in the DF group was 
significantly lower compared to the other groups (DF+HM or DHF). DSS cases 
were excluded from this analysis, as the number of DSS cases was too small 
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(n=2). The association between NS1 and clinical severity has been studied before 
with discordant results [4,6,7,15,21]. The differences might be due to inadequate 
number of cases [21] or the application of different clinical category guidelines 
[4]. NS1 sensitivity was also significantly higher in patients with platelet counts 
below 100,000/mm3 measured at presentation only or nadir platelet counts 
below 100,000/mm3 if serial measurements were done. A positive NS1 result 
in secondary infections may therefore be a predictor for low platelet count. 
Although not significantly different, sensitivity tended to be higher in cases 
with spontaneous bleeding, effusion and hemoconcentration. The association 
between NS1 and clinical severity is thought to be related to the cross-reactivity 
of anti-dengue NS1 antibodies with platelets and endothelial cells, and the 
role of NS1 in the occurrence of vascular leakage through complement and 
cytokine responses [33,34]. Recent findings have also shown that NS1 positivity 
is correlated with higher viremia or antigenemia which was found in more 
severe cases [13,15]. The overall sensitivity of the NS1 test and its sensitivity 
in secondary infections in our study is lower than what has previously been 
published. There are several possible reasons for this difference. This and other 
studies have demonstrated that the sensitivity of NS1 in secondary infections is 
much lower than in primary infections. As a consequence, the overall sensitivity 
will be affected by the proportion of primary or secondary infections in the 
sample set used. Compared to studies conducted in other endemic countries, 
our study has a low proportion of primary infections. Our study also included 
outpatients (36.4%). As has previously been reported and is found in this study, 
NS1 sensitivity is associated with disease severity. Therefore, outpatients in 
our study, which were mostly mild cases, may have contributed to the lower 
NS1 sensitivity. Additionally, we found that among secondary cases, post-
secondary (≥2) cases (cases with pre-illness neutralizing antibodies to more 
than one serotype) had lower sensitivities than secondary cases with pre-illness 
neutralizing antibodies to only one serotype. Based upon the data from the 47 
subjects that were tested for pre-illness neutralizing antibodies and the mean 
age of our volunteers, we suspect that many of the cases in our study were post-
secondary infections. Finally, the proportion of secondary infections caused by 
DENV-2 and DENV-4, serotypes with lower sensitivities in our study, was higher 
than in other studies. 
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The strengths of this study are: 1) work was conducted in a setting where all 
dengue serotypes were equally distributed and the ratio between primary and 
secondary infections reflected the regional epidemiology. 2) accurate clinical 
outputs were available as patients were monitored closely. 3) this study provides 
a wealth of laboratory data to assess the correlation between NS1 detection and 
serotype distribution, and dengue immune status including serotype specific 
pre-existing immunity, which have not been reported elsewhere. This study has 
also several limitations. First, male participants were more predominant than 
females. However, despite fewer samples from females, the detection of NS1 
was significantly higher in females than males. Second, ultrasonography was not 
performed on a subset of volunteers. As a consequence, several DF+HM cases 
might be more accurately included in the DHF group. However, the numbers are 
probably small as daily hemoconcentration was performed on all individuals. 
Third, PRNT was only conducted on pre-illness sera from 47 patients. Although, 
the results showed a strong association between sensitivity and the presence of 
neutralizing antibodies to DENV-2, further study is needed.
In conclusion, the NS1 test is not recommended as a standalone diagnostic 
test for dengue infection in regions where secondary infections predominate. 
However, as the sensitivity and specificity in acute specimens from primary 
infections is excellent, use of the test may prove of value to travelers returning 
from dengue endemic areas. Furthermore, as the sensitivity in secondary cases 
is associated with clinical severity, NS1 may be useful to predict severe disease. 
However, further studies with larger sample sizes and in other geographic 
regions are needed to confirm this association.
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Author (Year/Country) N (Gold standard)
Overall 
sensitivity1
Sensitivity1 and proportion of specimens (both in %) by category
Immune status Serotype
Day of specimen collection Severity of Illness Viremia (pfu/ml)
1o case 2o case DENV1 DENV2 DENV3 DENV4 Unknown
Osorio (2010/Colombia) 212 (isolation, RT-PCR, 
serology)
70.8% 83-902 (29.4) 40-502 
(70.6)
80-902 
(27.4)
50-602 (20) 80-902 
(43.7)
40-502 
(8.9)
exact data not 
available
day 1-3:70-802 (NA), day 4-7 60-702 
(NA)
Non Severe: 70-802 
(75.7), 
Severe: 50-602 
(24.3)
NA
Libraty (2002/Thailand) 32 (RT-PCR) 81.3% 0 81.3 (100) 0 81.3 (100) 0 0 0 NA DF: 71(43.8), 
DHF I,II,III: 89(56.3)
associated with NS1 
level which is higher in 
DHF than DF
Guzman (2010/multiple) 1284 (isolation, RT-
PCR, serology)
66% (34-76%) ND ND 87 (32.3) 63 (20) 82 (11.1) 79 (3.7) 43.4 (37) Latin America2, day2: 40-50, day3: 
60-70, day 4: 60-80, day 5: ND, day 6: 
ND; Southeast Asia2, day2: 70-80, 
day3: 70-80, day 4: 60-70, day 5: 50-
60, day 6: 30-40
Latin America: 
DF 41, DHF 68; 
Southeast Asia: 
DF: 70, 
DHF: 68
NA
Hang (2009/Vietnam) 125 (RT-PCR or 
serology)
83.2% 95.8 (19) 78.5 (74) 98 (50.4) 55 (20) 96 (25) ND (2.4) ND (11.2) day 0-3 90.6 (60), day 4-6 70 (40) NA Significantly higher in 
NS1 positive patients
Najioullah (2011/
Martinique)
264 (RT-PCR) 61.2% 85 (28.6) 48 (71.4) 0 61.2 (100) 0 0 0 day 1-5: 64.4 (NA), day 6: 37.9 (NA), 
day 7-8: 61.9 (NA)
NA NA
Chaterji (2011/Singapore) 154 (isolation, RT-
PCR)
80.5% 94.7 (48.7) 67.1 (51.3) 79.6 (35.1) 73.9 (29.9) 87 (35.1) 0 0 day 1: 64.1 (25.3), day 2: 82.8 (37.7), 
day 3: 89.5 (37), An increased 
sensitivity for secondary infection 
between days 0 and 3
NA NA
Thomas (2010/Martinique) 67 (RT-PCR) 67.1% 69.2 (74.2) 61.5 (25.7) 0 61.9 (30) 0 69.4 (70) 0 day 1-3: 69.4 (70), day 4: 61.9 (30) The proportion of 
NS1 was prolonged 
in secondary or 
severe infections
NS1+ correlated with 
viral loads
Blacksell (2008/Laos) 38 (RT-PCR, serology) 63.2% 75 (10.5) 60.1 (89.5) 77.8
(23.7)
60
(13.2)
0
(5.3)
66.7 (23.7) 61.5 (34.2) day 1-4: 76.9 (16.5)
day 5-7: 75 (83.5)
NA NA
Lima (2010/Brazil) 220 (isolation, RT-PCR 
+ serology)
83.6% 95 (74.1) 71.4 (25.9) 98
(22.7)
90 (22.7) 86.2 (26.4) 0 64.5 (28.2) day 1-4: >80 (N/A), day 5-7: 75 (N/A) NA NA
Lapphra (2008/Thailand) 171 (isolation, RT-PCR, 
serology)
63.2% 76.9 (7.6) 64.5 (92.4) NA NA NA NA N/A Not associate with days of fever 
(63.2-75.7)
DF: 65.1 (88.3); 
DHF: 68.4 (11.7)
NA
Kumarasamy (2009/
Malaysia)
213 (isolation, RT-
PCR)
93.4% 97.3 (86.4) 70 (13.6) NA NA NA NA 0 NA NA NA
Bessoff (2008/Puerto Rico) 208 (RT-PCR or 
isolation)
83.2% 98.3 (27.9) 77.3 (72.1) 92.9
(26.9)
82.2 (21.6) 86.5 (25) 70.9 (26.4) 0 day 1: 70-80, day 2: 80-100, day 3: 
70-80, day 4: 70-80, day 5: 80-100
NA Not related to NS1 
positvity
Tricou (2010/Vietnam) 245 (RT-PCR) 61.6% 80.3 (27.3) 55.1 (72.7) NA
(56.3)
NA (37.6) NA (6.6) 0 0 ≤day 3: 60.9 (63.7), > day 3: 62.9 
(36.3)
NA NS1 + samples 
significantly higher 
viremia than NS1-
Dussart (2008/French 
Guaina)
272 (isolation, RT-
PCR)
87.4% 
(serotyped 
samples)
96.3 (40.1) 73 (59.9) 90.9
(12.1)
85.7 (15.4) 87.1 (37.1) 87 (16.9) 60 (18.4) day 0-3 89.7 (72.1) NA NA
Duong (2011/Cambodia) 243 (isolation, RT-PCR, 
NS1, serology)
57.5% 87.5 (14.5) 53.5 (85.5) 80
(21)
60 (4) 63.6 (46.5) 53.3 (5.8) 8.5 (22.7) day 1-2 81 (8.8), day 3 60-80 (23), 
day 4 60-80(32.2), day 5 40-60 (20.1), 
day 6 20-40 (11.3), day 7-8 <20 (4.6)
DF 72.3 (39), DHF/
DSS 40.2 (35.8), 
Indeterminate 
NA (28)
NS1+ significantly 
higher in subjects with 
high viremia
Table S1.  NS1 Study Results
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Author (Year/Country) N (Gold standard)
Overall 
sensitivity1
Sensitivity1 and proportion of specimens (both in %) by category
Immune status Serotype
Day of specimen collection Severity of Illness Viremia (pfu/ml)
1o case 2o case DENV1 DENV2 DENV3 DENV4 Unknown
Osorio (2010/Colombia) 212 (isolation, RT-PCR, 
serology)
70.8% 83-902 (29.4) 40-502 
(70.6)
80-902 
(27.4)
50-602 (20) 80-902 
(43.7)
40-502 
(8.9)
exact data not 
available
day 1-3:70-802 (NA), day 4-7 60-702 
(NA)
Non Severe: 70-802 
(75.7), 
Severe: 50-602 
(24.3)
NA
Libraty (2002/Thailand) 32 (RT-PCR) 81.3% 0 81.3 (100) 0 81.3 (100) 0 0 0 NA DF: 71(43.8), 
DHF I,II,III: 89(56.3)
associated with NS1 
level which is higher in 
DHF than DF
Guzman (2010/multiple) 1284 (isolation, RT-
PCR, serology)
66% (34-76%) ND ND 87 (32.3) 63 (20) 82 (11.1) 79 (3.7) 43.4 (37) Latin America2, day2: 40-50, day3: 
60-70, day 4: 60-80, day 5: ND, day 6: 
ND; Southeast Asia2, day2: 70-80, 
day3: 70-80, day 4: 60-70, day 5: 50-
60, day 6: 30-40
Latin America: 
DF 41, DHF 68; 
Southeast Asia: 
DF: 70, 
DHF: 68
NA
Hang (2009/Vietnam) 125 (RT-PCR or 
serology)
83.2% 95.8 (19) 78.5 (74) 98 (50.4) 55 (20) 96 (25) ND (2.4) ND (11.2) day 0-3 90.6 (60), day 4-6 70 (40) NA Significantly higher in 
NS1 positive patients
Najioullah (2011/
Martinique)
264 (RT-PCR) 61.2% 85 (28.6) 48 (71.4) 0 61.2 (100) 0 0 0 day 1-5: 64.4 (NA), day 6: 37.9 (NA), 
day 7-8: 61.9 (NA)
NA NA
Chaterji (2011/Singapore) 154 (isolation, RT-
PCR)
80.5% 94.7 (48.7) 67.1 (51.3) 79.6 (35.1) 73.9 (29.9) 87 (35.1) 0 0 day 1: 64.1 (25.3), day 2: 82.8 (37.7), 
day 3: 89.5 (37), An increased 
sensitivity for secondary infection 
between days 0 and 3
NA NA
Thomas (2010/Martinique) 67 (RT-PCR) 67.1% 69.2 (74.2) 61.5 (25.7) 0 61.9 (30) 0 69.4 (70) 0 day 1-3: 69.4 (70), day 4: 61.9 (30) The proportion of 
NS1 was prolonged 
in secondary or 
severe infections
NS1+ correlated with 
viral loads
Blacksell (2008/Laos) 38 (RT-PCR, serology) 63.2% 75 (10.5) 60.1 (89.5) 77.8
(23.7)
60
(13.2)
0
(5.3)
66.7 (23.7) 61.5 (34.2) day 1-4: 76.9 (16.5)
day 5-7: 75 (83.5)
NA NA
Lima (2010/Brazil) 220 (isolation, RT-PCR 
+ serology)
83.6% 95 (74.1) 71.4 (25.9) 98
(22.7)
90 (22.7) 86.2 (26.4) 0 64.5 (28.2) day 1-4: >80 (N/A), day 5-7: 75 (N/A) NA NA
Lapphra (2008/Thailand) 171 (isolation, RT-PCR, 
serology)
63.2% 76.9 (7.6) 64.5 (92.4) NA NA NA NA N/A Not associate with days of fever 
(63.2-75.7)
DF: 65.1 (88.3); 
DHF: 68.4 (11.7)
NA
Kumarasamy (2009/
Malaysia)
213 (isolation, RT-
PCR)
93.4% 97.3 (86.4) 70 (13.6) NA NA NA NA 0 NA NA NA
Bessoff (2008/Puerto Rico) 208 (RT-PCR or 
isolation)
83.2% 98.3 (27.9) 77.3 (72.1) 92.9
(26.9)
82.2 (21.6) 86.5 (25) 70.9 (26.4) 0 day 1: 70-80, day 2: 80-100, day 3: 
70-80, day 4: 70-80, day 5: 80-100
NA Not related to NS1 
positvity
Tricou (2010/Vietnam) 245 (RT-PCR) 61.6% 80.3 (27.3) 55.1 (72.7) NA
(56.3)
NA (37.6) NA (6.6) 0 0 ≤day 3: 60.9 (63.7), > day 3: 62.9 
(36.3)
NA NS1 + samples 
significantly higher 
viremia than NS1-
Dussart (2008/French 
Guaina)
272 (isolation, RT-
PCR)
87.4% 
(serotyped 
samples)
96.3 (40.1) 73 (59.9) 90.9
(12.1)
85.7 (15.4) 87.1 (37.1) 87 (16.9) 60 (18.4) day 0-3 89.7 (72.1) NA NA
Duong (2011/Cambodia) 243 (isolation, RT-PCR, 
NS1, serology)
57.5% 87.5 (14.5) 53.5 (85.5) 80
(21)
60 (4) 63.6 (46.5) 53.3 (5.8) 8.5 (22.7) day 1-2 81 (8.8), day 3 60-80 (23), 
day 4 60-80(32.2), day 5 40-60 (20.1), 
day 6 20-40 (11.3), day 7-8 <20 (4.6)
DF 72.3 (39), DHF/
DSS 40.2 (35.8), 
Indeterminate 
NA (28)
NS1+ significantly 
higher in subjects with 
high viremia
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ABSTRACT
Chikungunya virus (CHIKV) is known to cause sporadic or explosive outbreaks. 
However, little is known about the endemic transmission of CHIKV. To ascertain 
the endemic occurrence of CHIKV transmission, we tested blood samples from 
patients with a non-dengue febrile illness who participated in a prospective 
cohort study of factory workers in Bandung, Indonesia. From August 2000 to 
June 2004, and September 2006 to April 2008, 1901 febrile episodes occurred 
and 231 (12.2%) dengue cases were identified. The remaining febrile cases were 
evaluated for possible CHIKV infection by measuring anti-CHIKV IgM and IgG 
antibodies in acute and convalescent samples. Acute samples of serologically 
positive cases were subsequently tested for the presence of CHIKV RNA by RT-
PCR and/or virus isolation. A total of 135 (7.1%) CHIKV infections were identified, 
providing an incidence rate of 10.1/1,000 person years. CHIKV infections 
were identified all year round and tended to increase during the rainy season 
(January to March). Severe illness was not found and severe arthralgia was not a 
prominently reported symptom. Serial post-illness samples from nine cases were 
tested to obtain a kinetic picture of IgM and IgG anti-CHIKV antibodies. Anti-
CHIKV IgM antibodies were persistently detected in high titers for approximately 
one year. Three patients demonstrated evidence of possible sequential CHIKV 
infections. The high incidence rate and continuous chikungunya cases in this 
adult cohort suggests that CHIKV is endemically transmitted in Bandung. Further 
characterization of the circulating strains and surveillance in larger areas are 
needed to better understand CHIKV epidemiology in Indonesia.
SUMMARY
Chikungunya is one of the neglected diseases. It has only attracted attention 
during outbreaks, in particular, the large epidemics in the Indian Ocean in 2005-
2006. To our knowledge, there has never been any surveillance to determine 
the transmission of this virus among humans in non-outbreak settings. Such 
surveillance is particularly important because it will provide a better estimate 
of the disease burden and valuable information on how this virus is maintained 
outside outbreaks. Our study, conducted between 2000 and 2008 in Bandung, 
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West Java, Indonesia, yielded several important findings. 1. Chikungunya is an 
important cause of fever among adults in Bandung, Indonesia. 2. The clinical 
symptoms are mostly mild and short lasting. 3. In addition to previously described 
epidemiological features involving episodic outbreaks, it is also continuously 
transmitted throughout the year. 4. A few patients may have experienced more 
than one chikungunya virus infection. 5. Only the Asian genotype was found and 
not the East Central South African genotype that was responsible for the 2005 
outbreak in the Indian Ocean. 6. The persistence of IgM for a long period after 
illness may complicate the interpretation of laboratory results. 
INTRODUCTION
Chikungunya virus (CHIKV) is an arthropod-borne virus belonging to the genus 
Alphavirus in the family Togaviridae [1]. CHIKV causes an acute illness similar to 
dengue, characterized by fever, headache, nausea, vomiting, abdominal pain, 
myalgia, rash and arthralgia [2]. Arthralgia of the large joints may be severe and 
long lasting [3]. CHIKV was first identified in Tanzania in 1952 [4]. Over the next 
decades, it remained a relatively rare disease causing mostly small outbreaks in 
both Africa and Asia [2]. This changed dramatically after a mutation in the CHIKV 
E1 glycoprotein gene (A226V) occurred. This mutation enhanced the infectivity 
of the virus and its transmission by Aedes albopictus [5]. In 2005, the mutated 
CHIKV spread from the Indian Ocean where it produced large epidemics in India, 
Southeast Asia and Italy [6-9]. 
CHIKV in Africa is predominantly maintained in an inter-epidemic sylvatic cycle 
in which the virus resides in wild primates and mosquitoes such as Aedes furcifer-
taylori and Aedes africanus. In Asia, Aedes aegypti, an anthrophophilic mosquito 
that lives in proximity with humans, has been the most significant vector [10]. In 
contrast, for the mutated CHIKV that caused the recent epidemic in the Indian 
Ocean, Aedes albopictus is the main vector [5]. 
In Indonesia, chikungunya was first reported in 1982 in East Sumatera. It then 
spread to other islands including Java, Kalimantan, Bali, Flores and Sulawesi [11]. 
After a hiatus of 15 years, sporadic outbreaks were reported simultaneously in 
several provinces on the island of Java in 2000-2002 [11]. 
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Since then, clusters of cases have been reported sporadically from several 
provinces although the total number of cases reported has never exceeded 
5,000 per year [12,13]. This number should be interpreted with caution, however, 
because similarities in symptoms between dengue and chikungunya [2] and 
logistic constraints in viral diagnostics in Indonesia [14] may have resulted in a 
gross underestimation of the incidence of chikungunya [15]. To better define the 
disease burden of chikungunya, active surveillance during non-outbreak periods 
is necessary. However, to our knowledge, no such studies have been conducted 
elsewhere. Therefore, to determine CHIKV transmission during inter-epidemic 
periods and the epidemiology of CHIKV infections in Indonesia, we analyzed 
the demographic, clinical and virological data collected from non-dengue acute 
febrile patients participating in a prospective adult cohort dengue study that 
was conducted in Bandung, West Java, Indonesia from 2000-2004 and 2006-
2008.
MATERIALS AND METHODS
STUDY DESIGN
This study was a part of “An epidemiology study of dengue and dengue 
hemorrhagic fever in adults”, approved by the Institutional Review Board of 
NAMRU#2, Jakarta (IRB#30855 and N2.2006.0001) and the National Institute of 
Health Research and Development (NIHRD), Ministry of Health, Indonesia (KS 
02.02.2.1.2181, KS 02.01.2.1732 and KS.02.01.2.1.2776) in compliance with all 
U.S. Federal Regulations governing the protection of human subjects. Details of 
the study design are described elsewhere [16]. In brief, it was a textile factory-
based prospective cohort study conducted in Bandung, West Java, Indonesia, a 
city that has more than 2 million inhabitants. The study was conducted in two 
phases, 2000-2004 and 2006 – 2008. Phase 1 was carried out in factories A and B, 
and phase 2 was carried out in factories A and C. A cohort of 2978 volunteers was 
maintained during the first phase and 2726 during the second phase with 44.5% 
of volunteers from cohort 1 also participating in cohort 2. All volunteers gave 
written informed consent prior to enrollment. During enrollment, demographic 
and health status data were obtained and baseline blood specimens were 
collected. On a quarterly basis, surveys were conducted, and blood samples 
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were taken to examine the volunteers’ dengue serological status. Between each 
survey, volunteers who experienced fever came to the factory clinic where a 
clinical evaluation was performed and acute and convalescent (at least 7 days 
apart) blood specimens were collected. Specimens were immediately tested for 
dengue using a battery of dengue diagnostic assays [16]. Patients were advised 
to be hospitalized at the discretion of the attending physician or if their platelet 
count was less than 150,000/mm3. Once a dengue infection was excluded, the 
samples were tested for evidence of CHIKV infection as described below. During 
phase 1 of the study, volunteers were not questioned about arthralgia and data 
concerning arthralgia was obtained when this symptom was a chief or other 
complaint during their illness or during post-illness serosurveys. During phase 2 
of the study, volunteers were specifically asked about arthralgia. There were no 
other differences in symptom ascertainment between phase 1 and 2. 
DIAGNOSIS OF CHIKV INFECTIONS
Convalescent sera from febrile volunteers who had been excluded as dengue 
cases were first tested to detect CHIKV IgM antibodies using enzyme-linked 
immunosorbent assay (ELISA). When positive, paired acute and convalescent 
sera were further tested for CHIKV IgM and IgG antibodies using an ELISA, and 
acute sera were processed for viral isolation and/or tested by RT-PCR to detect 
CHIKV genomes. CHIKV infection was confirmed when CHIKV genome or virus 
was detected, or when either seroconversion or a four-fold rise in titers of anti-
CHIKV IgM and IgG antibodies was detected. 
CHIKV IgM and IgG ELISA
Serum samples were assayed for the presence of IgG and IgM antibodies 
against CHIKV using ELISA as previously described [14,17]. The CHIK antigen was 
prepared from Vero E6 cell culture infected with CHIKV 23574, an Asian lineage 
virus isolated from CHIK infected patient. Uninfected Vero E6 cell culture was 
used as negative antigen. For detection of CHIK IgM, 96- well microtiter plates 
(Immulon 2, Dynex Technologies, Chantilly, VA) were coated with anti-human 
IgM antibodies (Kirkegaard and Perry, Gaithersburg, MD). Excess antibodies were 
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washed with 0.1% Tween Phosphate-buffered saline (PBS). Serum was diluted 
1:100 in dilution buffer (PBS, 0.1% Tween-20, and 5% skim milk), and incubated 
at 37ºC for one hour. Plates were then washed and antigens were added. 
After incubation, anti-CHIK hyperimmune mouse ascitic fluid and horseradish 
peroxidase-conjugated anti-mouse IgG (Kirkegaard and Perry, Gaithersburg, 
MD) were used to detect IgM specific to CHIKV. ABTS substrate was allowed to 
react for one hour and absorbance was determined at 415 nm. For the detection 
of CHIK specific IgG antibodies, a 96-well microtiter plate was coated directly 
with cell lysate antigens diluted in PBS. Horseradish peroxidase conjugated 
mouse anti-human IgG Fc (Kirkegaard and Perry, Gaithersburg, MD), and ABTS 
were used to detect bound antibody. The adjusted optical density value (OD) for 
each sample was determined by subtracting the OD obtained with the negative 
antigen from the OD obtained using the CHIK antigen. A sample was considered 
positive if its OD value exceeded the mean plus three standard deviations of 
the normal control sera. The endpoint of antibody titers was determined by 
testing ELISA-positive samples at serial two-fold dilutions starting from 1:100. 
The highest dilution showing a positive result was considered the endpoint titer. 
It has previously been established that our CHIK immunoassay does not show 
immunoreactivity against Ross River virus [17]. 
The kinetics of IgM and IgG antibodies to CHIKV were analyzed using specimens 
from the first nine patients who had complete serial quarterly serosurvey sera 
for two years. 
Virus isolation and CHIKV RT-PCR
Acute sera from cases diagnosed by seroconversion or a four-fold increase of 
anti-CHIKV IgM and IgG antibody titers were processed for virus isolation and 
analysis by RT-PCR. The methods used to perform these assays have been 
described previously [14,17]. For virus isolation, serum samples were diluted 1:10 
in PBS and applied to confluent monolayers of C6/36 cells in 24-well culture 
plates (Corning, New York). The plates were centrifuged at 400g for 45 minutes 
and then 1 ml of medium (MEM) added. The plates were then incubated at 30ºC 
for 14 days and observed daily for evidence of cytopathic effects (CPE). At the end 
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of 14 days or upon recognition of CPE, cells were removed from the plates and 
evaluated for the presence of virus by standard immunofluorescence assay using 
anti-CHIK hyperimmune mouse ascitic fluid and FITC conjugated anti-mouse IgG 
(Kirkegaard and Perry, Gaithersburg, MD). For RT-PCR, viral RNA was extracted 
using a QIAamp Viral RNA Isolation Kit (QIAGEN, Hilden, Germany). RNA was 
then used in a nested RT-PCR assay using JM1 (5’ GCAGAC GCAGAGAGGGCCAG 
3’; bp 1,201 to 1,220) and JM2 (5’ CGTGCTGCAAGG TAGTTCTC 3’; bp 1,440 to 
1,421) primers. A second nested PCR was performed using the product from 
the first reaction and primers JM3 (5’ GCTATTTGTAAGAAC GTCAG 3’; bp 1,221 to 
1,240) and JM4 (5’ TACCGTGCTGCGGTCGGGAA 3’; bp 1,420-1,401). Amplified PCR 
products were resolved by electrophoresis on a 2% agarose gel and visualized 
using ethidium bromide.
Genomic Sequencing 
Sequencing of the structural polyprotein coding region of 20 chikungunya virus 
isolates was performed (Genbank accession numbers: KC879559-KC879578), 
using primers that were previously described [18]. Cycle sequencing reactions 
were conducted using the BigDye 3.3 Terminator Ready Reaction mix (Applied 
Biosystems, Carlsbad, California). Cycle sequencing was performed at least twice 
per primer per sample. The sequencing products were separated from unbound 
dye using BigDye X-Terminator (Applied Biosystems) and analyzed on an ABI 
3130 XL Genetic Analyzer (Applied Biosystems). 
Sequence data analysis was performed using Sequencher 3.1 (Genecodes, Ann 
Arbor, MI) with the default parameters to improve the overall sequence quality. 
ClustalX 2.0.9 [19] was used to perform multiple sequence alignment. The 
alignment parameters used were 50 points penalty for gap opening, 2 point 
penalty for gap extension, and all gaps were reset before each alignment. Several 
reference sequences were used for the alignment: six Asian genotype viruses 
(among them a vaccine strain), five East/Central/South African (ECSA) genotype 
viruses, and one West African genotype virus. After obtaining the alignment, 
excess sequence (outside the coding region for the structural proteins) was 
discarded. The phylogenetic tree was constructed using the neighbor-joining 
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method [20] with MEGA4 software [21]ur*C3. The distance model used was the 
Kimura 2 parameter model to correct for multiple substitutions and to account 
for unequal transition/transversion ratio. The tree was constructed with 1000 
bootstrap replicates. 
Statistical analysis
Descriptive data (mean age and standard deviation) were analyzed using STATA 
version 9.0 (StataCorp 2005, College Station, TX). 
RESULTS
Study Population
A total of 4380 volunteers were enrolled into the study, consisting of 1324 
volunteers who joined from the beginning of this study (August 2000), 1654 
who discontinued their participations after the first phase (June 2004) and 1402 
new enrollees in the second phase (September 2006 to April 2008). The mean 
(SD) age and age range of volunteers at enrollment were 37.1 (±7.7) and 18 to 66 
years old. A higher proportion of the study population was male (ratio 1.85: 1). 
Chikungunya Cases
The proportion and incidence rate of chikungunya cases
A total of 1431 acute febrile episodes (AFE) occurred among 2978 volunteers 
in the first phase of the study, which lasted for 47 months. CHIKV infection was 
identified in 96 (6.7%) of these AFE, yielding a yearly incidence rate of 10.1 per 
1,000 persons. During the second phase of the study in which 2726 volunteers 
were followed for 20 months, 39 chikungunya cases were diagnosed among 
470 AFE, resulting in a slightly higher percentage and incidence rate (8.3% and 
10.3/1,000 persons/year). In total, the percentage and incidence rate were 7.1% 
and 10.1/1,000 (persons/year), respectively. The number of chikungunya cases 
per month over the years and the total number of cases per year are shown in 
figure 1. The number of cases remained relatively stable over the years, except for 
two peaks in early 2004 and 2008, when chikungunya accounted for 11.2% and 
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11.7% of the AFE. In contrast, no cases were found in the second half of 2000 and 
only one case in the last four months of 2006. Cases were found almost all year 
round, however November had the lowest number of cases and cases tended 
to increase during the wet season from January to March. Chikungunya cases 
resided throughout the city without apparent clustering by residence although 
the majority of cases were from the subdistricts near the factories where most 
workers lived (data not shown).
Figure 1.  Monthly, annual total number and annual incidence rates for laboratory confirmed 
chikungunya (CHIK) cases. 
The number of CHIK cases per month is represented by skinny black rectangles. The total number of cases for a 
year is indicated by light gray rectangles and the incidence rate for a year is indicated by dark gray rectangles. 
The rectangles representing annual data are placed at the midpoint (July) for their respective year.
Chapter 7
122
Diagnosis of CHIKV infections, antibody kinetics and virus sequencing
In 69 (51.1%) of the 135 CHIKV infections, the diagnosis of acute CHIKV infection 
was confirmed by positive RT-PCR, viral isolation and serology results. In 47 
(34.8%) cases the diagnosis was confirmed by positive RT-PCR and serology 
results, while 19 (14.1%) cases only had serological evidence of CHIK infection. 
Of these 19 cases, 10 were negative for RT-PCR and isolation, eight did not have 
RT-PCR performed and one did not have viral isolation performed due to an 
insufficient volume of serum. 
Post-illness sera from nine patients, who had serial specimens taken during 
serosurveys over two years, were tested to evaluate the kinetics of CHIKV IgM 
and IgG antibodies (figure 2A & 2B). These nine patients did not have any anti-
Figure 2A.  Immunokinetics of anti-chikungunya virus IgM
The mean +/- SD titer for each timepoint (W=weeks, M=months) after illness onset. N = the
number of samples for a given timepoint.
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CHIKV IgM or IgG antibodies in their pre-illness samples and IgM antibodies were 
undetectable in the acute specimen of seven of these patients. The two patients 
in which IgM was detectable in the acute sample came to the clinic later in 
disease on day five and seven of illness and had anti-CHIKV IgM titers of 400 and 
3200 respectively. 
In convalescent and late convalescent sera, titers increased strongly, followed by 
a subsequent slow decline thereafter. In most patients (8/9), IgM antibodies were 
detectable for a long period after acute infection, ranging from 5-22 months. In 
one patient, the IgM titer became undetectable three months after the onset 
of illness. The demographic and clinical findings of this patient did not differ 
from the rest. IgG antibodies were not detected in 8 of 9 acute samples while 
Figure 2B.  Immunokinetics of anti-chikungunya virus IgG
The mean +/- SD titer for each timepoint (W=weeks, M=months) after illness onset. N = the number of 
samples for a given timepoint. 
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one sample had a titer of 100. In convalescent sera, which were collected 2-3 
weeks after onset of fever, IgG antibodies were detected at low titers (200-800) 
in 7 of 9 patients and at high titers (1600 and 3200) in two patients. IgG titers 
peaked (6400 to 1:25600 dilution) at 3-4 months after the onset of illness, then 
decreased slightly and remained stable at high titers (1600 to 3200) for two years 
after illness.
CHIKV could be isolated from specimens collected until day 4 of the illness whereas 
RNA was detectable by RT-PCR until 6 days post illness onset. Sequencing analysis 
was performed on 20 isolates from the first and second phases of the study. All 
isolates had alanine at position 226 in the E1 gene. Nucleotide similarity between 
these isolates was >99.4%, and amino acid similarity was >99.7%. A phylogenetic 
tree was constructed based on 1320 bases of the structural polyprotein coding 
region. All samples sequenced from this study clustered together and belong to 
the Asian genotype (figure 3).
Figure 3:   Phylogenetic analysis of the CHIKV isolates. 
Neighbor-joining tree of the structural polyprotein coding regionof CHIKV. The sequences obtained in this 
study are highlighted in bold.Numbers indicate bootstrap values for the groups to the right.
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Clinical manifestations
Most patients came to the clinic on day two or three of fever (57 and 56 patients 
out of 135 patients, respectively). Table 1 lists their clinical manifestations. 
Table 1.  Signs, Symptoms and Laboratory Results for CHIK cases
Symptoms N % Pos 
Myalgia 124/134 92.5
Headache 119/134 88.8
Arthralgia
1st phase 37/95 38.9
2nd phase 34/39 87.2
Nausea 71/134 53.0
Retro-orbital pain 51/134 38.1
Cough 37/134 27.6
Abdominal Pain 33/134 24.6
Sore throat 31/134 23.1
Coryza 31/134 23.1
Rash 17/134 12.7
Vomiting 15/134 11.2
Diarrhea 14/134 10.4
Leukopenia(<4000/mm3) 20/134 14.9
Thrombocytopenia (<150,000/mm3) 15/134 11.2
The most frequent were myalgia (92.5%), headache (88.8%), and arthralgia (38.9% 
during the first phase and 87.2%, during the second phase). Among 34 patients 
with arthralgia in the second phase of the study, the most commonly involved 
joints were the knees (85.3%), shoulders (64.7%), smaller joints and elbow 
(58.8%). The initial working diagnoses made by clinicians during enrollment at 
the health centers in cases with laboratory confirmed chikungunya included 
undifferentiated fever (71.1%), dengue fever (12.6%), upper respiratory tract 
infection (8.1%), typhoid fever (3%), chikungunya fever (1.5%), measles and 
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gastroenteritis (each 0.7%). Clinical manifestations were mostly mild and no 
severe cases occurred. Seven patients (5.2%) were hospitalized because their 
platelet level was under 150,000/mm3, five from the first cohort and two from 
the second cohort. As chikungunya diagnostic assays were not available at the 
hospitals, discharged clinical diagnoses were acute viral infection and dengue 
fever in 5 and 2 patients, respectively. Approximately one third (32.6%) of 
patients did not skip work at all, 36.3% were absent for 1 to 3 days, 19.3% for 4 
to 6 days and 11.9% for more than a week. The average number of days absent 
was 2.7 days.
Evidence of possible recurrent CHIKV infections
We identified two patients with a laboratory confirmed acute CHIKV infection in 
whom serology results on a blood sample collected three months before illness 
suggested a previous CHIKV infection. In the first volunteer, an acute CHIKV 
infection was confirmed by RT-PCR, virus isolation and serology. In the second 
patient, CHIKV infection was confirmed by RT-PCR and serology (Table 2).
Table 2.  Lab results for possible recurrent CHIKV infections
ID Number First infection Second infection
Date of illness Lab results Date of illness Lab results
005-1411 unknown Pre-illness specimen 4 JAN2003 Positive RT-PCR and 
(21 SEP 2002) Isolation
CHIKV IgM: 400 CHIKV IgM: 800 to 400
CHIK IgG: 800 CHIKV IgG: 6400 to 6400
005-2048 unknown Pre-illness specimen 6 MAR2001 Positive RT-PCR
(25 NOV2000) CHIKV IgM: 100 to 400
CHIKV IgM: 400 CHIKV IgG: 3200 to 6400
CHIK IgG: 800
005-1449 11 JUN 2002 Positive RT-PCR and 19 DEC2006 Negative RT-PCR and 
Isolation Isolation
CHIKV IgM: neg to 6400 CHIKV IgM: 400-1600
CHIKV IgG: neg to 100 CHIKV IgG: 1600-6400
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Both patients reported fever, headache and myalgia, but no arthralgia. We 
also identified a 34-year-old male for whom we had evidence of two possible 
chikungunya episodes during our study. The first episode was in June 2002 when 
an acute CHIKV infection was confirmed by positive RT-PCR, virus isolation and 
IgM and IgG sero-conversion; the second episode occurred four and half years 
later and was confirmed by a four-fold rise in IgM (Table 2). For both episodes, 
dengue was excluded as all dengue diagnostic tests were negative. Clinical 
manifestations in both episodes were similar, including high fever, headache, 
sore throat, malaise and bilateral arthralgia. Results from hematology and 
chemistry tests did not show pathognomonic findings.
DISCUSSION
Our studies, conducted between 2000 and 2008 in a large town in West Java, 
Indonesia, revealed several important epidemiological findings, including: 1. 
Among adults, CHIKV was an important cause of acute febrile illness. 2. CHIKV 
infections did not occur in epidemics as commonly reported, but were found 
throughout the year. 3. The clinical symptoms of CHIKV infection in this cohort 
were mostly mild and short-lived. 4. CHIKV infections were caused by the Asian 
genotype and not by the mutated East Central South African strain (ECSA), 
although only a limited number of samples were genotyped. 5. The persistence of 
IgM for a long period after illness may complicate the interpretation of laboratory 
results, and finally 6. We found evidence of possible recurrent CHIKV infections. 
We have previously reported an incidence rate of acute dengue of 18.1 cases per 
1,000 persons per year (15.9% of febrile episodes) in the same cohort in 2000 to 
2002 [16] and our present findings show that the corresponding incidence rate 
of chikungunya in these years was 7.9 cases per 1,000 persons per year (6.9% of 
febrile episodes). In 2004 and 2008, the incidence rates for chikungunya were in 
the same range as those for dengue (data not shown).The overall prevalence of 
CHIK between August 2000 to June 2004 and September 2006 to April 2008 was 
7.1% of febrile episodes, and the overall incidence rate during this time frame 
was 10.1 cases per 1,000 persons per year.
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Another finding of our study was that chikungunya infections were generally 
mild and of short duration. Only two-thirds of cases requested medical leave 
from work, with most only requesting 2-3 days of leave. The percentage 
of chikungunya cases in our study that were hospitalized was significantly 
lower than for the dengue cases detected in our study (unpublished data). 
Additionally, during the first phase of our study, when data on arthralgia was 
not specifically asked, only 38.9% of volunteers reported it as a chief or other 
complaint, suggesting this symptom was minor or absent. Also, we did not 
find volunteers with prolonged illness or complications. Similar to our clinical 
findings, mild chikungunya cases were also reported among young migrant 
workers in Singapore during a 2008 outbreak [22]. This is in contrast to what 
was reported in previous outbreaks where debilitating arthralgia was a frequent 
symptom in acute disease, sometimes persisting for months to even years [23-
25] and in the recent La Reunion and India outbreaks where severe disease with 
neurological involvement was also reported [26,27].
Genotyping of the CHIKV in twenty patients showed that infections were caused 
by the Asian genotype and not the ECSA genotype, which was responsible 
for the 2005 outbreak in the Indian Ocean and has since then spread to India 
and Southeast Asia, causing unprecedented nationwide outbreaks in Malaysia, 
Singapore and Thailand [7]. The detection of the ECSA genotype has not 
been reported in Indonesia and the Asian genotype was the only genotype 
identified in Taiwan travelers returning from Indonesia in 2007-2008 [28] and 
in hospitalized patients in Surabaya in 2011 [15]. As ECSA genotype has been 
detected elsewhere in Southeast Asia [18,29-31], this genotype may have 
circulated in Indonesia as well, but remains unidentified as routine chikungunya 
surveillance has not been established. Still little is known about differences in 
clinical presentation and epidemiology between infections caused by the Asian 
and the ECSA genotype. Our findings suggest that the illness caused by this 
Asian genotype is often relatively mild and that infections occur year round in 
Bandung, Indonesia. Interestingly, infections by the same Asian genotype that 
were reported in travelers returning from Indonesia [32] and during outbreaks 
in Indonesia [11,17] appear to be associated with more severe disease. Selection 
bias, whereby chikungunya was only considered in those with more severe 
disease, and differences in the CHIKV strains that circulate during the inter-
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epidemic period and those causing outbreaks and/or severe illness might 
explain these differences. Another plausible explanation of mostly mild cases in 
our study was the young adult population in contrast to children or the elderly 
who commonly experience severe illness [33-35].
According to our literature review, CHIKV infections have commonly been 
associated with outbreaks [7] and many countries reported a long hiatus 
between outbreaks, for example 32 years in India, 15 years in Indonesia and 7 
years in Malaysia [11,36,37]. To the best of our knowledge, our study is the first 
to report year round CHIKV infections over several years. As such, it provides 
a better understanding of how CHIKV is maintained in the population. It was 
speculated that unreported infections were also the cause of an outbreak in 
Malaysia in 2006 [36]. One of the reasons chikungunya is not reported is the 
difficulty in distinguishing chikungunya clinically from other infections, such 
as dengue [2,38]. This may be especially challenging when arthralgia, which 
is considered a pathognomonic symptom of chikungunya, is not a prominent 
clinical feature. Moreover, chikungunya is generally perceived to occur only in 
outbreaks [39]. The limited sensitivity of currently available rapid diagnostic 
tests for chikungunya and the long persistence of CHIKV IgM antibodies may 
further complicate the correct diagnosis of chikungunya [14,40]. Advanced 
diagnostic tools such as virus isolation and RT-PCR are generally only available 
in large hospitals or research institutions. In our study, chikungunya cases were 
identified almost every month throughout the year from 2001-2004 and 2006-
2008. The peak of chikungunya cases was during or after the monsoon season 
when the population of Aedes aegypti is abundant. This finding is consistent with 
previous reports from other countries [41-43]. In addition, acute chikungunya 
infections were still detected, albeit at a lower frequency, during the dry season, 
suggesting that virus transmission was maintained during this period. This is not 
surprising as Aedes aegypti and albopictus were found abundantly in Bandung 
and elsewhere in Indonesia throughout the year despite extensive eradication 
efforts [11,44-47]. Based on the data from this study, we did not observe any 
clustering or focused geographical transmission (data not shown).
One of the powerful features of our prospective cohort study was that volunteers 
were followed for several years. Therefore, we were able to observe the kinetics 
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of CHIKV IgM and IgG antibodies longitudinally after infection. Our finding that 
IgM antibodies could be detected beyond one year was consistent with previous 
reports [41,48]. In a returning traveler from La Reunion Island, IgM antibodies 
remained detectable after two years and this was associated with persistent 
arthralgia [48]. In our study, among nine patients observed, IgM antibodies 
disappeared between five months and 19 months (median of 10 months) after 
infection. Post-illness sera were collected during programmed serosurveys 
and not related to any febrile episodes, arguing against the possibility that the 
high titers of anti-CHIKV antibodies were induced by a nonspecific polyclonal 
activation after unrelated infections. 
Persistence of IgM antibodies also has consequences for diagnostics. In the 
absence of virus culture or RT-PCR, IgM and IgG serology assays should be 
conducted using paired sera collected at least 10 days apart to confirm the 
increasing titers. We also identified three patients (2%) with symptomatic 
CHIKV infections with laboratory features suggestive of possible secondary 
chikungunya infection, which, to our knowledge, has not yet been reported. 
Indeed, the current dogma holds that CHIKV infection will provide life-long 
immunity [49]. In one of these three patients, the RT-PCR for CHIKV was negative 
and the diagnosis of an acute chikungunya infection was based on a rapid 
increase in both IgM and IgG. This rapid increase in IgM and IgG, which also may 
have resulted in rapid virus clearance, was different from the kinetics of IgM and 
IgG antibodies during primary infections. IgM antibodies in primary infections 
were often not detected in acute sera or only identified in low titers, followed 
by a rapid increase during convalescence, when IgG antibodies first became 
detectable. We could not perform sequence analysis to identify the differences 
between CHIKV isolates in primary and secondary infections because, in two 
cases, the first infections occurred prior to their participation in this study while 
in the third case, CHIKV could be isolated only from the first infection. Cross-
reactivity with viruses belonging to the Semliki group is a potential explanation. 
However, Ross River and O’nyong nyong viruses have never been reported in 
Indonesia and our CHIKV IgM immunoassay does not show immunoreactivity 
with the Ross River virus [17]. 
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In the absence of virological data from human cases or mosquitoes due to the 
scarcity of chikungunya research in Indonesia, we speculate that these three 
patients in Bandung were re-infected by different CHIKV strains. Further studies 
are needed to confirm this hypothesis, including close longitudinal observation 
of those who experienced first CHIKV infections and performance of plaque 
reduction neutralization tests, which were not available in our laboratory due to 
the BSL-3 containment requirement.
Our study has some limitations. First, data on arthralgia as a symptom during 
the first phase of the study was collected based on passive reports from 
patients during their visits. On the other hand, it may also provide us some 
information regarding the percentage of patients who consider arthralgia as 
a prominent symptom. Listing arthralgia as one of the subjective symptoms 
that should be routinely included in questionnaires during acute illness may 
unintentionally increase the likelihood of subjects endorsing this symptom. 
Second, as mentioned above, the diagnosis of previous infections in two cases 
and recurrent infection in one case was based solely on results obtained by 
ELISA. Detecting the presence of virus either by tissue culture isolation or RT-
PCR, or performing plaque reduction neutralization assays on the serum samples 
would have provided more definitive evidence for recurrent infections.
In conclusion, our findings provide an estimate of the disease burden of CHIKV 
infections in Bandung, Indonesia and especially provide new information on its 
endemic transmission during inter-epidemic periods. These data highlight the 
importance of considering chikungunya in the differential diagnoses of acute 
febrile illnesses. Further studies are required to determine the significance of 
persistent IgM antibodies and the relation to arthralgia, the possibility of repeat 
CHIKV infections and the differences between strains in their potential to cause 
severe illness and epidemic versus endemic transmission. In addition, national 
surveillance needs to be established to monitor for the possible introduction 
of the ECSA genotype into Indonesia, as the transmission of this genotype may 
have a greater impact on public health. Finally, our findings highlight the need 
for development of affordable and sensitive rapid antigen diagnostic tests for 
early diagnosis of CHIKV infections and the need for a vaccine, especially since 
vector control has been unsuccessful so far.
Chapter 7
132
ACKNOWLEDGEMENTS
We would like to thank all volunteers for their valuable working hours, Dr Ardini 
Raksanegara and Ms Hodijah at the factory clinics, research teams from the Faculty 
of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital and NAMRU#2 for 
their dedication to this study, Wibowo Arindrarto for his work on chikungunya 
sequencing of 2001-2004 isolates, Kendra Chittenden from USAID Indonesia and 
Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) for their 
support during the preparation of this manuscript. 
Evidence for endemic chikungunya virus infections in Bandung, Indonesia
133
7
References
1. Schwartz O, Albert ML (2010) Biology and pathogenesis of chikungunya virus. Nat 
Rev Microbiol 8: 491-500.
2. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT (2012) Chikungunya: a re-
emerging virus. Lancet 379: 662-671.
3. Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, et al. (2008) Persistent 
Arthralgia Associated with Chikungunya Virus: A Study of 88 Adult Patients on 
Reunion Island. Clinical Infectious Diseases 47: 469-475.
4. Robinson M (1955) An epidemic of virus disease in Southern Province, Tanganyika 
Territory, in 1952–53. I. Clinical features. Trans R Soc Trop Med Hyg 49: 28–32.
5. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S (2007) A Single Mutation in 
Chikungunya Virus Affects Vector Specificity and Epidemic Potential. PLoS Pathog 3: 
e201.
6. Kumar NP, Joseph R, Kamaraj T, Jambulingam P (2008) A226V mutation in virus during 
the 2007 chikungunya outbreak in Kerala, India. J Gen Virol 89: 1945-1948.
7. Pulmanausahakul R, Roytrakul S, Auewarakul P, Smith DR (2011) Chikungunya in 
Southeast Asia: understanding the emergence and finding solutions. International 
journal of infectious diseases : IJID : official publication of the International Society for 
Infectious Diseases 15: e671-e676.
8. Yap G, Pok KY, Lai YL, Hapuarachchi HC, Chow A, et al. (2010) Evaluation of Chikungunya 
diagnostic assays: differences in sensitivity of serology assays in two independent 
outbreaks. PLoS Negl Trop Dis 4: e753.
9. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, et al. (2007) Infection with 
chikungunya virus in Italy: an outbreak in a temperate region. The Lancet 370: 1840-
1846.
10. Vazeille M, Moutailler S, Pages F, Jarjaval F, Failloux AB (2008) Introduction of Aedes 
albopictus in Gabon: what consequences for dengue and chikungunya transmission? 
Trop Med Int Health 13: 1176-1179.
11. Laras K, Sukri NC, Larasati RP, Bangs MJ, Kosim R, et al. (2005) Tracking the re-
emergence of epidemic chikungunya virus in Indonesia. Trans R Soc Trop Med Hyg 
99: 128-141.
12. Pusdatin (2009) Profil Kesehatan Indonesia 2008. Departemen Kesehatan Republik 
Indonesia: 47-48.
13. Pusdatin (2008) Profil Kesehatan Indonesia 2007. Departemen Kesehatan Republik 
Indonesia: 45.
14. Kosasih H, Widjaja S, Surya E, Hadiwijaya S, Butarbutar DPR, et al. (2012) Evaluation 
Chapter 7
134
of two IgM rapid immunochromatographic tests during circulation of Asian lineage 
Chikungunya virus. Southeast Asian Journal of Tropical Medicine and Public Health 
43: 55-61.
15. Mulyatno KC, Susilowati H, Yamanaka A, Soegijanto S, Konishi E (2012) Primary 
isolation and phylogenetic studies of Chikungunya virus from Surabaya, Indonesia. 
Jpn J Infect Dis 65: 92-94.
16. Porter KR, Beckett CG, Kosasih H, Tan RI, Alisjahbana B, et al. (2005) Epidemiology of 
Dengue and Dengue Hemorrhagic Fever in a Cohort of Adults Living in Bandung, 
West Java, Indonesia. 72: 60-66.
17. Porter KR, Tan R, Istary Y, Suharyono W, Sutaryo, et al. (2004) A serological study of 
Chikungunya virus transmission in Yogyakarta, Indonesia: evidence for the first 
outbreak since 1982. Southeast Asian J Trop Med Public Health 35: 408-415.
18. Ng LC, Tan LK, Tan CH, Tan SS, Hapuarachchi HC, et al. (2009) Entomologic and 
virologic investigation of Chikungunya, Singapore. Emerg Infect Dis 15: 1243-1249.
19. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, et al. (2003) Multiple sequence 
alignment with the Clustal series of programs. Nucleic Acids Res 31: 3497-3500.
20. Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing 
phylogenetic trees. Mol Biol Evol 4: 406-425.
21. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics 
Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
22. Win MK, Chow A, Dimatatac F, Go CJ, Leo YS (2010) Chikungunya fever in Singapore: 
acute clinical and laboratory features, and factors associated with persistent 
arthralgia. J Clin Virol 49: 111-114.
23. Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, et al. (2008) Persistent 
arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion 
island. Clin Infect Dis 47: 469-475.
24. Larrieu S, Pouderoux N, Pistone T, Filleul L, Receveur MC, et al. (2010) Factors associated 
with persistence of arthralgia among Chikungunya virus-infected travellers: report of 
42 French cases. J Clin Virol 47: 85-88.
25. Chopra A, Anuradha V, Ghorpade R, Saluja M (2012) Acute Chikungunya and persistent 
musculoskeletal pain following the 2006 Indian epidemic: a 2-year prospective rural 
community study. Epidemiol Infect 140: 842-850.
26. Chandak NH, Kashyap RS, Kabra D, Karandikar P, Saha SS, et al. (2009) Neurological 
complications of Chikungunya virus infection. Neurol India 57: 177-180.
27. Tournebize P, Charlin C, Lagrange M (2009) [Neurological manifestations in 
Chikungunya: about 23 cases collected in Reunion Island]. Rev Neurol (Paris) 165: 
48-51.
Evidence for endemic chikungunya virus infections in Bandung, Indonesia
135
7
28. Huang JH, Yang CF, Su CL, Chang SF, Cheng CH, et al. (2009) Imported chikungunya 
virus strains, Taiwan, 2006-2009. Emerg Infect Dis 15: 1854-1856.
29. Duong V, Andries AC, Ngan C, Sok T, Richner B, et al. (2012) Reemergence of 
Chikungunya virus in Cambodia. Emerg Infect Dis 18: 2066-2069.
30. Sam IC, Chan YF, Chan SY, Loong SK, Chin HK, et al. (2009) Chikungunya virus of Asian 
and Central/East African genotypes in Malaysia. J Clin Virol 46: 180-183.
31. Theamboonlers A, Rianthavorn P, Praianantathavorn K, Wuttirattanakowit N, 
Poovorawan Y (2009) Clinical and molecular characterization of chikungunya virus in 
South Thailand. Jpn J Infect Dis 62: 303-305.
32. Mizuno Y, Kato Y, Takeshita N, Ujiie M, Kobayashi T, et al. (2011) Clinical and radiological 
features of imported chikungunya fever in Japan: a study of six cases at the National 
Center for Global Health and Medicine. Journal of Infection and Chemotherapy 17: 
419-423.
33. Haas H, Robin S, Ramful D, Houdon L, Minodier P, et al. (2009) [Chikungunya virus 
infections in children]. Arch Pediatr 16 Suppl 2: S72-79.
34. Pellot AS, Alessandri JL, Robin S, Samperiz S, Attali T, et al. (2012) [Severe forms of 
chikungunya virus infection in a pediatric intensive care unit on Reunion Island]. Med 
Trop (Mars) 72 Spec No: 88-93.
35. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, et al. (2007) Outbreak 
of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult 
patients. Clin Infect Dis 44: 1401-1407.
36. AbuBakar S, Sam IC, Wong PF, MatRahim N, Hooi PS, et al. (2007) Reemergence of 
endemic Chikungunya, Malaysia. Emerg Infect Dis 13: 147-149.
37. Lahariya C, Pradhan S (2006) Emergence of chikungunya virus in Indian subcontinent 
after 32 years: A review. J Vector Borne Dis December, 43: 151-160.
38. Lee VJ, Chow A, Zheng X, Carrasco LR, Cook AR, et al. (2012) Simple Clinical and 
Laboratory Predictors of Chikungunya versus Dengue Infections in Adults. PLoS Negl 
Trop Dis 6: e1786.
39. Hertz JT, Munishi OM, Ooi EE, Howe S, Lim WY, et al. (2012) Chikungunya and Dengue 
Fever among Hospitalized Febrile Patients in Northern Tanzania. The American 
Journal of Tropical Medicine and Hygiene 86: 171-177.
40. Rianthavorn P, Wuttirattanakowit N, Prianantathavorn K, Limpaphayom N, 
Theamboonlers A, et al. (2010) Evaluation of a rapid assay for detection of IgM 
antibodies to chikungunya. Southeast Asian Journal of Tropical Medicine and Public 
Health 41: 92-96.
41. Ray P, Ratagiri VH, Kabra SK, Lodha R, Sharma S, et al. (2012) Chikungunya infection in 
India: results of a prospective hospital based multi-centric study. PLoS One 7: e30025.
Chapter 7
136
42. Thaikruea L, Charearnsook O, Reanphumkarnkit S, Dissomboon P, Phonjan R, et al. 
(1997) Chikungunya in Thailand: a re-emerging disease? Southeast Asian J Trop Med 
Public Health 28: 359-364.
43. Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, et al. (2008) Multidisciplinary 
prospective study of mother-to-child chikungunya virus infections on the island of 
La Reunion. PLoS Med 5: e60.
44. Mulyatno KC, Yamanaka A, Ngadino, Konishi E (2012) Resistance of Aedes aegypti (L.) 
larvae to temephos in Surabaya, Indonesia. Southeast Asian J Trop Med Public Health 
43: 29-33.
45. Bangs MJ, Larasati RP, Corwin AL, Wuryadi S (2006) Climatic factors associated with 
epidemic dengue in Palembang, Indonesia: implications of short-term meteorological 
events on virus transmission. Southeast Asian J Trop Med Public Health 37: 1103-
1116.
46. Akbar MR AR, Djatie T, Kodyat S (2008) PCR Detection of Dengue Transovarial 
Transmissibility in Aedes aegypti in Bandung, Indonesia. Proc ASEAN Congr Trop Med 
Parasitol 3: 6.
47. Ahmad I, Astari S, Tan M (2007) Resistance of Aedes aegypti (Diptera: Culicidae) in 
2006 to pyrethroid insecticides in Indonesia and its association with oxidase and 
esterase levels. Pak J Biol Sci 10: 3688-3692.
48. Malvy D, Ezzedine K, Mamani-Matsuda M, Autran B, Tolou H, et al. (2009) Destructive 
arthritis in a patient with chikungunya virus infection with persistent specific IgM 
antibodies. BMC Infect Dis 9: 200.
49. Powers AM (2010) Chikungunya. Clin Lab Med 30: 209-219.
Evidence for endemic chikungunya virus infections in Bandung, Indonesia
137
7

Chapter 8
Surveillance of influenza in Indonesia, 
2003–2007
Influenza and other respiratory viruses, 2013
Herman Kosasih1,2, Roselinda1, Nurhayati2, Alexander Klimov3, Xu Xiyan3, 
Stephen Lindstrom3, Frank Mahoney4, Charmagne Beckett2, Timothy H. Burgess2, 
Patrick J. Blair2, Timothy M. Uyeki3, Endang R. Sedyaningsih1
1 Ministry of Health, Republic of Indonesia, Jakarta, Indonesia.
2 U.S. Naval Medical Research Unit (NAMRU), Jakarta, Indonesia.
3 U.S. Centers for Disease Control and Prevention, Influenza Division, Atlanta, GA, USA.
4 U.S. Centers for Disease Control and Prevention, Jakarta, Indonesia.
Chapter 8
140
ABSTRACT
BACKGROUND
Longitudinal data are limited about the circulating strains of influenza viruses 
and their public health impact in Indonesia. We conducted influenza surveillance 
among outpatients and hospitalized patients with influenza-like illness (ILI) 
across the Indonesian archipelago from 2003 through 2007.
METHODOLOGY
Demographic, clinical data, and respiratory specimens were collected for 4,236 
ILI patients tested for influenza virus infection by RT-PCR and viral culture.
PRINCIPAL FINDINGS
Influenza A and B viruses co-circulated year round with seasonal peaks in influenza 
A virus activity during the rainy season (December–January). During 2003–2007, 
influenza viruses were identified in 20,1% (4,236/21,030) of ILI patients, including 
20,1% (4,015/20,012) of outpatients, and 21,7% (221/1,018) of inpatients. One 
H5N1 case was identified retrospectively in an outpatient with ILI. Antigenic drift 
in circulating influenza A and B virus strains was detected during the surveillance 
period in Indonesia. In a few instances, antigenically drifted viruses similar to the 
World Health Organization (WHO) vaccine strains were detected earlier than the 
date of their designation by WHO.
CONCLUSION
Influenza A and B virus infections are an important cause of influenza-like illness 
among outpatients and hospitalized patients in Indonesia. While year-round 
circulation of influenza viruses occurs, prevention and control strategies should 
be focused upon the seasonal peak during rainy season months. Ongoing 
virologic surveillance and influenza disease burden studies in Indonesia are 
important priorities to better understand the public health impact of influenza 
in South-East Asia and the implications of influenza viral evolution and global 
spread.
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INTRODUCTION
While the disease burden and seasonality of influenza virus activity in temperate 
regions of the Northern and Southern Hemispheres have been well characterized 
with clear peaks during winter months [1,2], such data are limited for developing 
countries with tropical and subtropical climates [3]. Recent studies suggest that 
South-East Asia is an important region in the global ecology and evolution 
of influenza viruses [4,5]. The ongoing epizootic of highly pathogenic avian 
influenza A (H5N1) virus among poultry with sporadic transmission to humans 
further highlights the importance of influenza virus surveillance and response 
measures in South-East Asia [6,7].
In tropical and subtropical developing countries, influenza is often under-
diagnosed and the disease burden and clinical severity are under-estimated [3]. 
However, recent studies have revealed that influenza virus infections in tropical 
climate countries, including in South-East Asia, cause similar severity and disease 
burden as in temperate countries [8,9]. Beginning in 2003, a widespread, ongoing 
epizootic of highly pathogenic avian influenza A (H5N1) virus has impacted 
poultry in Indonesia. First detected in 2005, sporadic H5N1 virus transmission 
to humans has resulted in high mortality [7]. Since H5N1 virus infection can 
also cause severe influenza-like illness (ILI) among exposed persons, virologic 
surveillance is needed to understand the relative impact of H5N1 virus and 
seasonal influenza A and B viruses among persons with ILI in Indonesia.
Influenza surveillance was implemented among outpatients at six sentinel sites 
in three districts in Java, Indonesia between September 1999 and January 2003 
[10]. In this report, we describe the findings of expanded influenza surveillance at 
additional sites across the Indonesian archipelago, including among hospitalized 
patients, during 2003–2007.
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METHODS
SURVEILLANCE SITES
We conducted surveillance for influenza-like illness (ILI) among patients seeking 
care at primary health centers (outpatients) and hospitals (outpatients and 
inpatients) across Indonesia during January 2003 to December 2007. The number 
of participating facilities expanded from five sentinel sites in five districts in 2003 
to 22 sites in 18 districts in 2004–2005 and 48 sites (28 outpatient sites at primary 
health care centers and hospitals, and 20 inpatient sites) in 26 districts in 2006–
2007, covering 22 of 33 Indonesian provinces (Figure 1).
Figure 1.  Location of Indonesia influenza surveillance sites (blue) and provinces with surveillence 
sites (red), 2003–2007
Suma-
tera
Java
Kali-
mantan
Bali Lombok Sulawesi Maluku Timor Papua Total
Number of health facilities and (districts), by year
2003 0 3(3) 0 1(1) 0 1(1) 0 0 0 5(5)
2004 – 
2005
3(3) 9(5) 2(2) 1(1) 1(1) 2(2) 1(1) 1(1) 2(2) 22(18)
2006 – 
2007
9(6) 23(8) 4(3) 1(1) 1(1) 4(2) 1(1) 1(1) 4(3) 48(26)
Total population, million
50·7 136·6 13·8 3·9 2·6 17·4 2·6 1 3·6 232·2
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SURVEILLANCE METHODS
Patients ‘enrollment and specimen collection’
We enrolled patients who presented at primary health centers (outpatients) 
and hospitals (outpatients and inpatients) who met the inclusion criteria of ILI, 
defined as a measured axillary temperature of ≥37.80C or history of feverishness, 
and either cough or sore throat without any other diagnosis. Among patients 
meeting the ILI case definition, a convenience sample of up to 20 ILI cases per 
week was enrolled. Clinicians or trained nurses obtained demographic data and 
clinical symptoms, performed physical examinations, and collected nasal and 
throat swabs from enrolled ILI cases. Swab specimens were placed into sterile 
Hanks’ balanced salt solution (HBSS) viral transport media (VTM) that contained 
gelatin, 100 µ/ml penicillin, 100 µg/ml, streptomycin, and 25 U/ml mycostatin. 
Specimens were refrigerated (40C) and shipped weekly to laboratories in 
Jakarta for testing Specimens from suspected H5N1 patients were shipped to 
laboratories in Jakarta within 24 hours of collection for urgent H5 testing [6].
Laboratory evaluation
From 2003 to September 2005, all respiratory specimens were tested for 
influenza viral RNA by conventional reverse transcription polymerase chain 
reaction (RT-PCR) assay. The QIAamp Viral RNA kit (QIAGEN, Valencia, CA, USA) 
was used to extract viral RNA from prepared samples. Samples were assayed 
using multiplex nested reverse transcription RT-PCR (MnRT-PCR) to detect 
human influenza viral RNA. In the MnRT-PCR, viral RNA was amplified utilizing 
cocktails of oligonucleotide primers [11] directed collectively against the matrix 
protein (MP), hemagglutinin (HA), and neuraminidase (NA) genes for influenza 
A (H1N1) and A (H3N2) viruses, and the MP and HA genes for influenza B virus. 
Primers targeting H5 were not included in the nested MnRT-PCR. Amplicons were 
separated by electrophoresis on 2% agarose gel containing ethidium bromide 
for virus type and sub-type identification. Positive specimens were inoculated 
into Madin–Darby canine kidney (MDCK) tissue cells for viral isolation.
Beginning in October 2005, all specimens were first screened for influenza A 
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(H5) viral RNA using real-time RT-PCR (rRT-PCR) as described below. Negative 
H5 specimens were tested for influenza A (H1N1) (H3N2) and influenza B viral 
RNA using conventional RT-PCR as described above. Specimens testing positive 
for seasonal influenza A or B viruses were placed into MDCK tissue cells for viral 
isolation. Virus isolates were characterized by hemagglutination inhibition (HAI) 
assay as previously described [12]. All influenza virus testing was performed at 
the National Institute of Health Research and Development, Ministry of Health 
(NIHRD, MoH), Indonesia, and U.S. Naval Medical Research Unit #2 (NAMRU#2), 
Jakarta, utilizing the same standard operating procedures. A convenience 
sample of approximately 45% of isolates was sent for confirmation and antigenic 
characterization at the World Health Organization Influenza Collaborating Center 
(WHO-CC) at the U.S. Centers for Disease Control and Prevention (CDC), Atlanta, 
Georgia, periodically until mid-2006. 
rRT-PCR assay
Starting in October 2005, all specimens were first screened for H5 by rRT-PCR. 
Ribonucleic acid (RNA) was extracted from nasal and throat swabs using QIAamp 
viral RNAmini kits (QIAGEN, Hilden, Germany) following the manufacturer’s 
instruction and stored at -700C. For detection of A (H5) viral RNA, rRT-PCR was 
initially conducted using an H5 primer set, [13] and then later in 2006, using 
primers and probes designed by the CDC to specifically recognize the subclade 
2.1 viruses circulating among poultry with sporadic transmission to humans in 
Indonesia. One-step rRTPCR was performed in a final volume of 25 µl containing 
5 µl of extracted RNA, 12.5 µl of buffer mix and 0.5 µl Superscript III ⁄ Platinum 
Taq-Enzyme mix, 20 unit of RNase-out (Invitrogen, Carlsbad, CA, USA), 0.8 µm for 
each primer, and 0.2 µm of each probe. H5 cDNA positive controls were provided 
by the CDC and used to quantify each rRT-PCR assay. An ABI 7900 real-time 
thermocycler was used for all rRT-PCR reactions. The thermocycling parameters 
for all targets consisted of 500C for 30 minutes, 950C for 2 minutes, and 45 cycles 
with 950C for 15 seconds, 550C for 30 seconds.
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Virus culture, isolation, and identification
For virus culture, a 0.2 ml aliquot of each specimen was inoculated onto MDCK 
cells that had been prepared in sterile 24-well plates, and resulting viruses were 
reacted with type-specific monoclonal antibodies as previously described [14]. 
To identify the strains, HAI assay was performed using turkey red blood cells. All 
isolates were tested against standard reference antisera, which were regularly 
updated by the CDC.
Data storage and analysis
Questionnaires consisting of demographic, epidemiology, and clinical data, 
along with laboratory data (RT-PCR and virus isolation results) and available 
climate data (rainfall, temperature, and relative humidity provided by the 
Climatology, Meteorology, and Geophysics Agency, Jakarta, Indonesia) from 18 
districts were entered into an Access (Microsoft, Bellevue, WA, USA) database. 
Data were analyzed using Stata software (Stata Corporation, College Station, 
TX, USA). Chi-squared test was used for comparison between two proportions 
of categorical data. Nonparametric tests were used to assess the correlation 
between numerical and proportional data.
Human subjects approval
The protocol was approved by the ethical research committees at NIHRD and 
NAMRU# 2 (DoD protocol 1999-30849).
RESULTS
During the 5-year surveillance period, a total of 21,030 participants, including 
outpatients (n=20,012) and inpatients (n=1,018), who presented to surveillance 
sites with ILI were enrolled. The median age of participants was 17 years (mean 
age, 21.1 years; range, 1 month to 90 years). Among all participants, 1,851 (8.9%) 
were aged <2 years, 2,936 (14.1%) were 2-4 years, 4,435 (21.3%) were 5-12 years, 
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1,220 (5.9%) were 13-17 years, 8,589 (41.3%) were 18-49 years, 1,413 (6.8%) were 
50–64 years, and 359 (1.7%) were 65 years and older (Table 1).
Overall, 20.1% (4,236/21,030) of ILI cases throughout the study period tested 
positive for influenza viruses. The proportion of ILI cases that tested positive 
for influenza viruses by age-group was highest in school-aged children (Table 
1). The percentages of outpatients (20.1%) and inpatients (21.7%) testing 
positive for influenza viruses were similar. The proportion of seasonal influenza-
associated pneumonia, diagnosed by clinicians based on clinical manifestations 
and chest radiography results, among hospitalized ILI cases sampled was 18% 
(23/128). Among all ILI cases that tested positive for influenza viruses, influenza 
A virus and influenza B virus were identified in 64.9% (2,749) and 35.1% (1,487) 
of cases, respectively. Among the influenza A viruses that were subtyped (n = 
2,314 viruses), 64.6% were identified as H3N2, 34.9% as H1N1, and 0.4% as H5N1.
The proportion of ILI cases that tested positive for influenza viruses per year 
was generally consistent throughout the study period and varied from 18.7% 
(in 2003) to 23.8% (in 2004). However, the proportion of ILI cases that tested 
positive for influenza viruses varied considerably across island sites, ranging from 
Bali (14.2%) and Timor (15.3%) to Papua (25.9%) and Maluku (26.6%). Across the 
surveillance sites, influenza viruses were detected year round. The distribution of 
influenza virus types and influenza A virus subtypes varied temporally (Table 2).
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Table 2.  Influenza virus types and influenza A subtypes detected by year
*Excludes H5N1 viruses and specimens not further tested.
**Denominator differs from all influenza B virus positive specimens detected by RT-PCR
Year
ILI cases
RT-PCR
# influenza 
positive
% of all 
influenza 
positive
#isolates
# and (%) 
of influenza 
positives with 
isolates
2003 593
Influenza A
H1N1
H3N2
Influenza B
Total
10
75
26
111/593
9.0
67.6
23.4
18.7
7
34
9
50
7./10 (70)
34/75 (45.3)
9/26 (34.6)
50/111 (45)
2004 1403
Influenza A
H1N1
H3N2
Influenza B
Total
12
219
103
334/1403
3.6
65.6
30.8
23.8
8
94
70
172
8/12 (66.7)
94/219 (42.9)
70/103 (67.9)
172/334 (51.5)
2005 3964 Influenza A
H1N1
H3N2
H5N1
Influenza B
Total
59
303
1
386
749/3964
7.9
40.5
0.1
51.5
18.9
22
47
233
302
22/59 (37.3)
47/303 (15.5)
233/386 (60.4)
302/748 (40.4)*
2006 6926
Influenza A
A not further 
tested
H1N1
H3N2
H5N1
Influenza B
Total
108
422
343
3
384
1260/6926
8.6
33.5
27.2
0.2
30.5
18.2
196
54
167
417
196/422 (46.4)
54/343 (15.7)
167/326 (51.2)**
417/1091 (38.2)*
2007 8144
Influenza A
A not further 
tested
H1N1
H3N2
H5N1
Influenza B
Total
327
305
556
6
588
1782/8144
18.4
17.1
31.2
0.3
32.9
21.9
89
51
183
323
89/305 (29.2)
51/556 (9.2)
183/470 (38.9)**
323/1331 (24.3)*
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All influenza viral isolates (n=1,264) were first characterized at NAMRU#2 and 
then a subset (n=473 isolates from 2003 to mid-2006) was further characterized 
at CDC. In 2003, surveillance was conducted in five sites, and 111 influenza virus 
infections were identified; influenza A (H3N2) viruses predominated, followed by 
influenza B and A (H1N1) viruses. The most frequent strains identified were A/
Fujian/411/2002-like H3N2, B/Hongkong/330/2001-like (B/Victoria/2/87 lineage, 
2002–2003 Northern and 2003 Southern Hemisphere vaccine strain), and A/New 
Caledonia/20/99-like H1N1 (2002–2003 Northern and 2003 Southern Hemisphere 
vaccine strain) viruses. The number of surveillance sites expanded during 2004–
2007. In 2004, A (H3N2) viruses also predominated, with A/California/7/2004-
like H3N2, B/Sichuan/379/99-like, and A/New Caledonia/20/99-like H1N1 (2003-
2004 Northern and 2004 Southern Hemisphere vaccine strain) viruses the most 
frequently detected strains. In 2005, influenza B viruses of the B/Victoria/2/87 line 
age predominated and most viruses were related antigenically to the reference 
strain B/Ohio/05/2005. The frequency of circulating A (H3N2) viruses was slightly 
less than influenza B viruses and most were identified as A/California/7/2004-
like. Influenza A (H1N1) viruses were detected at low frequency and all isolates 
were A/New Caledonia/20/99-like (2004–2005 Northern and 2005 Southern 
Hemisphere vaccine strain). In 2006, influenza A (H1N1), A (H3N2), and type B 
viruses were detected at similar frequencies; most H1N1 viruses were related 
antigenically to A/New Caledonia/20/99-like (2005–2006 Northern and 2006 
Southern Hemisphere vaccine strain); the majority of H3N2 viruses were related 
antigenically to the A/California/7/2004 (2005–2006 Northern and 2006 Southern 
Hemisphere vaccine strain); and the majority of influenza B viruses belonged to 
the B/Victoria/2/87-lineage and were identified as B/Malaysia/2506/2004-like. In 
2007, influenza A (H3N2) and B viruses were identified in similar frequencies. 
The majority of H3N2 viruses were related antigenically to A/Wisconsin/67/2005 
virus (2006–2007 Northern and 2007 Southern Hemisphere vaccine strain); 
and the majority of B viruses were of the B/Victoria-lineage viruses and related 
antigenically to B/Malaysia/2506/2004 virus (2006–2007 Northern and 2007 
Southern Hemisphere vaccine strain). Overall, during 2003–2007, influenza A 
(H3N2) viruses were isolated less frequently (18.7%) than A (H1N1) (39.9%) or B 
(50.5%) viruses.
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Influenza A (H5N1) virus infection was identified in one outpatient and nine 
inpatients from six surveillance sites (five cases from Tangerang, and one each 
from Bali, Padang, Jakarta, Makassar, and Yogyakarta). Initial diagnoses in these 
cases included severe bronchopneumonia, dengue, or typhoid fever. All nine 
confirmed H5N1 hospitalized cases presented with severe illness late in the 
clinical course, received late oseltamivir treatment, and all died. One H5N1 case 
presented with ILI to a hospital outpatient surveillance site, was not suspected 
with H5N1 at clinical presentation, was neither treated nor hospitalized, and 
subsequently died. H5N1 virus infection was retrospectively confirmed from 
a respiratory specimen collected through ILI surveillance. These 10 cases 
represented 8.5% of all confirmed H5N1 cases (n = 117) identified in Indonesia 
between 2005 and 2007. 
Influenza virus detection by RT-PCR and subsequent viral isolation were higher 
in ILI patients presenting with a measured temperature of ≥37.80C (22.6% and 
44.7%, respectively) compared to those with a history of feverishness, but 
without a documented fever at presentation (17.4% and 38.3%). Among 4236 
patients who tested positive by RT-PCR, 62.5% were positive in both nasal and 
throat swab specimens, compared to 19.6% of nasal swabs only, and 16.9% of 
throat swabs alone. Nasal swabs yielded slightly higher isolation of influenza 
viruses compared to throat swabs [1225/3043 (40.3%) versus 1155/3054(37.8%), 
P = 0.04, chi-squared test]. 
Figure 2 shows the monthly proportion of influenza positive ILI cases identified 
by RT-PCR. Seasonal peaks in influenza A virus activity, especially with H3N2 virus 
strains, were observed during December and January, followed by increases in 
influenza B virus activity during March to May. The seasonality of influenza A 
virus was largely consistent across all nine islands although some had increased 
activity during May and July (Sumatra, Maluku, and Papua). Two eastern 
provinces of Indonesia appeared to have a bimodal peak in influenza activity 
during December-January and June-July although data were limited (data 
not shown). We observed a high correlation between the mean proportion of 
influenza A positives among ILI cases and mean precipitation from 18 districts 
(Figure 3; r = 0.87). When assessed per district, influenza A virus activity appeared 
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Figure 2.  Percentage of ILI cases testing positive for influenza viruses by RT-PCR by month, 2003 – 
2007
to correlate well with rainfall in 10 districts (in one district, r > 0.8; in nine districts, 
r = 0.6–0.8); poor-to-moderate correlation was observed in other districts (in one 
district, r = 0.4–0.6; in two districts, r = 0.2–0.4; in three districts, r = 0–0.2; and in 
two districts, r = 0.01 to 0.2.) The last five districts are located in Kalimantan and 
two eastern islands of Indonesia (Maluku and Papua). Influenza A virus activity 
did not appear to correlate with mean monthly temperature or relative humidity 
(data not shown). Influenza B virus activity did not appear to be correlated with 
mean monthly temperature, mean monthly rainfall, or monthly relative humidity 
for any sites (data not shown).
Retrospective analysis identified a small number of influenza A viruses that were 
isolated from respiratory specimens collected through surveillance in Indonesia 
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8before the collection of specimens elsewhere that yielded influenza A (H1N1) and 
(H3N2) viruses that were subsequently recommended as WHO influenza vaccine 
strains (Table 3). A/Solomon Islands/3/2006 (H1N1) virus was first identified in 
August 2006; this antigenic variant virus spread widely and was selected as the 
Northern Hemisphere H1N1 vaccine component in February 2007 to replace A/
New Caledonia/20/99 (H1N1). An H1N1 virus detected in Indonesia during March 
2006 was identified as A/Solomon Islands/3/2006-like (in early 2007), suggesting 
detection of this virus in Indonesia approximately 5 months earlier than the 
designated WHO Northern Hemisphere vaccine strain. Similarly, a few H3N2 
viruses were identified in Indonesia earlier or at the same time as antigenically 
equivalent H3N2 vaccine strains that were recommended as WHO H3N2 vaccine 
strains (A/California/7/2004-like and A/Wisconsin/67/2005-like viruses).
Figure 3.  Comparison of rainfall precipitation and the proportion of ILI cases that tested positive for 
influenza A, 2003-2007 indonesia*
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Table 3.  Detection of influenza A virus strains in Indonesia and temporal relations to Global 
Detection of WHO Designated influenza A vaccine virus strains, 2003-2007
*With sequence confirmation
Influenza vaccine 
strain
Month, year 
selected 
as WHO 
vaccine 
strain
Date of 
collection 
of influenza 
vaccine 
virus
Date of 
collection 
of 
Indonesia 
virus
Indonesia virus 
name
Antigenic 
characterization*
A/California/07/2004 
(H3N2)
A/Wisconsin/67/2005 
(H3N2)-like
A/Solomon islands/03/2006
(H1N1)-like
February 2005
February 2006
February 2007
Sept 16, 2004
Aug 31, 2005
Aug 21, 2006
Sept 16, 2004
Feb 18, 2005
March 3, 2006
Indonesia/1857/2004
Indonesia/1711/2005
Indonesia/3208/2006
A/California/07/2004 
(H3N2)-like
A/Wisconsin/67/2005 
(H3N2)-like
A/Solomon 
islands/03/2006 
(H1N1)-like
DISCUSSION
Surveillance conducted at sites across the Indonesian archipelago during 
2003–2007 identified a substantial proportion of influenza virus infections 
among patients presenting with influenza-like illness. While influenza activity 
was detected year-round, the proportion of ILI patients with influenza and 
predominant viruses varied from year-to-year and geographically. There was 
evidence for a mixed seasonal distribution of influenza viruses in some parts 
of eastern Indonesia (Maluku and Papua). However, the observed seasonality of 
influenza A virus activity among ILI cases at our surveillance sites in most regions 
of Indonesia, particularly in the western and middle islands which are more 
densely populated, indicated a peak in December and January, which correlates 
with the rainy season. Seasonality for influenza B virus was less apparent.
Similar to our surveillance findings, influenza A (H1N1) virus activity was low 
during 2003–2005 in Australia [15-17], Malaysia [18], and Thailand [19]. However, 
in 2006, A (H1N1) viruses were the predominant subtype in Malaysia [18], 
Thailand [19], and Indonesia. In 2007, A (H1N1) activity increased in Australia [20]. 
Between 2003 and 2007, A (H3N2) virus was the most predominant subtype in 
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Indonesia and in neighboring countries [15-21]. Similar to our findings, influenza 
B viruses were less frequently detected than influenza A viruses, but still were 
identified in a moderately high proportion of ILI cases in Malaysia and Thailand 
(approximately 20% to 40% each year) [18,19], except in 2005 when B viruses 
predominated in Malaysia and Indonesia (approximately 52%) [18]. In Australia, 
influenza B virus activity was variable during 2003–2007 (6% in 2003 to 29% in 
2006 and 9% in 2007) [15-17,20,21].
Influenza A and B viruses, including antigenically drifted strains as observed in 
other countries, were also detected in Indonesia during the surveillance period, 
and in a few instances were detected earlier than designated WHO representative 
reference or influenza vaccine strains. A sink-source model in which evolution of 
influenza A (H3N2) virus strains circulating in the tropics seed winter epidemics 
in temperate region has been proposed; this model emphasizes the importance 
of South-East Asia for the emergence of new variants and novel strains [4,5]. 
Although we did not conduct comprehensive antigenic characterization of 
influenza viruses circulating in Indonesia or compare our limited results with 
global data, we believe that improved influenza surveillance in Indonesia, the 
4th most populated country, can inform better understanding of the evolution 
of influenza viruses in South-East Asia.
Given the influenza virus seasonality observed among ILI cases at most 
Indonesian sentinel sites, use of influenza vaccine in Indonesia should target 
the December-January winter seasonal peak. For this reason and the similarity 
with most circulating A (H1N1) and A (H3N2) virus strains during 2003–2007, the 
timing of the availability of Northern Hemisphere influenza vaccine is best suited 
for Indonesia. This timing of peak influenza activity is different than that found 
in other countries in the region which also experience year-round activity, but 
generally experience a mid-year peak, although the timing of peak activity may 
vary from year-to-year [18,22-24].
Historically, influenza vaccine use is quite low in Indonesia with fewer than 
300,000 doses administered every year [25]. With very limited data on influenza 
disease burden in Indonesia and no data on cost-effectiveness of influenza 
vaccination, the Ministry of Health recommends influenza vaccine for high-risk 
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populations such as the elderly, those with underlying chronic diseases, Hajj 
pilgrims, and healthcare workers [26]. The main reasons for low influenza vaccine 
coverage are the cost of vaccine and the wide belief that influenza virus infection 
only causes mild illness [25]. Oseltamivir is the only antiviral for influenza used in 
Indonesia, but is not widely available. Although oseltamivir has been provided 
in limited quantities at government primary health centers and hospitals since 
2006, it is not available at pharmacies and its use is restricted to treatment of 
persons with suspected or confirmed H5N1 virus infection [27].
Among samples tested, the percentage of ILI cases testing positive for 
influenza viruses was highest among school-age children in Indonesia. While 
health utilization data for Indonesians of all ages with influenza-like illness are 
needed, the high burden of influenza among school-age children presenting to 
surveillance sites is consistent with reports from other countries in the region 
and underscores the potential of this group as a source of transmission and the 
importance of influenza vaccination [23,24]. Furthermore, seasonal influenza 
represented 21.7% of all ILI cases tested in the inpatient setting, among which 18% 
were associated with pneumonia. Since influenza diagnostic testing is generally 
not performed as part of clinical management of outpatients or hospitalized 
patients, the findings in this work can inform physicians in Indonesia who are 
not aware of the public health impact of seasonal influenza. Furthermore, given 
the relatively high frequency of influenza among hospitalized ILI patients, both 
healthcare personnel and other hospitalized patients may be at risk of and 
contribute to nosocomial influenza virus transmission; the role of influenza 
vaccination and importance of infection control must be emphasized.
We identified 10 H5N1 cases from patients’ respiratory specimens collected at 
hospital surveillance sites, 8.6% of the 116 H5N1 cases reported in Indonesia 
during the surveillance period [28]. Nine cases were in suspected H5N1 patients 
with severe illness admitted to hospitals that were surveillance sites, while one 
H5N1 case presented with ILI and was not suspected with H5N1. This highlights 
the value of laboratory-based influenza surveillance to detect human infections 
with seasonal influenza viruses as well as H5N1 virus [29]. As our surveillance 
network relied upon a convenience sample of ILI cases among outpatients and 
inpatients, it is possible that other H5N1 virus infections were missed.
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We recognize several limitations to our surveillance findings. First, denominator 
data on the catchment population for sentinel sites were not collected and 
data on the total number of outpatient and inpatient visits and total ILI cases 
were not collected to calculate the incidence of ILI and influenza. We utilized a 
convenience sample of ILI cases, not a systematic sample. Therefore, influenza 
disease burden could not be estimated. Nevertheless, we documented a 
substantial proportion of outpatients and hospitalized patients with influenza. 
Second, we did not follow the outcomes of our inpatients to estimate seasonal 
influenza-associated mortality. Third, sentinel sites were selected based on the 
population density. More sentinel sites existed on two islands, Sumatra and 
Java in the West, and our findings may not be representative of all of Indonesia, 
including less populous eastern islands. Finally, the yield of viral isolation was 
lower over the surveillance period because of cold-chain issues and difficulties 
in isolating H3N2 viruses. However, as we utilized RT-PCR as the primary method 
of identification, we believe that our findings accurately reflect influenza virus 
activity among our surveillance sites.
In conclusion, our findings demonstrate that influenza is an important public 
health problem among outpatients and hospitalized ILI patients in Indonesia. 
This has implications for understanding the public health impact of influenza 
in tropical climates as well as the development of policies for the use of 
influenza vaccines in Indonesia. In addition to strengthening and improving 
epidemiological data collection for patients with influenza, collecting more data 
on influenza disease burden is needed, especially among hospitalized patients 
and high-risk groups for influenza complications. Also, data are needed on the 
economic impact of influenza and the role of climactic factors (such as absolute 
humidity, rainfall, and temperature) in influenza activity and seasonality in 
Indonesia.
ACKNOWLEDGEMENTS
We thank all of the volunteers, clinicians, and nurses from participating sentinel 
surveillance sites and the administrative and laboratory staff at NIHRD, and 
NAMRU#2, especially Chairin Ma’roef, and Ungke Antonjaya. We thank the 
Chapter 8
158
Influenza Division, CDC for providing updated influenza primers, probes, and 
antisera, laboratory support for the field and laboratory surveillance activities. 
We also thank Jens Levy (CDC Thailand) for critical review of the manuscript. 
We dedicate this work to the memory of our beloved colleague Dr. Endang R. 
Sedyaningsih.
DISCLAIMER
The author(s) declare that they have no conflict of interest. This work was funded 
in part by grants from the U.S. Department of Defense Armed Forces Health 
Surveillance Center, Division of Global Emerging Infections Surveillance (AFHSC 
⁄ GEIS) and the U.S. Centers for Disease Control and Prevention (CDC). The views 
expressed are those of the authors and do not necessarily represent the official 
policies of the CDC, the U.S. Department of Defense or the Department of the 
Navy.
Surveillance of influenza in Indonesia, 2003–2007
159
8
References
1. Monto AS (2008) Epidemiology of influenza. Vaccine: D45-D48.
2. Viboud C, Alonso WJ, Simonsen L (2006) Influenza in tropical regions. PLoS Med 3: 
e89.
3. Leo YS, Lye DC, Chow A (2009) Influenza in the tropics. Lancet Infect Dis 9: 457-458.
4. Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, et al. (2008) The 
genomic and epidemiological dynamics of human influenza A virus. Nature 453: 
615-619.
5. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, et al. (2008) The global circulation of 
seasonal influenza A (H3N2) viruses. Science 320: 340-346.
6. Sedyaningsih ER, Isfandari S, Setiawaty V, Rifati L, Harun S, et al. (2007) Epidemiology 
of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J Infect Dis 196: 
522-527.
7. Kandun IN, Tresnaningsih E, Purba WH, Lee V, Samaan G, et al. (2008) Factors associated 
with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 
372: 744-749.
8. Simmerman JM, Lertiendumrong J, Dowell SF, Uyeki T, Olsen SJ, et al. (2006) The cost 
of influenza in Thailand. Vaccine 24: 4417-4426.
9. Simmerman JM, Uyeki TM (2008) The burden of influenza in East and South-East Asia: 
a review of the English language literature. Influenza Other Respir Viruses 2: 81-92.
10. Beckett CG, Kosasih H, Ma’roef C, Listiyaningsih E, Elyazar IR, et al. (2004) Influenza 
surveillance in Indonesia: 1999-2003. Clin Infect Dis 39: 443-449.
11. Zhang WD, Evans DH (1991) Detection and identification of human influenza viruses 
by the polymerase chain reaction. J Virol Methods 33: 165-189.
12. Hobson D, Curry R, Beare A, A W-G (1972) The Role of serum haemagglutination-
inhibition antibody in protection against challenge infection with influenza A2 and 
B viruses. J Hyg 70: 767–777.
13. World Health Organization (2012) Recommendations and laboratory procedures 
for detection of avian influenza A(H5N1) virus in specimens from suspected human 
cases http://www.who.int/influenza/resources/documents/RecAIlabtestsAug07.pdf 
1 may 2012.
14. Gaush CR, Smith TF (1968) Replication and plaque assay of influenza virus in an 
established line of canine kidney cells. Appl Microbiol 16: 588-594.
15. Yohannes K, Roche P, Hampson A, Miller M, Spencer J (2004) Annual report of the 
National Influenza Surveillance Scheme, 2003. Commun Dis Intell 28: 160-168.
16. Li J, Hampson A, Roche PW, Yohannes K, Spencer JD (2005) Annual report of the 
Chapter 8
160
National Influenza Surveillance Scheme, 2004. Commun Dis Intell 29: 125-136.
17. Firestone SM, Barr IG, Roche PW, Walker JC (2006) Annual report of the National 
Influenza Surveillance Scheme, 2005. Commun Dis Intell 30: 189-200.
18. Saat Z, Abdul Rashid TR, Yusof MA, Kassim FM, Thayan R, et al. (2010) Seasonal 
influenza virus strains circulating in Malaysia from 2005 to 2009. Southeast Asian J 
Trop Med Public Health 41: 1368-1373.
19. Chittaganpitch M, Supawat K, Olsen SJ, Waicharoen S, Patthamadilok S, et al. (2012) 
Influenza viruses in Thailand: 7 years of sentinel surveillance data, 2004-2010. 
Influenza Other Respir Viruses 6: 276-283.
20. Owen R, Barr IG, Pengilley A, Liu C, Paterson B, et al. (2008) Annual report of the 
National Influenza Surveillance Scheme, 2007. Commun Dis Intell 32: 208-226.
21. O’Brien K, Barr IG (2007) Annual report of the National Influenza Surveillance Scheme, 
2006. Commun Dis Intell 31: 167-179.
22. Simmerman JM, Chittaganpitch M, Levy J, Chantra S, Maloney S, et al. (2009) Incidence, 
seasonality and mortality associated with influenza pneumonia in Thailand: 2005-
2008. PLoS One 4: e7776.
23. Blair PJ, Wierzba TF, Touch S, Vonthanak S, Xu X, et al. (2010) Influenza epidemiology 
and characterization of influenza viruses in patients seeking treatment for acute fever 
in Cambodia. Epidemiol Infect 138: 199-209.
24. Nguyen HT, Dharan NJ, Le MT, Nguyen NB, Nguyen CT, et al. (2009) National influenza 
surveillance in Vietnam, 2006-2007. Vaccine 28: 398-402.
25. Tan. (2011) Dokter Keluarga bisa perluas cakupan imunisasi dewasa http://www.
majalah-farmacia.com/rubrik/onenews.asp?IDNews=2194 1 may 2012. Farmacia 10: 
64.
26. Dirjen BUK (2003) Imunisasi influenza untuk anak dan dewasa. http://buk.depkes.
go.id/index.php?option=com_docman&task=doc_details&gid=258&Itemid=58 
HTA Indonesia 19: 1-22.
27. Narulita Y (2008) Gambaran pelaksanaan majaemen logistik antiviral dalam 
penanganan flu burung di propinsi Banten tahun 2005–2008. Undergraduate thesis, 
for Public Health Faculty; University of Indonesia: 1-86.
28. World Health Organization (2007) Avian influenza – situation in Indonesia – update 
28 26 December 2007 http://www.who.int/csr/don/2007_12_26/en/index.html 1 
may 2012.
29. Brooks WA, Alamgir AS, Sultana R (2009) Avian influenza virus A (H5N1), detected 
through routine surveillance, in child, Bangladesh. Emerg Infect Dis 15: 1311–1313.
Surveillance of influenza in Indonesia, 2003–2007
161
8

Chapter 9
Evidence of human hantavirus infection 
and zoonotic investigation of hantavirus 
prevalence in rodents in western Java, 
Indonesia
Vector-borne and zoonotic Diseases, 2011
Herman Kosasih1, Ima Nurisa Ibrahim2, Rudi Wicaksana3, Bachti Alisjahbana3, 
Yumilia Hoo4, Iing H. Yo4, Ungke Antonjaya1, Susana Widjaja1, Imelda Winoto1, 
Maya Williams1, Patrick J. Blair1
1 U.S. Naval Medical Research Unit 2, Jakarta, Indonesia.
2 National Institute of Health Research and Development, Health Ecology Research and Development 
Center, Jakarta, Indonesia.
3 Hasan Sadikin Hospital, Bandung, Indonesia.
4 Immanuel Hospital, Bandung, Indonesia.
Chapter 9
164
ABSTRACT
During febrile surveillance in the western Java City of Bandung, Indonesia, a 
patient with clinical symptoms consistent with hantavirus infection was found 
to have elevated titers of hantavirus-specific immunoglobulin M (IgM) and IgG 
antibodies. A subsequent epizoological investigation demonstrated a higher 
prevalence of hantavirus IgG antibodies in rodents trapped in the vicinity of 
the patient’s home compared with rodents from a control area (13.2% vs. 4.7%, 
p=0.036). The Old World Seoul hantavirus was detected by reverse transcriptase 
– polymerase chain reaction in the organs of 71% of the seropositive rodents 
tested. This is the first report of a Seoul virus infection in Indonesia supported 
by clinical, serological, and epizoological evidences. These findings suggest that 
hantavirus infection should be on the clinical differential diagnosis when acutely 
ill febrile patients report for care in western Java.
INTRODUCTION
Hantaviruses are negative-stranded RNA viruses that belong to the Bunyaviridae 
family. The Old World hantaviruses include the Seoul, Dobrava, and Puumala 
viruses [1]. They are rodent-borne viruses and the causative agents of two 
disease syndromes, hemorrhagic fever with renal syndrome (HFRS), more 
prominent following infection with Old World hantaviruses, and hantavirus 
pulmonary syndrome (HPS), which is associated with New World hantaviruses. 
Hantaviruses cause chronic inapparent infections in rodents throughout the 
Americas, Asia, and Europe. Each hantavirus has a specific reservoir host with 
a limited geographic distribution. The common reservoirs for Hantaan (HTN), 
Seoul, Dobrava, Puumala, and Sin Nombre viruses are Apodemus agrarius, 
Rattus norvegicus, Apodemus flavicollis, Clethrionomys glareolus, and Peromyscus 
maniculatus, respectively [1]. Humans can become infected with hantaviruses 
through contact with urine, saliva, or feces from infected rodents, and evidence 
of HTN and Seoul virus infections have been reported in Southeast Asia. 
In Indonesia, the presence of hantavirus [2] and Seoul virus [3] antibodies in 
rodents has been demonstrated. However, reports of hantavirus infections in 
humans are limited. In 2001, acute sera from 2 of 25 suspected dengue patients 
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from Yogyakarta, central Java, were positive for hantavirus immunoglobulin 
M (IgM) and IgG as determined by immunofluorescence assay [4]. In separate 
studies, hantavirus IgM antibodies were found in 10 of 94 [5] or 20 of 118 [6] 
suspected dengue patients from Semarang and Yogyakarta, central Java. In this 
report, we present clinical findings from a patient in western Java with elevated 
titers of IgM and IgG antibodies against hantavirus and demonstrate evidence of 
Seoul virus infection in rodents captured near the patient’s home. This is the first 
report of a Seoul virus infection in Indonesia supported by clinical, serological, 
and epizoological evidences.
MATERIALS AND METHODS
PATIENT ENROLLMENT
Hospital-based surveillance for hantavirus was conducted at two large hospitals 
in Bandung, West Java, Indonesia, from September 2004 to August 2005. Patients 
eligible for enrollment were hospitalized patients >10 years old who met the 
clinical criteria of suspected HFRS or HPS (acute renal failure with unknown 
etiology or fever with at least one of the following symptoms: hemorrhagic 
manifestations, platelet count <100,000/mm3, renal insufficiency, liver 
dysfunction of unknown etiology, and/or noncardiogenic pulmonary edema). 
After obtaining informed consent, blood samples were taken during admission 
and when discharged or at least a week later. Samples were first screened by 
reverse transcriptase–polymerase chain reaction (RT-PCR) and serology for 
evidence of acute dengue infection. Patients RT-PCR positive for dengue or with 
dengue IgM results that increased between acute and convalescent samples 
were not tested further. This study was reviewed and approved by the Ethical 
Commission of the National Institute of Health Research and Development, 
Indonesian Ministry of Health, Jakarta, Indonesia, and by the Institutional Review 
Board for the ethical conduct of research on human subjects at the U.S. Naval 
Medical Research Unit No. 2, Jakarta, Indonesia.
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RODENT TRAPPING
Rodents were trapped for three consecutive nights at each study site. Domestic 
area trapping was conducted by placing one Sherman (H.B. Sherman Traps, 
Inc.) and one Tomahawk (Tomahawk Live Trap Co.) trap inside the house and 
one Tomahawk trap outside the house. Peridomestic trapping was conducted 
by placing Tomahawk traps at 5-m intervals in a straight line. All rodents 
were euthanized, and field identification of the animal species was made by 
a mammalogist. Blood and tissue samples were collected from the rodents 
and placed in liquid nitrogen. All aspects of animal use were conducted using 
protocols approved by the U.S. Naval Medical Research Unit No. 2 Institutional 
Animal Care and Use Committee and the National Institute of Health Research 
and Development, Indonesian Ministry of Health.
SEROLOGY
Human serum samples were tested for the presence of dengue-specific 
IgM using a commercially available kit (Focus Diagnostics) according to 
the manufacturer’s instructions. Human serum samples were tested for the 
presence of IgM and IgG antibodies against hantavirus using a commercially 
available ELISA kit (Focus Diagnostics) according to the manufacturer’s 
instructions and by an in-house ELISA using HTN virus antigen from HTN virus 
infected Vero E6 cell cultures (kindly provided by Dr. Ross Graham, USAMRID). 
A capture ELISA was run to detect the presence of IgM from human samples. 
Briefly, samples diluted 1:100 in serum dilution buffer (phosphate-buffered 
saline, 0.1% Tween-20, and 5% Bacto skim milk) were added to 96-well 
microtiter plates (Immulon 2; Dynex Technologies) coated with anti-human 
IgM antibodies (1:500; Kirkegard and Perry). After incubation and washing, HTN 
antigen diluted 1:6 in 2% normal human serum was added. After incubation 
and washing, anti-HTN rabbit IgG (1:2000), horseradish peroxidase-conjugate 
anti-rabbit IgG (1:2000), and ABTS substrate (Kirkegard and Perry) were used 
to detect antigen–antibody binding.
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An indirect ELISA was used to detect anti-HTN IgG from human and animal 
samples. Horseradish peroxidase conjugated anti-human IgG (Fc specific; Axell), 
anti-mouse IgG, or anti-rat IgG (Kirkegard and Perry) were used depending upon 
the species tested. A panel of normal sera was used to determine the cutoff. A 
sample was considered positive if its optical density (OD) value exceeded the 
mean plus 3 standard deviations of the normal sera. The endpoint ELISA titers 
were determined by retesting ELISA-positive samples at serial fourfold dilutions 
beginning at 1:100. The largest dilution giving a positive result was considered 
the endpoint titer.
MOLECULAR ANALYSIS
RNA was extracted from human serum samples using the QIAamp Viral RNA kit 
(Qiagen) or High Pure RNA Tissue kit (Roche Applied Science) for tissue samples, 
according to the manufacturer’s protocol.
RT-PCRs to detect dengue virus were performed as previously described [7]. 
RT-PCRs to detect hantaviruses were performed using primers specific for each 
genus, HTN, Seoul, Dobrava, Puumala, and Sin Nombre, as previously described 
[8].
A hantavirus real-time quantitative RT-PCR protocol was also performed in 
separate reactions using hantavirus group-specific primers and probes specific 
for Dobrava, HTN, Puumala, and Seoul viruses as previously described [9]. Positive 
results were confirmed by sequencing. Contigs were aligned using Sequencher 
4.9, and BLAST was performed against the GenBank database.
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RESULTS
Hospital-based surveillance for hantavirus was conducted at two large hospitals 
in Bandung, West Java, Indonesia (Figure 1), from September 2004 to August 
2005. Patients eligible for enrollment were hospitalized patients >10 years 
old who met the clinical criteria of suspected HFRS or HPS (acute renal failure 
with unknown etiology or fever with at least one of the following symptoms: 
hemorrhagic manifestations, platelet count <100,000/mm3, renal insufficiency, 
liver dysfunction of unknown etiology, and/or noncardiogenic pulmonary 
edema). A total of 406 hospitalized febrile cases were enrolled in the study. 
Patients were first screened for evidence of recent dengue infection using RT-
PCR and serology. Patients who were negative for dengue infection were then 
tested for evidence of hantavirus infection using RT-PCR and serology. The 
Figure 1.  Map of study location
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majority of patients (311/76.6%) had evidence of recent dengue infection, and 
one patient was positive for high titer hantavirus antibodies. Details from the 
patient with high titer hantavirus antibodies are described below.
A 25-year-old previously healthy man presented for treatment at a hospital in 
Bandung, West Java, Indonesia, on January 5, 2005. The patient suffered from 
a sudden onset of fever of 5 days in duration, headache, nausea, vomiting, and 
abdominal discomfort and complained of a loss of appetite and malaise. He 
lived in a rural area near Bandung and reported no history of travel outside the 
immediate area. The patient was feverish (390C) and had a positive tourniquet 
test, but no conjunctivitis. He was eupneic, with a normal blood pressure (120/80 
mmHg) and pulse rate (80/min-1). Routine laboratory blood screening showed 
a normal leukocyte count (9600mm_3), hematocrit (50%), blood urea nitrogen 
(25mg/dL), and creatinine (0.9 mg/dL). The patient’s platelet count (42,000mm-3), 
blood protein (5.8 g/dL), and albumin levels (3.3 g/dL) were low and his serum 
transaminases elevated (SGOT:130 U/L and SGPT: 76U/L). The following day (day 
6 of illness) his temperature decreased (380C), and his platelet count dropped 
slightly (38,000mm-3) while his hematocrit remained stable (51%). On day 7 of 
illness, the patient had defervescence (380C), and his platelet count increased to 
80,000mm-3. On day 8 of illness, his platelet count was above 100,000mm-3, and 
the patient was discharged from the hospital. Blood chemistry tests repeated on 
day 17 revealed normal blood urea nitrogen (24mg/dL), normal creatinine (0.9 
mg/dL), decreasing serum transaminases (SGOT: 44U/L and SGPT: 46U/L), and 
normal total protein (6.3 g/dL) and albumin (3.7 g/dL).
Sera were collected on illness days 8 and 17 for diagnostic tests. A commercially 
available ELISA kit (Focus Technologies) detected high and increasing levels of 
anti-hantavirus IgM (index >1.1=positive; day 8 sample index=18.5 and day 17 
sample index=20.6) and high levels of anti-hantavirus IgG (index >1.1=positive; 
day 8 and 17 sample index=23.2). An in-house ELISA also detected high and 
increasing titers of anti-hantavirus IgM (day 8, 1:1600; day 17, 1:6400) and IgG 
(day 8, 1:1600; day 17, 1:6400). A diagnosis of hantavirus infection was reported 
to hospital officials.
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To follow-up on the suspected case and determine the prevalence of disease 
among rodents in the area, a field study was conducted at 10 months after the 
patient presented to the hospital. Rodents were trapped around the patient’s 
home, which was also his working space (case area), and around a nonhantavirus 
patient’s home (control area) 4 km away. A total of 245 rodents were trapped, 
159 from the case area and 86 from the control area. R. norvegicus was the most 
predominant in both areas (74.8% and 69.8%), followed by Rattus tanezumi 
(22.6% and 22.1%) and Mus musculus (2.5% and 8.1%) (Table 1).
Table 1.  Distribution of trapped rodents
IgG, immunoglobulin G.
Rodent species
Case area Control area
Number 
of trapped 
rodents
Number of 
hantavirus IgG-
positive rodents
Number 
of trapped 
rodents
Number of 
hantavirus 
IgG-positive 
rodents
Rattus norvegicus 119 20/119 (16.8%) 60 4 (6.7%)
Rattus tanezumi 36 1/36 (2.8%) 19 0
Mus musculus 4 0 7 0
Total 159 21/159 (13.2%) 86 4/86 (4.7%)
Sera from trapped rodents in the case area and the control area were tested 
for anti-hantavirus IgG. A higher percentage of rodents positive for hantavirus-
specific IgG was detected from the case area when compared with the control 
area (13.2% vs. 4.7%; chi-square test, p=0.036). Twenty-four of the positive rodents 
were R. norvegicus (24/179=13.4%), whereas one was R. tanezumi (1/55=1.8%) 
(Table 1). Within the case area, there was a difference in the mean distance from 
seropositive rats to the patient’s home compared with the mean distance from 
seronegative rats to the patient’s home (49.9 vs. 77.5m; chi-square test, p=0.043) 
(Figure 2).
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Figure 2.  Map of patient’s home and distribution of trapped rodents
RT-PCR was conducted on lung, kidney, spleen, and liver samples from 13 
randomly chosen, IgG-positive rodents from the case area, and the 4 IgG-
positive rodents from the control area. Seoul virus was amplified in 9 of the 13 
rodents selected from the case area and in all 4 of the rodents selected from 
the control area. Seoul virus was most commonly detected in the lungs (9/17, 
52.9%), followed by the spleen (6/17, 35.3%) and kidney (6/17, 35.3%), and no 
rodents had RT-PCR–positive livers (Table 2).
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Sequence analysis of a 225-bp region of the S segment from two specimens 
collected in the case area demonstrated 99% identity with the S segment of a 
Seoul virus isolated from an R. norvegicus in Singapore (GQ 274945 Seoul virus 
isolate Singapore/06).
DISCUSSION
Hantavirus surveillance was conducted in hospitalized patients in West Java, 
Indonesia, between September 2004 and August 2005. During this time, the 
majority of enrolled patients had evidence of recent dengue infection, and one 
patient had serological evidence of hantavirus infection. In this patient, high 
and increasing titers of antibodies against hantavirus were detected; however, 
direct determination of the specific hantavirus serotype was not possible as the 
patient’s PCR results were negative and the facilities required to perform the 
necessary neutralization assays were not available. To further investigate this 
case, an epizoological investigation was conducted. Results of this investigation 
demonstrated a higher seroprevalence of hantavirus-specific antibodies in 
rodents trapped near the patient’s home/work compared with rodents trapped 
in a control area, and Seoul virus was detected in most of the seropositive 
rodents. Although previous molecular evidence had demonstrated the presence 
of Seoul virus in rodents collected from central Jakarta [3], this is the first report 
of its presence in Bandung, West Java. Clinical data also support the diagnosis of 
Seoul virus infection, as Seoul virus infection is milder than HTN virus infection, 
and is frequently accompanied by hepatic involvement [1,10] with no or minimal 
renal disease [11,12].
Table 2.  Rat organ positive in reverse transcriptase-polymerase chain reaction for Seoul virus
Lungs Liver Spleen Kidney Any
Control area 3/4 0/4 0/4 1/4 4/4
Case area 6/13 0/13 6/13 5/13 9/13
Total 9/17 (52.9%) 0/17 (0%) 6/17 (35.2%) 6/17 (35.2%) 13/17 (76.5%)
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Clinically mild hantavirus infection is undifferentiated from other viral or bacterial 
infections, especially dengue, which is endemic in Indonesia. Because many 
suspected dengue cases are not laboratory confirmed, hantavirus may represent 
the true etiology of some of these cases. In central Java, hantavirus IgM has been 
previously reported in up to 17% of suspected dengue cases [4-6]; however, this 
work in western Java detected evidence of hantavirus infection in <1% of the 
patients tested. The differences in the reported prevalences between these two 
locations could be due to differences in methodology or a true difference in 
prevalence between these two locations. Thus, to determine the prevalence of 
this disease among febrile patients throughout Indonesia, additional systematic 
studies should be conducted. 
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ABSTRACT
We report the presence of West Nile virus in a cryopreserved, dengue-negative 
serum specimen collected from an acute fever case on Java in 2004-2005. The 
strain belongs to genotype lineage 2, which has recently been implicated in 
human outbreaks in Europe.
The Indonesian archipelago has been predicted to be a ‘hotspot’ for the 
emergence of zoonotic and vector-borne pathogens [1]. Dengue (DENV), 
chikungunya (CHIKV), and Japanese encephalitis (JEV) are some of the 
arthropod-borne viruses (arboviruses) known to cause febrile illness in Indonesia 
but it is suspected that other, relatively uncommon arboviruses are also causing 
disease. Currently, there is only limited data on the etiology of febrile illnesses 
in Indonesia [2]. As part of an effort to build capacity to detect the etiologies 
of underlying acute febrile illnesses in Indonesia, we have begun an analysis 
of cryopreserved specimens collected in an earlier study of acute febrile illness 
which had previously tested negative for hantaviruses and DENV.
Archived samples were selected from an acute febrile illness study that enrolled 
hospitalized suspected hantavirus patients at two hospitals in Bandung, West 
Java, Indonesia during 2004-2005 [3]. Samples were collected from patients > 
10 years of age with fever of unknown etiology and at least one of the following 
symptoms: 1) hemorrhagic manifestations, 2) platelet count < 100,000/mm3, 3) 
renal insufficiency, 4) liver dysfunction, or 5) non-cardiogenic pulmonary edema. 
Serum samples were collected from patients at admission to the hospital and 
at discharge. Collections were made under institutional review board approvals 
from the National Institute of Health Research and Development, Indonesian 
Ministry of Health and the U.S. Naval Medical Research Unit No. 2, Jakarta, 
Indonesia. The samples were originally tested for hantavirus and dengue using 
reverse transcription-polymerase chain reaction (RT-PCR) and in-house and 
commercial immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent 
assay (ELISA) tests (Focus Diagnostics, Cypress, CA). 
Of 406 cases enrolled, 249 had evidence of recent DENV infection and one had 
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evidence of hantavirus infection. Infecting etiologies for the remaining 157 cases 
were negative for both DENV and hantavirus. We tested 154 acute specimens 
from these cases, which had been preserved at -800C, for other arboviruses. Initial 
testing was performed by using group/family specific primers inconventional 
RT-PCR assays followed by gel electrophoresis of the resulting amplicons [4]. The 
flavivirus group primer testing resulted in four positive samples (265-bp amplicon 
products) which were further tested with virus specific RT-PCR reactions and 
immunofluorescent assay of Vero cells infected with either DENV or JEV. The 
purified nucleic acid of one flavivirus positive sample that was negative for both 
DENV and JEV in the additional testing was subjected to nucleotide sequencing 
at the Eijkman Institute with the same primers used to generate the PCR product. 
A 242 basepair sequence from the NS5 gene was generated from the original 
265 bp PCR amplicon. Genetic comparisons revealed the closest match (99% 
nucleotide identity) with the first West Nile virus (WNV) strain isolated (B956), 
an isolate from Uganda within lineage 2 [5]. Phylogenetic analyses confirmed 
the relationship of the Indonesian strain with other lineage 2 WNV sequences 
(Figure 1).
Figure 1.  A 184 ns5 base-pair nucleotide sequence fragment from Bandung, Indonesia. Sample 
HTV236-01 was aligned with other WNV sequences from GenBank using BioEdit. The 
Maximum Likelihood tree was constructed by using software MEGA5. Bootstrap values are 
expressed as a percentage of 1,000 replicates.
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The WNV positive sample came from a 15 year old boy admitted for systemic febrile 
illness with epistaxis, gastrointestinal symptoms, elevated serum transaminases, 
leucopenia and thrombocytopenia. No neurological symptoms were reported 
and the patient was discharged after full recovery. Culture of the serum sample 
was attempted; however, the sample did not produce cytopathology in Vero 
cells propagated for10 days.
West Nile Virus, a zoonotic, mosquito-transmitted arbovirus belonging to the 
Flaviviridae family, is reported to be the most common cause of epidemic viral 
encephalitis in the United States. Phylogenetic analysis has supported the 
presence of two major genetic lineages. The lineage 1 viruses have typically been 
associated with large outbreaks and thus are considered to be more virulent 
than the lineage 2 strains [6]. However, several recent outbreaks in Europe have 
been caused by lineage 2 WNV strains [7-9]. Thus, it is possible that more recent 
lineage 2 strains are emerging with increased levels of virulence. The Indonesian 
strain might follow this trend but data regarding neurovirulence from Indonesia 
are lacking. The close phylogenetic relationship of the Indonesian strain with 
those from Uganda rather than strains from Australia is somewhat unexpected 
as there is relatively less movement of people and goods between Africa and 
Indonesia. Grouping of isolates, however, does not necessarily correlate with the 
geographic distribution of the virus [10] and may be a further indicator of the 
recent widespread movement of pathogenic arboviruses.
The WNV is considered a serious threat to public health and known to cause 
large outbreaks of epidemic encephalitis in Europe and North America with 
significant morbidity and mortality [11,12]. WNV has not been previously 
isolated in Indonesia, but a serological study detected the presence of antibody 
to this virus in Lombok, Indonesia [13]. Our study associates detection of WNV 
nucleic acid in Indonesia with human illness. Given that these samples were 
collected several years ago, the possibility that WNV may be currently circulating 
in Indonesia warrants further study. The clinical spectrum caused by WNV varies 
dramatically from inapparent infection (approximately 80% of cases) to non-
neurological febrile illness (~ 20% of cases), to the most severe form including 
neuroinvasive disease (<1%) [14]. Neuroinvasive disease cases have a mortality 
rate of about 10% and often display chronic manifestations. 
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There has been limited laboratory capacity in Indonesia to detect arboviruses 
other than dengue and the role of CHIKV, WNV, JEV and other vector-borne 
viruses, such as Zika virus, as causes of febrile illness or more serious encephalitis 
has likely been underestimated. Development of rapid and simple molecular 
diagnostic tests combined with the establishment of dedicated research 
facilities in Indonesia will lead to an increased understanding of both endemic 
and emerging pathogens. With this recent detection of WNV in a febrile human 
in Indonesia, it is clear that WNV should be considered a serious threat to public 
health in Southeast Asia. Enhanced surveillance studies in humans, vectors and 
animals as well as epidemiological surveys are warranted in Indonesia.
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ABSTRACT
In 1992, the Indonesian CDC implemented strategies to control and prevent 
dengue fever (DF) by including community involvement to reduce larva 
breeding sites and a mass health education program. To contribute to this effort, 
we incorporated an educational component into a prospective study of DF 
conducted at two textile factories in Bandung. This education provided: a lecture 
on the signs and symptoms of dengue and ways to prevent the disease, posters 
in the health clinic at each factory and handouts given to each volunteer with 
an explanation of symptoms. Upon enrollment, each participant completed a 
questionnaire to gather demographic information. Additionally they were given 
a brief (non-standardized) test (PRE-test) of their dengue knowledge, which was 
verbally administered by the study physicians. Five questions (15 point system) 
were designed to assess the participant’s ability to recognize and describe 
aspects of dengue in lay terms. The subject material included: the symptoms of 
acute DF, transmission of dengue virus, and basic steps for disease prevention. 
The same questionnaire was re-administered 18 months later (POST-test), and 
the results were compared. A total of 2,340 participants completed both the 
PRE- and POST-tests; there were 1,373 males and 967 females, median age 36 
years (range 18-59). Only 0.3% of participants scored EXCELLENT (15-14 points) 
on the PRE-test whereas 8.4% scored EXCELLENT on the POST-test. Fewer 
participants scored VERY BAD (2-0 points) on the POST-test compared to the 
PRE-test (1.4% vs 4.0%). The average raw scores for the PRE- and POST-tests were 
7.8 and 10.1, respectively. Improvement of individual scores correlated highly 
with educational level. No significant correlation was identified for gender, 
age, factory location or a diagnosis of dengue during the study. These findings 
demonstrate that our prospective study enhanced knowledge and awareness of 
dengue in the volunteers.
INTRODUCTION
Dengue fever (DF) and dengue hemorrhagic fever (DHF) continue to cause 
thousands of deaths and morbidity annually. In many Asian countries, severe 
disease affects children the greatest while milder cases typically occur among 
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adults. Although dengue illness in adults is often mild or unapparent, the 
disease burden may significantly impact economic growth and productivity. The 
average dengue illness may require up to 7-10 days of convalescence prior to 
the individual’s returning to work. Many cases can cause even more prolonged 
illness requiring several weeks convalescence. During epidemic years, the 
financial impact can be quite substantial, especially in developing countries 
such as Indonesia. 
The role of community education programs is well recognized by health 
officials as an important factor in efforts to control and prevent dengue illness. 
The Indonesian Ministry of Health Communicable Diseases Center (CDC), in 
conjunction with the WHO, has established a mass health education campaign 
along with programs to reduce larva-breeding sites. The campaign primarily 
conveys messages to cover, empty/clean water containers (‘3M’s’ in indonesian 
language) or discard unused containers or other items that may fill with water, 
which may become selective breeding sites for Aedes mosquito larvae. Few 
evaluations of the impact of health education or community messages have been 
conducted in Indonesia. Public health education programs in other countries 
have clearly demonstrated success in increasing awareness of the disease and its 
transmission [1-3]. To contribute to the Indonesian CDC’s program of increasing 
awareness to combat and prevent dengue infection, we incorporated an 
educational component into our prospective study of DF and DHF among adults 
at two textile factories in Bandung, West Java. Although our study budget did 
not allow for a comprehensive public health educational program, we desired 
to provide this benefit to the participants while accomplishing the primary 
objective of improving our understanding of dengue infections among adults. 
This report briefly summarizes the findings of our efforts.
MATERIALS AND METHODS
In August 2000, a prospective study of DF and DHF in adults was initiated at 
two textile factories (Grandtex and Naintex) in Bandung, a large urban city on 
the island of Java, Indonesia. During enrollment, demographic information was 
collected from all participants (n=2,536) and a verbal PRE-test (non-standardized) 
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of dengue knowledge was administered in the Indonesian language (Fig 1). The 
study investigators designed this brief dengue knowledge assessment test in lay 
terms consisting of five questions to assess each participant’s basic knowledge 
of symptoms of dengue infection, transmission of dengue virus, and methods 
for the prevention of dengue illness. An arbitrary scoring system (maximum 
15 points) was designed to provide grades as shown in Figure 1. Shortly 
thereafter, a baseline educational program was developed to provide general 
dengue information to the cohort. This included a didactic lecture taught by 
the study physicians, printed informational handouts, and posters printed by 
the Indonesian CDC which were displayed at or near each factory occupational 
health clinic throughout the duration of the prospective study. The same verbal 
dengue knowledge assessment test (POST-test) was re-administered 18 months 
later (February 2002) and compared with the results of the PRE-test. Data were 
evaluated descriptively and analyzed using nonparametric statistical analyses.
The Institutional Review Boards of the US NAMRU-2 and the Indonesian National 
Institute of Health Research and Development approved the prospective study 
and verbal questionnaires (DoD#30855). All participants granted informed, 
written consent prior to their enrollment.
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Dengue Knowledge
Symptoms (max point 5)
1. What are the symptoms of patients who suffer from 
dengue hemorrhagic fever?
- fever 
- body aches/headache
- red spot 
- bleeding from nose or gum etc
- other symptoms (see below)a
1 point
1 point
1 point
1 point
1 point
Transmission (max point 5)
2. how is this disease transmitted?b
1.by Aedes mosquito(2) 2.by mosquito(1) 3.No idea(0)
3. when does this mosquito usually bite?
 1.in the morning and afternoon(2) 2.in the morning(1)
 3.in the afternoon(1) 5.at night(2) 4.no idea(0) 
4. where is the mosquito’s breeding place?
 1.clear water(1) 2.dirty water(0) 3.rice terrace(0) 4.no idea(0)
Prevention (max point 5)
5. what prevention steps need to be taken to aoid this 
disease?
- spray the mosquitos (fogging)
- put abate powder in the water
- bury unused cans, etc
- wash water containers
- close water containers
1 point
1 point
1 point
1 point
1 point
Grade Score
Excellent 15-14
Very Good 13-12
Good 11-9
Fair 8-6
Bad 5-3
Very Bad 2-0
aacceptable answers : stomachache, fatigue, nausea, vomiting, shock
bonly answer # 1 or 2 is correct
Figure 1.  Dengue knowledge assessment test
RESULTS
A total of 2,340 participants in the cohort completed both the PRE and POST 
dengue knowledge assessment tests. There were 1,373 males and 967 females 
at the two factories combined; the mean age of workers was 36.2 years (range 
18-59). A summary of responses is shown in Fig 2. The average raw scores for the 
PRE and POST-tests were 7.8 and 10.1, respectively. 
The majority scored FAIR (39.9%) or GOOD (38.4%) on the PRE-tests. However, 
the average grade shifted to GOOD (42.5%) or VERY GOOD (23.8%) for the 
POST-testing. Only 0.3% of participants scored EXCELLENT (15-14 points) on the 
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PRE-test whereas 8.4% scored EXCELLENT on the POST-test. Fewer participants 
scored VERY BAD (2-0 points) on the POST-test compared to the PRE-test (1.4% 
vs 4.0%). Improvement of individual scores correlated highly with educational 
level (Pearson rank correlation=0.389, significant at 0.01 level, 2-tailed). Factory 
workers with college education scored higher on average than those with 
high school, secondary and primary school education (Table 1). No significant 
correlation was identified for gender, age, factory location or a diagnosis of 
dengue during the prospective study.
Figure 2.  Results of dengue knowledge assessment test.
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In question-specific analysis, interesting trends were found. At PRE- and POST-
testing, most workers knew that fever and petechiae were symptoms of dengue 
illness (85.4%, 96.2%, respectively), but very few 12.6% (295) related body aches/
headache as a symptom on the PREtest compared to 45.6% (1,066) on the POST-
test. Bleeding from the nose or gums was also not a well-known symptom at 
baseline (46.6%). During both the PRE/POST-tests, the preferred answer for the 
method of disease transmission was by ‘Aedes mosquito’ versus ‘mosquito’. Only 
4.6% (108) answered incorrectly that Aedes aegypti bite at night while most (78%, 
1,831) answered correctly that the mosquito’s breeding place is in clear water. 
The final question relating to vector control measures included five theoretically 
correct sub-answers of which three are contained in the 3M educational 
messages: bury, wash, and close containers. Responses were evenly distributed 
among these three answers. Surprisingly at PRE-testing, the use of Abate® 
powder and fogging were not thought to be adequate prevention techniques 
even though many communities are made aware of the use of these methods 
to control outbreaks via the publicity it raises. These findings demonstrate that 
our prospective study enhanced knowledge and awareness of dengue in the 
study participants.
Table 1.  Comparison of dengue knowledge assessment test scores (pre and post) versus 
educational level.
Mean raw scores
p-value
PRE-test POST-test
Primary
Secondary
High
College
Total
6.27
7.38
8.30
8.96
7.77
8.90
9.67
10.51
11.35
10.08
<0.01
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DISCUSSION
The educational program provided during our prospective study appeared 
to enhance the knowledge and awareness of dengue among the study 
participants, as assessed by our verbal knowledge test. The most notable 
finding was that test performance correlated highly with educational level, 
albeit there was significant POST test improvement at all educational levels. 
No significant correlation was identified between test scores and age, factory 
location or gender. 
In a prior study, gender and age differences had been recognized as a determinant 
factor on knowledge of DF and DHF, for example housewives tended to have 
a better baseline dengue knowledge and elderly individuals tended to be 
less knowledgeable [4]. Perhaps this was not observed in our cohort since the 
women surveyed were in the workforce versus being homemakers, and the 
extreme elderly were not surveyed (maximum age, 59 years). Admittedly, our 
assessment methods may have been limited and were not intended to provide 
a stringent assessment of the Indonesia CDC’s overall mass health education 
program for the country. However, our cohort of textile workers provides a 
representative sampling of a segment of the population in the city of Bandung. 
Baseline educational skills and targeted health education should be considered 
key factors in developing knowledge and awareness of dengue and possibly 
other vector-borne diseases.
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ABSTRACT 
A two-year study using a cluster investigation method was conducted in West 
Jakarta, Indonesia to demonstrate the detection of dengue cases prior to onset 
of clinical illness. The clusters consisted of family members and neighbors of 
53 hospitalized dengue index cases. Among 785 adult and child volunteers 
enrolled, 17(2.2%) post enrollment dengue (PED) infections were identified. 
Eight PED cases were asymptomatic and nine were symptomatic. Symptomatic 
cases included eight with dengue fever and one with dengue hemorrhagic 
fever (DHF) (grade II). Among the eight asymptomatic PED cases, viremia was 
detected in two. Eleven volunteers had acute dengue infections at the time of 
enrollment. Four of the 11 developed DHF, resulting in a total of five DHF cases 
detected during the investigation. This study design can serve as a benchmark 
for future investigations that seek to define early immunologic events following 
dengue infections that contribute to the development of DHF.
INTRODUCTION
Infection with any of the four serotypes of dengue virus (DEN-1, DEN-2, DEN-3, 
and DEN-4) can be asymptomatic, result in a mild-to-moderate febrile illness 
termed dengue fever (DF), or a more severe illness characterized by bleeding 
and shock called dengue hemorrhagic fever (DHF) or dengue shock syndrome 
(DSS) [1,2]. After an initial infection with dengue virus, homologous serotype 
immunity persists for many years; however, individuals remain susceptible to 
infection with the remaining dengue virus serotypes. In several studies, DHF 
occurs 15–80 times more frequently in individuals experiencing a second dengue 
virus infection compared with individuals experiencing their first infection [3]. 
The biologic events that lead to a higher frequency of DHF in secondary dengue 
virus infections compared with primary infections are not completely known.
Antibody-dependent enhancement of dengue virus infection leading to 
increased viral load is a leading theory for severe diseases caused by dengue 
virus. Increased levels of circulating dengue virus have been documented in 
DHF cases compared with DF cases [4-6]. However, the immunologic events that 
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occur in the early stages of infection that lead to severe disease have not been 
characterized in patients. In the absence of an animal model for DHF, researchers 
are forced to try to characterize early immunologic events in patients with 
recently acquired dengue virus infections. A major limiting factor in such an 
investigation is identifying individuals prior to the onset of their clinical illness 
so that early events can be characterized. The current study was designed to 
overcome that problem by identifying individuals very early in the infection. 
Family members and nearest neighbors of index cases hospitalized with acute 
dengue virus infections were enrolled and followed longitudinally to determine 
the incidence rate of dengue virus infection. This proof-of-concept study was 
conducted to evaluate the hypothesis that monitoring persons clustered around 
an index case would be an efficient and practical way to obtain blood samples 
before, during, and after dengue infection.
MATERIALS AND METHODS
Study location and population. 
West Jakarta (West Java), Indonesia, was selected as the location to pilot the 
concept of a dengue cluster study for several reasons. The catchment area for 
cases is in a tropical, urban setting with approximately 2.5 million inhabitants of 
various socioeconomic strata, mostly of low income. On average, 5–10 persons 
may live in a single housing unit measuring 10 × 15 meters2. Most neighborhoods 
are densely populated, with dwellings in relatively close proximity to one 
another (approximately 10 meters apart) and constructed of cement and/or 
wood. The average house does not have piped water and some communities 
share toilet facilities. The government supplies potable water in large cans and 
water for bathing is often stored in a traditional uncovered, tub-like area (bak 
mandi) located in bathrooms. The bak mandi has long been a potential source 
of Aedes mosquito larvae,[7] in addition to other open containers used for water 
storage and various other miscellaneous items (i.e., flower pots, tires) containing 
water found in close proximity to human dwellings [8]. Aedes aegypti mosquitoes 
are ubiquitous throughout Indonesia and transmission of all four dengue virus 
serotypes is known to occur. According to the Indonesian Communicable 
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Disease Control, the three-year incidence of dengue disease in Jakarta was 
75.4, 52.4, and 108.5 cases per 100,000 population from 2001 to August 2003, 
respectively (unpublished data). 
Dengue virus laboratory tests. 
Serum samples were tested for the presence of IgM antibodies to dengue virus 
using commercial enzyme-linked immunosorbent assay (ELISA) kits (Focus 
Technologies, Cypress, CA). Hemagglutination inhibition (HI) assays and plaque 
reduction neutralization tests (PRNTs) were also performed to confirm dengue 
virus infection and to classify the infection as primary or secondary based on the 
antibody response [9]. Dengue virus RNA in blood was detected using a reverse 
transcriptase–polymerase chain reaction (RT-PCR) assay [10]. Blood samples 
collected from symptomatic volunteers during the acute stage of febrile illness 
and from suspected asymptomatically infected volunteers were tested for 
virus by culture in C6/36 cells, and virus was identified using serotype-specific 
monoclonal antibodies for dengue virus [11]. 
Study Design
Each cluster of volunteers was identified by an index case from the pediatric ward 
at Sumber Waras Hospital in West Jakarta. Physicians at this local community 
hospital have a well-established relationship with the surrounding community 
and are experienced in clinically diagnosing dengue virus infections. For the 
index cases, children 4–14 years of age were recruited. Ward clinicians were 
asked to select 1–2 cases per week based on clinical manifestations, together 
with the detection of IgM antibody to dengue virus by ELISA and/or dengue viral 
RNA by RT-PCR. In most cases, these diagnostic assays were performed within 48 
hours of index case identification. Other considerations in selecting index cases 
included automobile accessibility to their community and the willingness of the 
family to participate.
Usually within 48 hours of index case identification, family members and nearest 
neighbors greater than four years old who lived within a 10-meter radius of the 
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index case’s home were invited to participate. Volunteers who were afflicted 
with or who had a history of severe anemia, bleeding disorder, or any known 
immunologic disorder were excluded from the study. On enrollment, we 
measured the otic temperature, and collected blood samples and demographic 
data from each study volunteer. Volunteers were followed for 14 consecutive 
days for fever and other clinical manifestations suggestive of acute dengue virus 
infection. During the monitoring period, we collected additional blood samples 
from each volunteer every 2–3 days. We also collected blood specimens from 
each volunteer who developed a fever or dengue-like signs or symptoms and 
processed them for a diagnosis of dengue. To confirm that dengue virus was 
the cause of fever, we tested samples within 24–48 hours of collection for 
dengue viral RNA by RT-PCR and for IgM antibody to dengue virus by ELISA. If 
a sample collected from a febrile volunteer was positive for IgM antibodies to 
dengue virus, the enrollment blood sample for that volunteer was tested for 
IgM antibodies to dengue virus to determine if seroconversion had occurred. 
These laboratory tests were performed at the Virology Laboratory of the U.S. 
Naval Medical Research Unit No. 2. Blood samples treated with EDTA were also 
obtained at the onset of fever and sent to Sumber Waras Hospital for hematocrit 
and platelet count determinations.
Febrile volunteers with a positive IgM ELISA or RT-PCR result were encouraged 
to be hospitalized for close monitoring and serial laboratory tests. Volunteers 
refusing hospitalization were monitored closely as outpatients until they were 
afebrile for two consecutive days. Convalescent blood samples were obtained 
two weeks later and again at six months.
Hospitalized volunteers were bled daily until two days after defervescence, two 
weeks later, and approximately six months after discharge from the hospital. 
Blood samples were routinely tested for hemoglobin, hematocrit, platelets, white 
blood cells, protein, and albumin. A tourniquet test was done on admission and 
daily ultrasound examinations for ascites and pleural effusions were performed 
until two days after defervescence to detect evidence of plasma leakage. We 
classified hospitalized volunteers as DF or DHF (World Health Organization, 
1997) [12] following evaluation of the clinical data.
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We categorized all volunteers clustered around the index cases into one of three 
groups: non-dengue (ND) infection, dengue infection at enrollment (ED), or 
post-enrollment dengue (PED) infection. A PED case was defined as a volunteer 
who developed fever after enrollment and demonstrated seroconversion 
for IgM antibodies to dengue virus and/or dengue viremia by RT-PCR or virus 
isolation. Volunteers who developed fever but were negative for IgM antibodies 
to dengue virus or viremia were later classified as PED infections if there was a 
four-fold increase in the HI antibody titer to dengue virus between enrollment 
and the two-week post-enrollment blood samples. For equivocal HI results (less 
than a four-fold increase in titer), pre-enrollment and two-week post-enrollment 
PRNT50 titers were compared for a ≥ fourfold increase against one or more dengue 
virus serotypes. For volunteers who never developed fever, laboratory evaluation 
of serum samples (dengue serology and virus detection) was still conducted 
throughout the 14-day monitoring period. Asymptomatic volunteers who were 
positive for viremia and/or showed a four-fold increase in HI titer between the 
enrollment and two-week post-enrollment blood samples were also classified 
as PED cases.
Volunteers that demonstrated evidence of infection (IgM, RT-PCR, or virus 
isolation), with or without symptoms at the time of enrollment were classified as 
ED cases. All other volunteers were classified as ND cases.
The U.S. Naval Medical Research Unit No. 2 Institutional Review Board and the 
Indonesian Ministry of Health Ethical Review Committee reviewed and approved 
the human use protocol (DoD# 30861) used in the study, in compliance with all 
U.S. federal regulations governing the protection of human subjects. Informed 
written consent was obtained from all participants, and if < 15 years of age, from 
a parent or legal guardian.
RESULTS
Over a two-year period from October 2001 to October 2003, 53 confirmed 
dengue index cases were identified in the pediatrics ward at Sumber Waras 
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Hospital (Table 1 and Figure 1). Infections by all dengue virus serotypes were 
identified among the index cases. The predominant serotype identified was 
DEN-1 (10), followed by DEN-2 (8), DEN-3 (5), and DEN-4 (2). The serotype was 
not determined in 28 index cases. None of the index dengue infections was fatal. 
From these 53 dengue index cases, 53 cluster investigations were performed 
where family members and nearest neighbors surrounding the residence of each 
index case were monitored for dengue virus infection. A total of 785 volunteers 
were recruited from the 53 community clusters, of which 541 completed the 
entire 14-day monitoring period. The 244 volunteers who did not complete the 
entire monitoring period were included in the analysis since at least one blood 
specimen was available for evaluation from each volunteer. Table 1 shows the 
demographics of the volunteers in the study. 
Among the 785 cluster volunteers, 175 (22.3%) were classified as ED cases. Table 
1 also shows the demographics of ED cases. Eleven ED cases were found to 
be viremic for dengue at enrollment by the RT-PCR. The DEN-1 serotype was 
identified in three cases and DEN-2 in eight cases. Confirmatory virus isolation 
was accomplished in 5 of the 11 cases. The remaining 164 ED cases had evidence 
of recent dengue virus infection, as indicated by IgM antibodies to dengue virus 
at enrollment and were classified as convalescent infections (Figure 1). 
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Nine of the 11 viremic ED cases had fever at enrollment. The nine febrile volunteers 
were hospitalized for close monitoring within 24–48 hours of enrollment 
after dengue serologic and/or RT-PCR results were known. Four of the febrile 
hospitalized ED cases were subsequently diagnosed with DHF (three grade I and 
one grade II). All four DHF cases were caused by a DEN-2 virus. Analysis of HI and 
PRNT titers suggested that two of the DHF cases were secondary infections and 
two were primary infections. The volunteers with primary infections were 10 and 
8 years old, whereas those with the secondary infections were 20 and 21 years 
old. 
Figure 1.  Map of index cases and corresponding dengue infections identified in respective clusters 
in West Jakarta, Indonesia. Each circle represents an index case. Each square represents 
an acute dengue case identified at enrollment by detection of virus (ED acute infection) 
or during a two-week period of monitoring by detection of virus or by seroconversion 
(post-enrollment dengue infection). The numbers inside the circles represent convalescent 
dengue infections detected by the presence of IgM antibody only at enrollment (ED 
convalescent infection). The study hospital (Sumber Waras Hospital) is indicated. 
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Seventeen (2.2%) volunteers were diagnosed as PED cases during the 14-day 
monitoring period (Table 2), and most (15 of 17, 88%) were among nearest 
neighbors (Table 1).
Table 1.  Demographics of volunteers and corresponding dengue infections identified in West 
Jakata, Indonesia*
Number of Index 
cases
Community 
volunteers
ED cases PED cases
Total 53 785 175 17
Males:females 23:30 317:468 84:91 8:9
Adults NA 453 87 8
Children (4-14 years old) 53 332 88 9
Mean age (years) 6.6 25.57 19.2 20.2
Family members NA 164 32 2
Nearest neighbors NA 621 143 15
*ED = enrollment dengue cases; PED = post-enrollment dengue cases; NA = Not Applicable
Of the 17 PED cases, 10 were positive by the RT-PCR (1 DEN-1, 7 DEN-2, 1 DEN-
3, and 1 DEN-4), and the serotype was confirmed by virus isolation in 5 cases. 
The other seven PED cases became positive for IgM antibodies to dengue virus 
during monitoring, and dengue infections were also evident by serocoversion 
≥ 4-fold increase in antibody titer) by HI or PRNT. Four of the 17 PED cases were 
primary infections based on HI and PRNT50 results, and all others were secondary 
infections. 
Nine of the 17 PED cases experienced symptomatic illnesses. Eight of the nine 
were DF and one was diagnosed as DHF grade II. The HI and PRNT patterns 
comparing preillness and convalescent blood samples suggested a secondary 
infection in all but three cases (Table 2).
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Table 2.  Characteristics of 17 post-enrollment dengue (PED) infection cases identified
Study No. Age (years)/sex DEN Serotype
Clinical 
Classification*
Serotype 
response
CL 0102 9/F 4† DF Secondary
CL 0118 18/M Asymptomatic Secondary
CL 0417 37/F Asymptomatic Secondary
CL 0710 14/F Asymptomatic Secondary
CL 1002 7/M 2 DF Primary
CL 1211 5/M DF Secondary
CL 1514 30/F 2 DF Secondary
CL 1806 10/F 2† DHF grade II Secondary
CL 2202 8/M 2† DF Primary
CL 2204 40/F 2† Asymptomatic Secondary
CL 2408 47/F 1 Asymptomatic Secondary
CL 3213 24/M 2† DF Primary
CL 3716 9/M Asymptomatic Secondary
CL 3911 32/F 2 DF Secondary
CL 4202 11/M 3 DF Secondary
CL 5115 36/M Asymptomatic Secondary
CL 5304 7/F Asymptomatic Primary
* DF = dengue fever; DHF = dengue hemorrhagic fever.
† Positive by both dengue virus reverse transcriptase–polymerase chain reaction and virus isolation
in C3/36 cells.
The one PED DHF case was hospitalized five days after enrollment with a fever of 
38.8°C and a positive tourniquet test result, along with a history of epistaxis prior to 
admission that continued for two days while hospitalized. Small pleural effusions 
and ascites developed on day three, but resolved by day five. The platelet count 
was normal on admission but decreased to 40,000/mm3 by hospital day six. From 
admission, total protein and albumin levels decreased from 8.1 g/dL to 5.2 g/dL 
and from 3.5 g/dL to 2.9 g/dL, respectively (normal levels: protein = 6.4–8.7 g/dL 
and albumin = 3.5–5.2 g/dL) on day six. The patient remained hemodynamically 
stable throughout hospitalization and was discharged on day 10. 
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Asymptomatic dengue virus infections occurred in eight of the PED cases (Table 
2). Dengue viremia was detected in two of the eight cases, with DEN-1 identified 
in one case by RT-PCR and DEN-2 identified in the second case by both RT-PCR 
and virus isolation. In the case with DEN-1, virus was detected in the blood 
sample obtained on day 10. For the case with DEN-2, virus was detected in the 
blood sample obtained on day 4. To our knowledge, these cases, together with 
the two asymptomatic ED viremic cases mentioned earlier, represent the first 
documentation of asymptomatic dengue viremia in human volunteers from 
naturally acquired infections.
Table 3 shows the serotype-specific relationship of dengue viruses identified 
from index and cluster cases. There were seven instances in which the virus 
was identified from both the cluster case and the corresponding index case 
(four ED cases and three PED cases). The infecting serotype of the cluster case 
corresponded with the infecting serotype of the index case in four instances 
(all DEN-2) and in three instances the infecting serotypes were different. We did 
not detect a specific pattern of the infecting serotype between the ED and PED 
cases.
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Table 3.  Summary of known dengue virus (DEN) serotypes for the index case and corresponding 
cluster dengue cases (11 viremic ED cases and 17 PED cases)*
Cluster case
ID no.
Cluster case
serotype†
Index case
serotype
ED cases
CL 0602 DEN-2 DEN-1
CL 0906 DEN-2 DEN-2
CL 1001 DEN-2 DEN-3
CL 1101 DEN-2 DEN-2
CL 1105 DEN-2 -
CL 1108 DEN-2 -
CL 1201 DEN-2 -
CL 3701 DEN-1 -
CL 3702 DEN-1 -
CL 3815 DEN-2 -
CL 4007 DEN-1 -
PED cases
CL 0102 DEN-4 -
CL 0118 - -
CL 0417 - -
CL 0710 - DEN-2
CL 1002 DEN-2 DEN-1
CL 1211 - -
CL 1514 DEN-2 -
CL 1806 DEN-2 DEN-2
CL 2202 DEN-2 -
CL 2204 DEN-2 -
CL 2408 DEN-1 -
CL 3213 DEN-2 DEN-2
CL 3716 - -
CL 3911 DEN-2 -
CL 4202 DEN-3 -
CL 5115 - -
CL 5304 - DEN-4
* ED = enrollment dengue; PED = post-enrollment dengue; ID no. = subject identification number; 
− = negative result.
† Serotype identified by dengue virus reverse transcirptase–polymerase chain reaction and/or virus 
isolation.
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DISCUSSION
Our cluster investigation method was designed as an alternative approach to 
the commonly used prospective cohort study method for investigating the 
natural history of dengue virus infection. Unlike the cohort study, the cluster 
investigation method allows the collection of clinical information and biologic 
samples during the early pre-infection stage. This allows for more precise 
characterization of the early immunopathologic events that contribute to either 
mild or severe clinical manifestations of dengue virus infection. 
Among 785 volunteers in this investigation, we observed 17 PED (new) dengue 
infections that were both symptomatic and asymptomatic, including one case 
of DHF. The calculated incidence rate of dengue infection was 567 cases per 
1,000 person-years of follow-up. Based on the one observed DHF case, the 
calculated DHF incidence rate was 33 DHF cases per 1,000 person-years of 
follow-up, resulting in a DHF to DF incidence rate ratio of 1:18. This ratio closely 
approximates other epidemiologic observations, showing that DHF occurs 
in roughly 5% of dengue virus infections in areas where all four serotypes of 
dengue virus are endemic [13-15].
We detected 175 individuals who had either a recent dengue virus infection 
or who were acutely infected at the time of enrollment and diagnosed with 
DHF. Eleven of the 175 volunteers were found to be viremic. Combining these 
11 cases with the PED cases, a total of 28 acutely infected dengue cases were 
observed among the volunteers (Figure 1), resulting in a calculated incidence 
of 933 acute dengue cases per 1,000 person-years of follow-up. Of the 28 acute 
dengue cases, five were classified as DHF resulting in an overall DHF incidence 
of 166 cases per 1,000 person-years.
Virologic analysis of dengue cases confirmed that all four serotypes circulated in 
West Jakarta. The DEN-1 serotype was the predominant virus identified among 
the index cases, but DEN-2 caused most of the cluster cases, including all five 
DHF cases. We plan to genetically characterize these viruses and compare 
them to other circulating Asian strains. Using banked sera, we will also examine 
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the kinetics of infection in both symptomatic and asymptomatic cases by 
a quantitative RT-PCR. Although an association between the level of dengue 
viremia and severity of symptomatic disease was previously established, these 
analyses may provide some insight into whether there is a correlation between 
the level of viremia and symptomatic or asymptomatic dengue virus infection.
An attractive feature of the cluster investigation method is that it does not 
rely on outbreak events to accumulate a sizeable number of cases. When 
longitudinally following a randomly selected cohort, the study population may 
or may not experience outbreak-related dengue virus transmission, so that to 
arrive at a sufficient number of DHF and DF cases for statistical analysis, one may 
have to follow a particular cohort for many months to years. With the cluster 
investigation method that selects index cases as a reference point, only days to 
weeks of follow-up are required to define past and present virus activity in an 
area. A shorter follow-up period would significantly reduce cost and personnel 
needs.
Cohort studies to date have been unsuccessful in documenting asymptomatic 
viremia in humans from naturally acquired dengue infection [16]. Given the natural 
history of dengue virus infection, such silent viremia would seem plausible, but 
with the design of typical longitudinal cohort studies, infected volunteers are only 
identified upon the development of symptoms. Asymptomatic infections are 
only detected by seroconversion of blood samples collected at pre-determined 
time points. Using a cluster design approach, we were able to document eight 
asymptomatic dengue infections, two of which demonstrated viremia. To our 
knowledge, this is the first documentation of asymptomatic viremia in naturally 
acquired human dengue infections.
The one obvious disadvantage of the cluster method is that volunteers are 
required to participate in an intensive period of surveillance where, despite being 
healthy at the time, they are asked to donate blood samples every 2–3 days for a 
period of two weeks. We had little difficulty recruiting the requisite 10–15 people 
per cluster and often had to refuse additional enrollment of willing volunteers. 
With augmented resources and experience, we plan to expand our study design 
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to new areas (East Jakarta and another major city in West Java, Indonesia) and 
to increase the number of index cases (6–8 per week) and persons recruited per 
cluster (up to 20). The major challenge to our cluster study design is maintaining 
adequate support (finances and trained personnel) for the intensive community 
monitoring. We believe that the yield of the cluster investigation method is 
equal to or substantially greater than that of other prospective study methods 
used to examine the epidemiology of naturally acquired dengue virus infection. 
As this method is applied to other countries with varying cultural sensitivities 
and expectations, differing levels of success may be encountered.
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SUMMARY AND DISCUSSION
After sporadic outbreaks were reported during the 18th and 19th centuries, 
dengue emerged as the most important arbovirus only after severe DHF/DSS 
occurred in Southeast Asia after the World War II [1]. Since then, the epidemiology, 
virology, immunology, clinical pathogenesis, treatment and prevention of 
dengue virus infections have been studied by various researchers on different 
continents. Nevertheless, many controversies and gaps remain to be elucidated. 
For instance, the commonly quoted statement “dengue causes 50-100 million 
cases globally every year” may not reflect the reality but should be regarded 
as “dengue infections”, which include a large proportion of asymptomatic 
infections [1]. Many more controversies and knowledge gaps still exist such 
as: the usefulness and limitations of the WHO clinical classifications criteria of 
the years 1997, 2009 and 2011; insight into the pathogenesis of severe dengue 
(virulence of dengue virus subtypes, abnormal or accelerated T cell responses, 
autoimmune phenomena or second infections) [2]; the unavailability of rapid 
and accurate diagnostic tests [3], animal models [4] and antivirals [5]; and a safe 
and effective vaccine [6].
To improve our understanding of the epidemiology and pathogenesis of 
dengue infections, prospective studies which can accurately identify and 
characterize dengue infections and their severity are needed [7]. Different 
kinds of prospective studies can be used, including population-based cohort 
studies or cluster studies in communities, and hospital based studies. The 
first population-based dengue cohort study was carried out among school 
children in Rayong, Thailand in 1984, followed by five similar studies carried 
out in Bangkok, and other cities including Yangon in Myanmar, Yogyakarta 
in Indonesia and Managua in Nicaragua [7].These cohort studies had several 
outcomes including a better understanding of disease burden on different 
populations, including the economic impact and the characterization of the 
determinants of disease severity. In addition, populations with a well-defined 
natural history of dengue infections were identified, also providing the field 
site infrastructure to conduct phase III dengue vaccine efficacy studies [7]. 
The need for longitudinal cohort studies in adults also became evident as 
Summary and discussion | Ringkasan | Samenvatting
215 13
the number of uncomplicated and complicated dengue infections in adults 
increased during the last three decades, including during outbreaks [8-10]. In 
addition, prospective cluster studies within certain communities were carried 
out in order to analyze transmission among household members, and to be 
able to identify early and new onset infections that allow identification of 
clinical and immunologic predictors of severe disease [11,12].
This thesis describes results from several prospective studies carried out in West 
Java, Indonesia. The first is a prospective cohort study conducted at three textile 
factories in Bandung from 2000-2004 and 2006-2009, involving 4380 adults 
who were monitored daily and had blood taken quarterly. The second was a 
prospective community clusters study in 2001-2003 in West Jakarta, where family 
members and close neighbors of an index patient were followed for two weeks 
to collect pre-illness and consecutive specimens as well as signs and symptoms 
of a possible dengue infection. In addition, this thesis also presents the findings 
from a large dengue outbreak in 2004, the national influenza surveillance carried 
out between 2003 and 2007, and a hospital-based hantavirus surveillance study 
performed between 2004 and 2005. These studies were funded by the United 
States Naval Medical Research Unit no 2 (US-NAMRU#2), in collaboration with 
Sumber Waras Hospital, Jakarta, Hasan Sadikin Hospital and Faculty of Medicine 
Universitas Padjadjaran, Bandung, and the National Institute of Health Research 
and Development, Ministry of Health, Jakarta, Indonesia.
Chapter 2 presents the epidemiology, virology and clinical aspects of dengue 
infections in a cohort of 4380 adult factory workers in Bandung, West Java, 
who were observed for a period of 79 months. This study demonstrates that 
dengue contributed to 12.41% of fever cases and that the actual annual 
dengue incidence rate was 17.3 cases/1000 population per year, 43 times 
higher than the national reports. This study further reveals that the actual 
number of dengue infections per population per year should also considered 
asymptomatic infections which was 2.6x the incidence rate. This new 
epidemiological data is important for clinicians and health policy makers, 
as the study demonstrates that it is important to include dengue in the 
differential diagnosis of undifferentiated febrile illnesses. It is also necessary 
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to develop strategies to control dengue transmission which is much more 
frequent than previously known. Furthermore, dengue cases were found during 
almost the whole year, with the peak during the wet season that generally ranges 
from December to March. All serotypes were detected as circulating every year, 
although they were rarely found simultaneously in the same month. This finding 
demonstrates that Bandung is a hyper-endemic area of dengue infections. From 
a total of 268 confirmed cases, only one DSS case was diagnosed. The remaining 
were DHF grade one and grade two, and the mild form, dengue fever with or 
without hemorrhagic manifestations. Severe cases were associated with DENV-
3, which was consistently reported as the main cause of outbreaks in Indonesia. 
Our data also suggest that asymptomatic cases were associated with DENV-4. 
In this study, we also found evidence of successive dengue infections in seven 
patients. This finding confirms that infections with certain serotypes may not 
protect individuals from infections with other serotypes. Finally, our study has 
not only provided precious data demonstrating the importance of dengue in 
West Java but has also characterized the natural course of disease in an adult 
population, which is a prerequisite for future vaccine studies. 
While chapter 2 provides data on natural dengue infections during endemic 
conditions, data from a dengue outbreak in 2004, that included 50,000 cases 
and 603 deaths in Indonesia, is reported in chapter 3. The data are important, 
since periodic outbreaks of dengue have emerged in Indonesia since 1968. The 
chapter provides epidemiological, clinical and virological data from 10 hospitals 
in five municipalities in Jakarta, Indonesia. Our investigations confirm that all 
municipalities were affected by this outbreak, while all four dengue serotypes 
were simultaneously circulating, with DENV-3 as the most predominant. 
Genotype analysis reveals that the circulating DENV-3 was identical to that 
which caused the 1998 epidemic. Simultaneous circulation of four or multiple 
serotypes with DENV-3 as the most predominant has also been reported in 
previous dengue outbreaks in Indonesia, including during the largest outbreak in 
1998. The circulation of multiple serotypes with DENV-3 predominance - besides 
the presence of naïve populations and the circulation of novel or more virulent 
virus strains - might therefore create the conditions for a dengue outbreak to 
occur in an endemic situation. Our investigation also shows that all age groups 
were affected and that the proportion of DHF was significantly higher during 
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an outbreak compared to endemic conditions, despite the possibility of an 
underestimation of DHF cases due to the lack of serial full blood counts to 
demonstrate hemoconcentration. Finally, similar to the previous report from 
Semarang [13], dengue was not confirmed in a large proportion (33%) of cases.
The first two chapters have described West Java as a hyper-endemic region where 
all four DENV seroytpes were circulating. According to the antibody dependent 
enhancement theory (ADE), this condition puts the populations at increased 
risk to develop severe disease in case of secondary infections. In chapter 4, 
evidence is given of three heterologous successive dengue infections in four 
study participants. The first infection was prior to their enrolment in the study, 
and two infections were during their participation in this study. These patients, 
of ages ranging between 29 and 42 years old, did not have (or only had low) 
titer neutralizing antibodies to the infecting serotypes prior to their secondary 
infections. Only one of the four secondary infections resulted in a more severe DHF 
grade II. Prior to the secondary infection, this patient had evidence of a previous 
DENV-2 infection and a low titer (PRNT50 29) to the infecting serotype (DENV-4). 
The sequence of infecting serotypes in the other study participants who only 
experienced dengue fever varied, from DENV-1 to DENV-3, DENV-2 to DENV-3 
and DENV-2 to DENV-4. All tertiary infections resulted in a mild form of dengue 
infection. In two cases, DENV-3 followed a previous DENV-4 infection while in the 
other two cases, the serotypes of the third infection could not be determined. 
Pre-illness sera prior to the third infections showed neutralizing antibodies to all 
serotypes. The intervals between the second and third infections were 5, 11, 18 
and 18 months, respectively. A milder form of illness during tertiary infections 
might correlate with the short duration of viremia because dengue viruses could 
only be isolated in one of the four cases. Altogether, our study provides evidence 
that the presence of cross-reactive neutralizing antibodies does not necessarily 
protect against future dengue infections. On the contrary, as shown in one case, 
it may lead to a more severe case (DHF).
As primary dengue infection is one of the risk factors for developing severe 
secondary infections [3], it is important to distinguish between these two types 
of infections. According to the WHO guidelines [3,14], the hemagglutination 
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inhibition (HI) test can be applied for this purpose. In chapter 5, the performance 
of HI test in discriminating primary and secondary infection is therefore compared 
with the IgG ELISA antibody assay using plaque reduction neutralization 
antibody test (PRNT) as the gold standard. IgG ELISA assay is recommended 
since results are comparable to PRNT and easier to perform. We found that the 
HI test can be used, however using modified criteria. According to our results, 
titers ≤80 in convalescent specimens are indicating primary infections and titers 
>640 should be considered secondary infections. Titers between 160 and 640 
in convalescent specimens are difficult to interpret and other tests such as the 
IgG ELISA or PRNT should subsequently be used in these cases. In addition, apart 
from discriminating between primary and secondary infection, the HI test is 
also recommended to confirm a dengue diagnosis. [3,14]. However, the test is 
cumbersome to perform, as it may cross-react with other Flaviviruses such as 
Japanese encephalitis, and only provides retrospective diagnosis.
Hence, better diagnostic tests are needed. The gold standard, virus culture 
and isolation assay, are technically difficult and time consuming. In addition, 
molecular assays such as RT-PCR are robust but expensive, and can only be done 
in large laboratories or research institutes [3]. Finally, serological tests, especially 
the rapid diagnostic tests are easy to perform, but IgM antibody results can only 
be interpreted correctly if specimens are taken five days after onset of illness [3]. 
In secondary cases, paired IgG testing is often required as IgM antibodies may 
not be detected [3]. Several commercial assays to detect dengue non-structural 
1 (NS1) protein have therefore been developed recently. NS1 is encoded by the 
virus genome, secreted by infected cells in a soluble form, and can be detected 
in the early stage of the disease several days prior to the appearance of anti-
dengue IgM antibodies. The test is relatively inexpensive, easy to perform, and 
fast. In chapter 6, the diagnostic and predictive values of an NS1 antigen assay 
to early diagnose dengue infections early was evaluated. We found a sensitivity 
of 46.8%, which was the lowest compared to studies from other countries. 
However, the sensitivity in primary infection was 100% and the test is therefore 
useful in travel medicine. The sensitivity also varies across the infecting serotypes, 
with the highest in DENV-3 (47.1%), followed by DENV-1 (40.9%), DENV-2 (30%) 
and DENV-4 (27%). Furthermore, we found NS1 is less frequently detected in 
those patients with previous infections with more than one serotype, while NS1 
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was more frequently detected in females, those with more severe cases (dengue 
fever with hemorrhagic manifestations and DHF) and individuals with lower 
platelet counts (<100,000/mm3).
The importance of an early, rapid, robust and cheap confirmation of the 
diagnosis dengue is not only important for the management at the individual or 
community level, but also leads to considerations of alternative diagnosis when 
dengue cannot be confirmed [3]. Chapters 7, 8, 9 and 10 discuss four infectious 
diseases that should be considered by clinicians in West Java in the differential 
diagnosis of febrile patients when signs and symptoms are undifferentiated. 
Chapter 7 reports on chikungunya infections among adult study participants 
in Bandung. Unlike previous studies where chikungunya is often reported from 
focal epidemics, our study found continuous chikungunya infections, suggesting 
that this virus is endemically transmitted in Bandung. Furthermore, chikungunya 
should be considered in differential diagnosis of undifferentiated febrile illness as 
the proportion of chikungunya infections among the acute febrile illness cases 
is high (7.1%), while arthralgia is not a prominent reported symptom. We also 
identified possible repeated chikungunya infections in three patients, suggesting 
that either chikungunya antibodies from previous infections might not provide 
life-long immunity and/or different strains might circulate in Bandung. Finally, 
we documented the persistence of IgM antibodies and concluded that this 
phenomenon complicates the diagnosis as paired specimens are needed to 
observe the increasing titers in convalescent specimens. 
Chapter 8 reports on influenza, including the highly pathogenic influenza A/
H5N1, to consider in the differential diagnosis of dengue. Results were collected 
from a national influenza surveillance program, conducted from 2003 to 2007, 
which included data from six sites in three cities from West Java. Among patients 
with influenza like illness, influenza was identified in 20.1% of patients. Unlike 
in countries with a temperate climate, Influenza viruses circulated throughout 
the year in Indonesia with the peak during the rainy season from December to 
March. It is important to distinguish dengue from influenza not only because 
the treatment is different but also because precautions for the family, school or 
working place are different. This is particularly important with regard to influenza 
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A/H5N1, that may have a mortality rate up to 82% [15], but the outcome of which 
is more favorable when Oseltamivir is administered early [16]. Influenza A/H5N1 
was often not considered during the acute febrile illness because alternative 
diagnoses were made (dengue, typhoid fever, diarrheal disease, respiratory tract 
infection). In febrile patients with shortness of breath, dengue with pulmonary 
edema was often mistakenly diagnosed. This national surveillance also 
documented antigenic drift in circulating influenza A and B virus strains, which 
were similar to the World Health Organization (WHO) vaccine strains but which 
were detected much earlier than the date of their designation.
Chapter 9 documents by means of by clinical, serological and epizoological 
data, the first Indonesian Seoul virus infection, which belongs to the hantavirus 
genus. Signs and symptoms, although consistent with hantavirus infection, such 
as fever, myalgia, bleeding tendency, leucopenia, thrombocytopenia, increased 
serum transaminases, often resemble severe dengue and the two infectious 
diseases may be difficult to differentiate. Therefore, hantavirus infection was 
diagnosed by elevated hantavirus IgM and IgG antibodies, and in the absence of 
evidence of dengue infection. Furthermore, the diagnosis of hantavirus infections 
was also supported by the higher prevalence of hantavirus IgG antibodies in 
rodents trapped in the vicinity of the patient’s home, compared with rodents 
from a control area (13.2% vs. 4.7%, p=0.04) as well as the detection of Seoul 
virus in the organs of 71% of the seropositive rodents.
Chapter 10 presents the first evidence of West Nile virus (WNV) in Indonesia. This 
virus was discovered from archived samples collected during an acute febrile 
illness study that enrolled patients suspected of hantavirus infection at two 
hospitals at Bandung, West Java, Indonesia during 2004-2005. The WNV positive 
sample came from a 15 year old boy admitted for systemic febrile illness with 
epistaxis, gastrointestinal symptoms, elevated serum transaminases, leucopenia 
and thrombocytopenia. No neurological symptoms were reported and the 
patient was discharged after full recovery. Genetic comparisons revealed the 
closest match with the first WNV strain isolated an isolate from Uganda within 
lineage 2. This lineage is less virulent than the lineage 1, the common cause of 
viral encephalitis in the US, and typically associated with large outbreaks.
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Apart from dengue virus, the infectious agents described in chapters 7 to 10 
are only four of many other viruses that need to be considered in the differential 
diagnosis of febrile patients presenting in Indonesia. The development of point 
of care assays that may differentiate bacterial from viral infections are therefore 
of great value as it may rationalize prescription of antimicrobial drugs and the 
management of febrile patients. Furthermore, since dengue is a prevalent illness 
with a sometimes complicated course, a robust diagnostic point of care assay to 
confirm or exclude dengue in acute febrile cases is urgently needed.
While the development of a dengue vaccine is challenged by the requirement 
to provide protection to the four serotypes without exposing the recipients to 
the risks of ADE, the only preventive community measures that are presently 
available are eliminating mosquito breeding places, improvement of knowledge 
to increase awareness, which temporary precautions to take, when to report to 
the authorities, and what the warning signs are to send a patient to a hospital 
[3]. Two studies provide valuable information associated with the prevention in 
communities. The first study aimed to enhance the knowledge and awareness 
of dengue in adult populations working in two textile factories in Bandung. The 
second study was a close virological and clinical observation in the communities 
to anticipate prospective cases after an index case was identified.
Chapter 11 explores how the incorporation of education into our prospective 
dengue study affects knowledge about dengue. Education was undertaken in 
the form of lectures, posters and handouts, describing the signs and symptoms 
of dengue, the methods of transmission, and how to prevent the disease. Upon 
enrolment, a questionnaire was verbally administered by the study physicians, 
exploring participant knowledge regarding dengue. The same questionnaire 
was re-administered 18 months later. Of the 2340 participants that completed 
both tests, only 0.3% of participants scored ‘excellent’ on the pre-test whereas 
8.4% scored ‘excellent’ on the post-test. Fewer participants scored ‘very bad’ on 
the post-test compared to the pre-test (1.4% vs. 4.0%). The average raw scores for 
the pre- and post-tests were 7.8 and 10.1, respectively. Improvement of individual 
scores correlated highly with educational level. These findings demonstrate that 
our prospective study enhanced knowledge of dengue in the volunteers.
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Chapter 12 describes two week-observation periods in families of 53 index 
cases and their close neighbors in West Jakarta in 2002-2003. In total, 785 family 
members or close neighbors were observed, and 192 (24.5%) dengue infections 
were documented, consisting of 175 (22.3%) cases prior to or during enrolment 
and 17 (2.2%) newly developed cases after enrolment. These 17 newly developed 
dengue cases consisted of eight asymptomatic infections, eight dengue fever 
infections, and one DHF grade II infection. This study demonstrated that one 
hospitalized dengue patient can be linked to approximately 3.6 other dengue 
infections occurring in close proximity of where the index patient is living, 
suggesting the importance of community involvement to conduct preventive 
measures and observation. Furthermore, our study showed that asymptomatic 
cases may also significantly contribute to the spreading of dengue virus since 
viremia was detected in two out of the eight asymptomatic cases.
Options for future research
Several research questions remain unanswered also because of the technical 
limitations of our studies and new findings need confirmation or have generated 
novel research questions for future studies. A selection of these questions is 
listed below.
1) Determination of the causes of undifferentiated fever: 
Approximately 62% of the acute febrile cases from the prospective cohort 
study (chapter 1) and 30% of the fever cases with thrombocytopenia from the 
hospitalized hantavirus study (chapter 9) need further examination to identify 
etiologies other than dengue. As no similar studies have been conducted 
previously, further tests will provide clinicians with guidance for differential 
diagnosis, public health authorities with data about the burden of each disease 
and valuable information when a novel agent is identified.
2) Improve the evidence of endemic transmission, mild illness and repeated 
chikungunya infections: 
Surveillance should be conducted in larger areas involving more clinics and 
Summary and discussion | Ringkasan | Samenvatting
223 13
hospitals to provide better epidemiological, virological and clinical data about 
chikungunya infections. To confirm the evidence of repeated chikungunya 
infections in our previous cohort, sequencing analysis should be done to 
determine different strains or genotypes circulating in West Java and plaque 
reduction neutralization test to demonstrate the presence of earlier chikungunya 
infections.
3) Improve the methods in cluster studies:
In our study, many dengue infections in family members or close neighbors had 
already occurred before enrollment. An earlier enrollment of community cases 
might be achieved when index cases are retrieved from primary health centers 
instead of hospitals.
4) Development of biomarkers that identify those at risk for severe disease. 
Dengue is a common cause of febrile illness but fortunately only a minority 
of patients will develop severe disease. However, so far there are no sensitive 
and specific biomarkers that can identify those at risk for severe disease. This 
puts a heavy burden on the health care system, especially during outbreaks. 
Soluble markers may be identified in pre and early illness serial specimens from 
asymptomatic, mild or severe dengue infections. 
5) Improve our understanding in the kinetics of neutralizing antibodies
Neutralizing antibodies as a response to a natural dengue infection with a 
certain serotype may provide protection from infection with other serotypes 
until three months post-illness. However, the titer that may provide protection 
and the titer that may cause ADE leading to severe cases have not been defined 
[17]. As neutralizing antibodies are also the parameter used to measure the 
immunogenicity of a vaccine [18], it is important to further study the kinetics 
of neutralizing antibodies after well-characterized primary, secondary and 
tertiary natural dengue infections using serial sera, collected on the quarterly 
basis. Finally, it is also important to evaluate immune response after vaccination 
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in patients with known primary natural infections.
6) Determine whether some subjects are protected against dengue infection:
Our study reveals that a small proportion (3.1%) of adults has never been 
exposed to dengue infections as indicated by their negative IgG antibodies. As 
seroconversion is estimated as high as 10% a year [1], it would be interesting to 
analyze why this adult population remains seronegative.
7) Evaluation of the various WHO classification systems:
The controversies regarding the clinical classification of the WHO from 1997 [14], 
2009 [3] and WHO 2011 [19] have not yet been resolved [20-24], and a multi-
center study using a well-designed protocol should be conducted. 
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Ringkasan
Setelah wabah sporadis terjadi pada abad ke-18 dan ke-19, dengue baru menjadi 
penyakit arbovirus terpenting setelah kasus DHF/DSS melanda Asia Tenggara 
selepas Perang Dunia II. Sejak saat itu, epidemiologi, virologi, imunologi, dan 
pathogenesis klinis, serta penatalaksanaan dan pencegahan infeksi virus 
dengue telah dipelajari oleh banyak peneliti di berbagai dunia. Namun banyak 
ketidaksesuaian pendapat serta gap (kepincangan) yang harus diselesaikan. 
Sebagai contoh, kalimat yang sering dikutip, “50-100 juta kasus dengue ditemukan 
di seluruh dunia setiap tahun”, lebih tepat untuk menunjukkan seluruh infeksi 
dengue dimana juga termasuk infeksi dengue yang asimptomatik.
Berbagai kontroversi dan kepincangan pengetahuan lain masih ada, seperti 
kegunaan dan keterbatasan kriteria klinis WHO tahun 1997, 2009, dan 2011; 
diperlukan pengertian yang lebih baik mengenai patogenesis dari dengue yang 
berat (virulensi dari subtipe virus dengue, respons berlebihan atau tidak normal 
dari sel T, fenomena autoimun, serta infeksi sekunder); tidak tersedianya alat 
diagnostik yang cepat dan akurat, hewan uji coba, obat untuk virus, serta vaksin 
yang aman dan efektif.
Untuk mendapatkan pengertian yang lebih baik mengenai epidemiologi dan 
patogenesis dari infeksi dengue, diperlukan penelitian-penelitian prospektif 
dimana infeksi dengue termasuk kasus dengue yang berat dapat dengan 
tepat diidentifikasi dan dikarakterisasi. Berbagai jenis penelitian prospektif bisa 
dilakukan, di antaranya penelitian kohort berbasis populasi atau penelitian 
pada berbagai kelompok di lingkungan rumah dan penelitian berbasis 
rumah sakit. Penelitian kohort dengue yang berbasis populasi pertama kali 
dilakukan terhadap anak sekolah di Rayong, Thailand, pada 1984, diikuti 
dengan penelitian yang sama di Bangkok, Yangon di Myanmar, Yogyakarta 
di Indonesia, dan Managua di Nikaragua. Beberapa hasil yang didapatkan 
dari penelitian kohort ini antara lain pengertian yang lebih baik tentang 
beban penyakit dengue pada berbagai populasi, termasuk impak ekonomi 
dan karakterisasi determinan-determinan beratnya penyakit. Penelitian ini 
juga mengidentifikasi populasi dengan sejarah infeksi dengue yang diketahui 
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dengan baik, sehingga dapat menyediakan infrastruktur untuk pelaksanaan 
penelitian vaksin dengue fase ketiga. Kebutuhan untuk penelitian kohort pada 
orang dewasa juga diperlukan karena jumlah infeksi dengue yang ringan 
dan berat pada populasi ini semakin meningkat dalam tiga dekade terakhir, 
termasuk saat mewabah. Di samping itu, penelitian prospektif terhadap 
sekelompok orang di lingkungan rumah dilakukan untuk melihat transmisi di 
antara anggota keluarga dan dapat mendeteksi dengan cepat suatu infeksi 
dengue baru, sehingga dimungkinkan untuk mendapatkan predictor klinis 
dan imunologis dari penyakit yang berat.
Tesis ini menjelaskan soal hasil beberapa penelitian prospektif yang dilaksanakan 
di Jawa Barat, Indonesia. Yang pertama adalah suatu penelitian prospektif pada 
suatu kohort, yang terdiri atas 4.380 orang yang bekerja di tiga pabrik tekstil 
di Bandung, sepanjang 2000-2004 dan 2006-2009. Para pekerja ini dimonitor 
setiap hari dan diambil darahnya setiap 3-4 bulan sekali. Penelitian prospektif 
kedua dilaksanakan terhadap sekelompok orang di lingkungan rumah, yang 
terdiri atas anggota keluarga dan tetangga terdekat, yang berlangsung selama 
dua minggu, di mana gejala penyakit dari yang diduga terinfeksi dengue serta 
spesimen sebelum sakit dan selama observasi dikumpulkan. Penelitian ini 
dilaksanakan di Jakarta Barat pada 2001-2003. Tesis ini juga menyajikan temuan 
dari wabah dengue besar yang terjadi pada 2004, hasil dari surveillance influenza 
berskala nasional mulai 2003 sampai 2007 dan surveillance hantavirus di rumah 
sakit antara 2004 dan 2005. Semua penelitian ini didanai oleh United States 
Naval Medical Research Unit No. 2 (US-NAMRU#2), bekerja sama dengan Rumah 
Sakit Sumber Waras, Jakarta; Rumah Sakit Hasan Sadikin dan Fakultas Kedokteran 
Universitas Padjadjaran di Bandung; serta Badan Penelitian dan Pengembangan 
Kesehatan Kementerian Kesehatan di Jakarta. 
Bab 2 menyajikan aspek epidemiologi, virologi, dan klinis dari infeksi dengue 
pada suatu kohort, yang terdiri atas 4.380 pekerja dewasa di Bandung, Jawa Barat, 
yang diobservasi selama 79 bulan. Penelitian ini menunjukkan bahwa dengue 
menyumbang 12,41% dari seluruh kasus demam dan angka kejadian dengue 
sebesar 17,3 kasus/1.000 populasi setiap tahun. Angka ini 43 kali lebih besar 
daripada laporan nasional. Lebih jauh lagi, penelitian ini juga menunjukkan, 
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untuk angka infeksi dengue yang sebenarnya, perlu diperhitungkan angka kasus 
asimptomatik yang besarnya 2,6 kali dari angka kejadian dengue di atas. Data 
epidemiologis baru ini penting untuk diketahui oleh klinisi dan para pembuat 
kebijakan kesehatan, karena penelitian ini menunjukkan bahwa sangatlah penting 
memasukkan dengue ke diagnosis banding penyakit yang disertai demam, serta 
membuat strategi untuk mengendalikan penularan dengue yang ternyata lebih 
tinggi daripada yang sebelumnya diketahui. Di samping itu, dengue ditemukan 
sepanjang tahun, dengan puncaknya saat musim hujan, yaitu pada Desember-
Maret. Semua serotipe virus dengue ditemukan setiap tahun, tapi keempat 
serotipe virus jarang ditemukan bersama-sama dalam satu bulan. Temuan 
ini memperlihatkan bahwa Bandung merupakan daerah yang hyperendemic 
untuk infeksi dengue. Dari 268 kasus yang terkonfirmasi, hanya satu kasus DSS 
yang didiagnosis. Sisanya adalah DHF derajat 1 dan derajat 2 serta bentuk 
yang ringan, yaitu demam dengue yang dapat atau tidak disertai manifestasi 
perdarahan. Kasus yang berat dalam penelitian ini berhubungan dengan DENV-
3, yang secara konsisten telah dilaporkan sebagai penyebab utama wabah 
dengue di Indonesia. Data kami juga menunjukkan adanya keterkaitan antara 
kasus asimptomatik dan DENV-4. Dalam penelitian ini ditemukan pula terjadinya 
infeksi dengue berulang pada 7 subyek. Temuan ini menguatkan pendapat 
bahwa infeksi oleh serotipe tertentu tidak dapat melindungi dari infeksi dengue 
oleh serotipe lainnya. Akhirnya, penelitian ini tidak hanya menghasilkan data 
yang menunjukkan pentingnya dengue di Jawa Barat, tapi juga menjelaskan soal 
karakterisasi kejadian dengue secara alamiah pada populasi orang dewasa yang 
penting diketahui untuk penelitian vaksin di masa yang akan datang. 
Sementara Bab 2 menjabarkan data infeksi dengue yang terjadi secara alamiah 
pada keadaan endemik, Bab 3 memaparkan ihwal data saat terjadi wabah dengue 
pada 2004, di mana dilaporkan sebanyak 50.000 kasus dengan 603 kematian. 
Data tersebut menjadi penting karena wabah dengue terjadi secara periodik sejak 
1968. Bab ini menyajikan data epidemiologi, virologi, dan klinis dari 10 rumah 
sakit di lima wilayah di Jakarta, Indonesia. Penelitian ini memastikan bahwa 
persebaran wabah terjadi di semua wilayah, dan keempat serotipe ditemukan 
bersama-sama saat wabah ini muncul dengan DENV-3 yang paling dominan. 
Analisis genotipe menunjukkan bahwa DENV-3 yang beredar identik dengan 
yang menyebabkan wabah pada 1998. Beredarnya seluruh serotipe dengan 
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DENV-3 sebagai yang paling dominan telah dilaporkan saat muncul wabah-
wabah sebelumnya, termasuk saat wabah terbesar pada 1998. Keadaan ini, di 
samping adanya populasi yang sama sekali belum pernah terinfeksi dengue dan 
bersirkulasinya strain virus baru atau yang lebih virulen, mungkin merupakan 
kondisi yang diperlukan untuk terjadinya wabah dengue di suatu daerah endemis. 
Ditemukan pula bahwa wabah mengenai seluruh golongan umur dan proporsi 
DHF jauh lebih tinggi saat terjadi wabah dibanding kondisi endemik. Padahal 
kemungkinan tidak terdiagnosisnya kasus DHF cukup besar karena kurangnya 
data hematologis serial untuk menunjukkan adanya hemokonsentrasi. Hal lain 
yang ditemukan adalah besarnya jumlah kasus dengue yang tidak bisa dipastikan, 
sama seperti laporan sebelumnya dari Semarang.
Pada dua bab pertama telah dijabarkan bahwa Jawa Barat merupakan suatu 
wilayah hyperendemic, di mana keempat serotipe virus dengue bisa ditemukan. 
Merujuk pada teori antibody dependent enhancement theory (ADE), keadaan ini 
menyebabkan populasi di sini mempunyai risiko yang lebih tinggi timbulnya 
penyakit yang lebih berat saat terkena infeksi dengue kedua kalinya. Pada Bab 
4, bukti-bukti terjadinya infeksi dengue tiga kali berturut-turut oleh serotipe 
yang berbeda-beda pada empat subyek telah dijabarkan. Infeksi pertama adalah 
sebelum masuk ke studi dan dua infeksi berikutnya saat berada dalam studi. 
Subyek ini berumur 29-42 tahun dan, sebelum terinfeksi kedua kalinya, mereka 
tidak atau hanya mempunyai antibodi netralisasi yang rendah terhadap serotipe 
virus yang menginfeksi tersebut. Hanya satu di antara keempat kasus berakhir 
dengan infeksi sekunder yang berat (DHF Grade II). Dalam kasus ini, sebelum 
sakit untuk kedua kalinya, subyek menunjukkan bukti pernah terkena infeksi virus 
DENV-2 dan adanya titer antibodi yang rendah terhadap virus yang kemudian 
menginfeksinya, DENV-4 (PRNT50 29). Urutan serotipe yang menginfeksi pada 
ketiga subyek lainnya ketika mereka hanya mengalami demam dengue adalah: 
DENV-1 ke DENV-3, DENV-2 ke DENV-3, dan DENV-2 ke DENV-4. Untuk infeksi 
ketiga, semua hanya menyebabkan infeksi dengue yang ringan. Pada dua 
kasus DENV-3 terjadi setelah infeksi oleh DENV-4. Sementara untuk dua kasus, 
serotipe ketiga tidak dapat diketahui. Serum yang diambil sebelum infeksi 
ketiga menunjukkan adanya antibodi netralisasi terhadap seluruh serotipe virus. 
Waktu antara infeksi kedua dan ketiga pada keempat subyek ini adalah 5, 11, 
18, dan 18 bulan. Bentuk yang lebih ringan pada infeksi ketiga ini mungkin ada 
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hubungannya dengan durasi viremia yang lebih pendek karena hanya satu dari 
empat kasus virus dengue bisa dideteksi. Penelitian ini memberi bukti bahwa 
adanya antibodi netralisasi yang cross-reactive tidak dapat melindungi dari infeksi 
dengue pada masa yang akan datang. Sebaliknya, seperti yang ditemukan pada 
satu kasus, bisa timbul kasus yang lebih berat (DHF).
Mengingat infeksi dengue primer merupakan faktor risiko terjadinya infeksi 
sekunder dengan gejala klinis yang berat, penting membedakan kedua jenis 
infeksi ini. Berdasarkan petunjuk dari WHO, uji hemagglutination inhibition (HI) 
bisa digunakan. Pada Bab 5, kemampuan uji HI untuk membedakan infeksi 
primer dan sekunder dibandingkan dengan uji antibodi IgG ELISA menggunakan 
plaque reduction neutralization antibody test (PRNT) sebagai standar emas. Uji IgG 
ELISA direkomendasikan karena hasilnya sesuai dengan PRNT dan lebih mudah 
dilakukan. Penelitian ini menunjukkan bahwa uji HI masih bisa digunakan, tapi 
kriterianya perlu direvisi. Berdasarkan hasil penelitian ini, titer di bawah ≤80 
pada serum konvalesen menunjukkan infeksi primer, sedangkan titer >640 
adalah infeksi sekunder. Titer di antara 160 dan 640 pada serum konvalesen 
sulit diinterpretasikan sehingga diperlukan uji lanjutan dengan IgG ELISA atau 
PRNT. Di samping untuk menentukan infeksi primer atau sekunder, uji HI juga 
digunakan untuk mengkonfirmasi infeksi dengue itu sendiri. Namun uji ini tidak 
praktis dalam pelaksanaannya, lantaran dapat menunjukkan hasil yang cross 
reactive dengan infeksi Flavivirus lain, seperti Japanese encephalitis, dan hanya 
memberikan diagnosis retrospektif.
Dengan demikian, diperlukan sebuah uji diagnostik yang lebih baik. Standar 
emas yang ada, seperti kultur virus dan uji isolasi virus, secara teknis sulit 
dilakukan dan membutuhkan waktu yang lama. Sementara itu, uji molekuler, 
seperti RT-PCR, bisa diandalkan, tapi biayanya mahal dan hanya dapat dilakukan 
di laboratorium besar atau institusi penelitian. Akhirnya uji serologis, khususnya 
uji diagnostik cepat, sangat mudah dilaksanakan, tapi hasil antibodi IgM hanya 
bisa diinterpretasikan jika spesimen diambil lima hari sesudah demam muncul. 
Pada kasus infeksi sekunder, uji IgG menggunakan spesimen akut dan konvalesen 
diperlukan karena sering kali antibodi IgM tidak dapat dideteksi. Untuk itu, 
beberapa uji komersial untuk mendeteksi protein dengue non-structural 1 (NS1) 
telah dibuat. Protein NS1 disandi oleh genom virus dan kemudian disekresikan 
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oleh sel yang terinfeksi dalam bentuk terlarut. NS1 ini dapat dideteksi pada fase 
awal penyakit, yaitu beberapa hari sebelum munculnya antibodi IgM. Uji ini 
relatif murah, mudah dikerjakan, dan cepat selesai. Pada Bab 6, nilai diagnostik 
dan prediktif dari uji antigen NS1 untuk diagnosis dini infeksi dengue dievaluasi. 
Penelitian ini menemukan bahwa sensitivitasnya rendah, yaitu 46,8% atau 
terendah dibanding hasil penelitian dari negara lain. Namun, karena sensitivitas 
untuk infeksi primernya sangat baik, yaitu 100%, uji ini sangat berguna dalam 
kedokteran wisata. Sensitivitas uji NS1 juga bervariasi antar-serotipe yang 
menginfeksi, tertinggi pada DENV-3 (47,1%), diikuti DENV-1 (40,9%), DENV-2 (30%), 
dan DENV-4 (27%). Lebih jauh lagi, penelitian ini menemukan bahwa antigen 
NS1 lebih jarang terdeteksi pada mereka yang telah terkena infeksi dengue oleh 
dua atau lebih serotipe. Sedangkan antigen NS1 lebih sering dideteksi pada 
wanita, dan pada kasus yang berat (dengue fever dengan manifestasi perdarahan 
dan DHF), serta subyek dengan jumlah trombosit yang rendah (<100.000/mm3).
Adanya suatu alat diagnostik yang cepat, akurat, murah, serta dapat mendeteksi 
dini infeksi dengue, selain berguna untuk penatalaksanaan pada pasien dan 
komunitas, bisa membantu untuk membuat diagnosis yang lain jika dengue 
tidak dapat ditegakkan. Bab 7, 8, 9, dan 10 menjabarkan empat penyakit infeksi 
yang perlu dipertimbangkan oleh para klinisi di Jawa Barat sebagai diagnosis 
banding pada pasien dengan demam di mana gejala dan tanda penyakitnya sulit 
dibedakan antara satu dan yang lain. Bab 7 melaporkan infeksi chikungunya yang 
ditemukan di antara subyek penelitian orang dewasa di Bandung. Tidak seperti 
penelitian sebelumnya, bahwa chikungunya sering dilaporkan dari kejadian 
wabah di suatu tempat, penelitian kami menemukan infeksi chikungunya yang 
terus-menerus, yang menunjukkan bahwa virus ini endemik di Bandung. Karena 
proporsinya pada penderita demam cukup tinggi (7,1%), chikungunya perlu tetap 
dipikirkan sebagai salah satu diferensial diagnosis, meskipun tidak ditemukan 
arthralgia. Kami menemukan pula kemungkinan adanya infeksi chikungunya 
berulang pada tiga subyek, yang menunjukkan bahwa antibodi chikungunya 
dari infeksi sebelumnya mungkin tidak dapat memberi kekebalan seumur hidup 
dan/atau adanya strain berbeda yang beredar di Bandung. Temuan penting 
lainnya adalah antibodi IgM yang bertahan untuk waktu yang lama mempersulit 
diagnosis dengan serologis karena dibutuhkan spesimen akut dan konvalesen 
untuk melihat kenaikan titer antibodi. 
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Bab 8 membahas influenza, termasuk influenza A/H5N1 yang sangat patogenik, 
sebagai salah satu diagnosis diferensial dari dengue. Data didapatkan dari 
program surveillance nasional sejak 2003 sampai 2007. Pada surveillance nasional 
ini terdapat enam tempat penelitian yang terletak di tiga kota di Jawa Barat. 
Influenza dikonfirmasi pada 20,1% dari subyek yang datang dengan influenza 
like illness. Tidak seperti di negara dengan empat musim, influenza ditemukan 
sepanjang tahun di Indonesia dengan puncaknya pada musim hujan antara 
Desember dan Maret. Kepentingan untuk dapat membedakan dengue dengan 
influenza bukan hanya karena penatalaksanaan untuk pasien yang berbeda, 
tapi juga bagaimana upaya pencegahan di keluarga, sekolah, dan tempat 
kerja yang berbeda. Hal ini khususnya sangat penting berkaitan dengan infeksi 
influenza A/H5N1, dengan angka kematian 82%, tapi hasilnya dapat lebih baik 
jika Oseltamivir diberikan lebih dini. Influenza A/H5N1 sering kali tidak dipikirkan 
di awal sakit. Malah sering didiagnosis sebagai penyakit lain (dengue, demam 
typhoid, diarrhea, infeksi saluran napas, dan lainnya). Pasien dengan badan panas 
dan sesak napas sering salah didiagnosis sebagai dengue dengan edema paru. 
Surveillance nasional ini menemukan pula adanya antigenic drift pada strain 
influenza A dan B, yang sama dengan strain vaksin yang digunakan oleh WHO, 
serta dideteksi lebih awal daripada strain vaksin tersebut.
Bab 9 membahas soal penemuan infeksi Seoul virus, yang termasuk dalam 
kelompok hantavirus, berdasarkan data klinis, serologis, dan epizoologis. Gejala 
dan tanda penyakit yang ada, seperti demam, nyeri otot, perdarahan, leucopenia, 
thrombositopenia, serta peningkatan SGOT dan SGPT, konsisten dengan infeksi 
hantavirus. Namun, karena mirip dengan gejala dan tanda pada kasus dengue 
yang berat, kedua penyakit ini menjadi sulit dibedakan. Dengan demikian, 
infeksi hantavirus ini didiagnosis dengan adanya peningkatan antibodi IgM dan 
IgG dan, pada saat yang sama, tidak ditemukan bukti adanya infeksi dengue. Di 
samping itu, diagnosis hantavirus diperkuat oleh tingginya prevalensi rodensia, 
yang mempunyai antibodi IgG terhadap hantavirus di lingkungan tempat 
tinggal pasien tersebut, dibanding di daerah kontrol (13,2% vs 4,7%, p=0.04) 
serta terdeteksinya virus Seoul pada organ dari 71% rodensia yang memiliki 
antibodi IgG terhadap hantavirus.
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Bab 10 menyajikan bukti penemuan West Nile virus (WNV) pertama di Indonesia. 
Virus ini ditemukan dari spesimen arsip yang dikumpulkan saat penelitian 
penyakit hantavirus di dua rumah sakit di Bandung pada 2004-2005. Virus 
WNV yang positif berasal dari spesimen seorang anak laki-laki berumur 15 
tahun dan masuk ke rumah sakit dengan panas badan, epistaksis, gangguan 
pencernaan, peningkatan SGOT dan SGPT, leucopenia, serta thrombositopenia. 
Tidak ditemukan gejala neurologis, dan pasien pulang dalam keadaan sembuh. 
Analisis genetik menunjukkan bahwa virus yang ditemukan ini mirip dengan 
strain WNV, yang pertama kali diisolasi dari Uganda dan termasuk dalam lineage 
2. Lineage ini lebih rendah virulensinya ketimbang lineage 1, yang merupakan 
penyebab umum encephalitis virus di Amerika Serikat, dan biasanya berkaitan 
dengan wabah besar. 
Di samping virus dengue, penyebab-penyebab infeksi lainnya yang dibahas pada 
Bab 7-10 adalah hanya empat dari banyak virus lain yang perlu dipertimbangkan 
sebagai diagnosis diferensial pada pasien yang datang dengan demam di 
Indonesia. Dibuatnya suatu alat uji cepat yang dapat membedakan antara infeksi 
virus dan bakteri akan sangat bernilai karena dapat membantu dalam pemberian 
anti-mikroba yang lebih rasional dan penatalaksanaan pasien dengan demam. 
Lebih jauh lagi, karena dengue merupakan penyakit yang prevalens dan kadang-
kadang disertai penyulit, suatu alat uji diagnostik yang akurat untuk memastikan 
infeksi dengue atau memastikan bukan infeksi dengue dalam kasus demam akut 
sangatlah dibutuhkan. 
Pembuatan suatu vaksin dengue terhambat oleh keharusan memproteksi 
keempat serotipe tanpa membuat penerima vaksin berisiko mengalami ADE. 
Cara pencegahan di komunitas yang saat ini ada adalah pemberantasan sarang 
nyamuk, peningkatan pengetahuan untuk meningkatkan kewaspadaan, langkah 
awal yang perlu dilakukan, kapan melapor kepada petugas kesehatan, serta 
tanda-tanda penting sebagai indikasi untuk mengirim seorang pasien ke rumah 
sakit. Dua penelitian menyediakan informasi yang berharga sehubungan dengan 
langkah preventif di masyarakat. Penelitian pertama bertujuan meningkatkan 
pengetahuan dan kesadaran akan dengue pada populasi orang dewasa yang 
bekerja di pabrik tekstil di Bandung. Penelitian kedua adalah observasi klinis dan 
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virologi di masyarakat untuk mengantisipasi kasus lainnya setelah satu kasus 
indeks ditemukan. 
Bab 11 menunjukkan bagaimana memasukkan pendidikan di dalam penelitian 
dengue prospektif telah mempengaruhi pengetahuan peserta mengenai 
dengue. Pendidikan yang diberikan dilakukan dalam berbagai bentuk, seperti 
penyuluhan, poster, dan brosur, yang menjelaskan perihal gejala dan tanda-tanda 
dengue, bagaimana cara penularannya, serta bagaimana cara pencegahannya. 
Saat peserta masuk ke penelitian, kuesioner disampaikan secara lisan oleh dokter 
penelitian untuk melihat bagaimana pengetahuan peserta mengenai dengue. 
Kuesioner yang sama ditanyakan kembali 18 bulan kemudian. Dari 2.340 peserta 
yang menyelesaikan kedua tes, hanya 0,3% yang mendapatkan hasil “sangat baik” 
pada pre-test, sedangkan 8,4% mendapatkan nilai “sangat baik” pada post-test. 
Jumlah peserta yang mendapatkan nilai “sangat buruk” berkurang pada post-
test dibanding pada pre-test (1,4% vs 4,0%). Nilai rata-rata saat pre-test dan post-
test adalah 7,8 dan 10,1, dari kemungkinan maksimum. Pendidikan berkaitan 
erat dengan nilai yang didapatkan. Hasil ini menunjukkan bahwa penelitian 
prospektif ini dapat meningkatkan pengetahuan tentang dengue pada subyek 
penelitian. 
Bab 12 memaparkan hasil pengamatan selama dua minggu terhadap keluarga 
dan tetangga dekat dari 53 kasus yang terkena dengue di Jakarta Barat pada 
2002-2003. Dari 785 anggota keluarga atau tetangga yang diamati, 192 (24,5%) 
infeksi dengue terpantau, terdiri atas 175 kasus (22,3%) yang telah terjadi sebelum 
pengamatan dimulai dan 17 kasus (2,2%) muncul pada saat pengamatan. Dari 
17 kasus baru tersebut, 8 adalah infeksi asimptomatik, 8 demam dengue, dan 1 
DHF grade II. Penelitian ini memperlihatkan bahwa satu orang yang dirawat di 
rumah sakit berkaitan dengan 3,6 kasus dengue yang terdapat di lingkungan 
dekat tempat tinggal kasus tersebut. Hal ini menunjukkan pentingnya 
keikutsertaan masyarakat untuk melaksanakan langkah-langkah pencegahan 
dan pengamatan. Di samping itu, penelitian ini juga menunjukkan pentingnya 
kasus asimptomatik dalam menyebarkan penularan virus dengue karena viremia 
ditemukan pada dua dari delapan kasus asimptomatik. 
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Tijdens de 18e en de 19e eeuw kwam knokkelkoorts meestal sporadisch voor 
terwijl na de Tweede Wereldoorlog ernstige DHF/ DSS uitbraken werden 
gerapporteerd in Zuidoost Azië waarna Dengue algemeen erkend werd als 
de belangrijkste Arbovirus infectie. Sindsdien is de epidemiologie, virologie, 
immunologie, pathogenese, preventie en behandeling van knokkelkoorts door 
verscheidende onderzoekers op verschillende continenten onderzocht en 
bestudeerd. Ondanks dit onderzoek, blijven er vele aspecten van knokkelkoorts 
onopgehelderd. Zo wordt vaak gerapporteerd dat “elk jaar wereldwijd ongeveer 
50 -100 miljoen gevallen van knokkelkoorts ontstaan ”, terwijl dit mogelijk 
niet overeen komt met de werkelijkheid omdat een groot aantal infecties 
asymptomatisch verloopt. 
Behalve onduidelijkheden in de epidemiologie, zijn er ook veel tegenstrijdigheden 
kennis lacunes over andere aspecten van de knokkelkoorts, zoals het nut en de 
beperkingen van de WHO-criteria voor klinische classificaties van de jaren 1997, 
2009 en 2011; het inzicht in the pathogenese van ernstige dengue (virulentie 
van dengue virus subtypen, abnormale of versnelde T cel reacties, auto-
immune verschijnselen of tweede infecties); de onbeschikbaarheid van snelle 
en nauwkeurige diagnostische tests; dier modellen; antivirale middelen; en de 
beschikbaarheid van een veilige en doeltreffend vaccin. 
Om ons inzicht wat betreft de epidemiologie en pathogenese van knokkelkoorts 
te verbeteren, zijn prospectieve studies nodig, die nauwkeurig de ernst 
van knokkelkoorts infecties kunnen identificeren en typeren. Verschillende 
soorten prospectieve studies kunnen daarvoor gebruikt worden, zoals 
grootschalige cohortstudies of clusterstudies in gemeenschappen evenals 
ziekenhuisgerelateerde studies. De eerste grootschalige cohortstudie werd 
in 1984 uitgevoerd onder schoolkinderen in Rayong - Thailand, gevolgd door 
vijf vergelijkbare studies uitgevoerd in Bangkok en andere steden, waaronder 
Yangon in Myanmar, Yogyakarta in Indonesië en Managua in Nicaragua. 
Deze cohortstudies leverden allerlei resultaten op, zoals een beter inzicht over 
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de ziektelast in de verschillende bevolkingsgroepen, de economische effecten 
en inzicht in de determinanten die de ernst van de ziekte bepalen. Bovendien 
werden populaties bestudeerd waarvan bekend was dat knokkelkoorts reeds 
langere tijd aanwezig was: gedegen kennis van deze populaties kunnen nuttig 
zijn voor het uitvoeren van fase III vaccin studies.
De noodzaak om longitudinale cohortstudies bij volwassenen uit te voeren 
werd ook duidelijk toen de laatste drie decennia het aantal ongecompliceerde 
en gecompliceerde knokkelkoorts infecties bij volwassenen toenam. Als 
gevolg daarvan werden binnen bepaalde gemeenschappen prospectieve 
clusterstudies uitgevoerd om besmetting onder leden van het huishouden 
te kunnen bestuderen en om infecties in de beginfase te kunnen traceren 
waardoor de klinische en immunologische voorspellers van een ernstige ziekte 
geïdentificeerd konden worden. 
Dit proefschrift geeft een beschrijving van de resultaten van verschillende 
prospectieve studies, zoals uitgevoerd in West-Java, Indonesië. 
De eerste studie betreft een prospectieve cohortstudie. Deze is in de periodes 
2000—2004 en 2006-2009 uitgevoerd in drie textielfabrieken te Bandung, 
waarbij 4380 volwassenen betrokken waren, die dagelijks werden gecontroleerd 
en waarbij elk kwartaal bloed afgenomen werd. 
De tweede studie is een prospectieve clusterstudie in een gemeenschap in West- 
Jakarta, uitgevoerd tijdens de periode 2001-2003, waarbij familieleden en buren 
van een dengue geïndiceerde patiënt gedurende twee weken werden gevolgd 
met als doel klinische informatie te verzamelen zowel als bloed monsters. 
Dit proefschrift geeft bovendien ook informatie over een grote knokkelkoorts 
uitbraak in 2004, de nationale influenza surveillance 2003-2007, en een 
ziekenhuisgerelateerde hantavirus surveillancestudie welke uitgevoerd is tussen 
2004 en 2005. Deze studies werden gefinancierd door Naval Medical Research 
Unit 2 uit de Verenigde Staten (U.S.-NAMRU #2) in samenwerking met het Sumber 
Waras ziekenhuis in Jakarta, het Hasan Sadikin Hospital en Faculty of Medicine 
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Universitas Padjadjaran in Bandung, en het National Institute of Health Research 
and Development van het ministerie van Volksgezondheid van Indonesië in 
Jakarta. 
Hoofdstuk 2 beschrijft de epidemiologie, virologie en klinische aspecten van 
dengue infecties, zoals die werden geobserveerd gedurende een periode van 
79 maanden in een cohort van 4380 volwassen fabrieksarbeiders uit Bandung te 
West-Java. Deze studie toont aan dat knokkelkoorts in 12.41% de oorzaak is van 
de koorts terwijl de jaarlijkse incidentie van dengue 17.3 gevallen/1000 inwoners 
was. Deze studie toont verder aan- dat bij de berekening van het werkelijke 
aantal dengue-infecties per inwoners per jaar - ook berekend moet worden 
de asymptomatische infecties, die 2.6x groter was dan de symptomatische 
geïndiceerde gevallen.
Deze nieuwe epidemiologische gegevens zijn belangrijk voor clinici en 
gezondheidsmedewerkers, omdat zij aantonen dat het belangrijk is om 
knokkelkoorts op te nemen in de differentiële diagnose van ongedifferentieerde 
koorts. Verder werden gedurende het gehele jaar knokkelkoorts gevallen 
gevonden met een piek tijdens het regenseizoen dat meestal van december 
tot maart plaats vindt. Alle serotypes werden gedurende het gehele jaar 
aangetoond, hoewel ze zelden gelijktijdig in dezelfde maand aanwezig waren. 
Tevens werd aangetoond dat Bandung een hyper-endemische Dengue gebied 
is. Uit een totaal van 268 bevestigde gevallen werd slechts één DSS geval 
gediagnosticeerd. De overige waren DHF fase I en II en de milde vorm van 
dengue koorts met of zonder hemorragische manifestaties. Ernstige gevallen 
werden geassocieerd met DENV-3, het serotye dat als de belangrijkste oorzaak 
van uitbraken in Indonesië wordt gerapporteerd. In deze studie vonden we 
ook herhaalde knokkelkoorts infecties bij zeven patiënten. Deze bevinding 
bevestigt dat een infecties met een bepaalde serotype, het individu niet tegen 
infecties met andere serotypes beschermd. Tot slot heeft onze studie niet alleen 
waardevolle gegevens opgeleverd voor het belang van knokkelkoorts in West-
Java, maar heeft ook het natuurlijke beloop van de ziekte gekarakteriseerd bij 
volwassenen, wat belangrijk is voor toekomstige vaccin studies. 
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Terwijl hoofdstuk 2 gegevens vermeld over de endemische aard van 
knokkelkoorts infecties, wordt in Hoofdstuk 3 een denque uitbraak uit 2004 
in Indonesië beschreven, waarbij 50.000 gevallen en 603 doden werden 
gerapporteerd. Het hoofdstuk bevat epidemiologische, klinische en virologische 
gegevens uit 10 ziekenhuizen uit vijf deelgemeenten van Jakarta. Onze 
bevindingen bevestigen dat alle deelgemeenten werden getroffen door deze 
uitbraak, terwijl alle vier de knokkelkoorts serotypes tegelijkertijd - met DENV-3 
als de meest overheersende- in omloop waren. Genotype analyse gaf aan dat 
de circulerende DENV-3 identiek was aan het type dat in 1998 de epidemie had 
veroorzaakt. Gelijktijdige circulatie van meerdere serotypes -met DENV-3 als de 
meest overheersende- werd ook beschreven in vorige knokkelkoorts uitbraken 
in Indonesië, zoals gedurende de grootste uitbraak in 1998.
Ons onderzoek toont ook aan dat alle leeftijdsgroepen getroffen werden en 
dat het aandeel van DHF significant hoger was tijdens een uitbraak vergeleken 
met “niet-uitbraak” omstandigheden, ondanks de mogelijke onderschatting 
van DHF gevallen vanwege het ontbreken van serieel bloedonderzoek om 
hemoconcentratie aan te tonen. Ten slotte, net als bij een eerder rapport uit 
Semarang, kon de diagnose knokkelkoorts in een groot deel (33%) van de 
gevallen niet bevestigd worden.
In de eerste twee hoofdstukken wordt West- Java beschreven als een hyper-
endemische regio waar alle vier de DENV serotypes circuleerden. Volgens 
de antibody afhankelijkheid versterkingstheorie (ADE) is het risico voor het 
ontwikkelen van ernstige ziekte onder dergelijke omstandigheden verhoogd. In 
hoofdstuk 4 worden drie heterologe opeenvolgende knokkelkoorts infecties bij 
vier personen beschreven. De eerste infectie was voorafgaand aan hun deelname 
aan de studie en de tweede infectie was na inclusie in de studie. Deze patiënten 
met een leeftijden van 29-42 jaar hadden voorafgaand aan hun secondaire 
infecties geen (of slechts een lage) titer van neutraliserende antibodies tegen 
het serotype. Slechts één van de vier secundaire infecties resulteerde in een 
ernstigere DHF graad II.
Voorafgaand aan de secundaire infectie had deze patiënt een aangetoonde 
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doorgemaakte DENV-2 infectie en een lage titer (PRNT50 29) voor het serotype 
(DENV-4). De volgorde van de serotypes bij de andere studiedeelnemers - die 
alleen dengue koorts ontwikkelden - varieerde van DENV-1 tot DENV-3, DENV-2 
tot DENV-3 en DENV-2 tot DENV-4. Alle tertiaire infecties resulteerden in een milde 
vorm van dengue infectie. In twee gevallen volgde DENV-3 na een vorige DENV-
4 infectie, terwijl in de andere twee gevallen, de serotypes van de derde infectie 
niet kon worden vastgesteld. Bloedmonsters voorafgaand aan de ziekte vóór de 
derde infecties toonde neutraliserende antilichamen tegen alle serotypes. De 
intervallen tussen de tweede en derde infecties waren respectievelijk 5, 11, 18 
en 18 maanden. 
Een mildere vorm van ziekte tijdens tertiaire infecties kan mogelijk correleren 
met de korte duur van de viremie, omdat het knokkelkoortsvirus alleen in één 
van de vier gevallen geïsoleerd kon worden. Al met al levert onze studie het 
bewijs dat de aanwezigheid van kruisreagerende neutraliserende antilichamen 
niet perse tegen toekomstige knokkelkoorts infecties beschermt. Integendeel, 
zoals aangetoond in één geval, een ernstiger beloop kan daarbij ook optreden 
(DHF).
Omdat een primaire dengue infectie één van de risicofactoren is voor het 
ontwikkelen van ernstige secundaire infecties, is het belangrijk onderscheid te 
maken tussen deze twee soorten infecties. Volgens de richtlijnen van de WHO 
kan de hemagglutinatie remmingstest (HI) hiervoor worden toegepast. 
In hoofdstuk 5 wordt onderzocht of de HI test het onderscheid kan maken 
tussen een primaire en secundaire infectie. De HI test werd daarbij vergeleken 
met de IgG ELISA en de Plaque Reduction Neutralization antibody Test (PRNT) 
werd als Gouden Standaard gebruikt. De ELISA IgG test wordt vaak aanbevolen 
omdat de resultaten in vergelijking met PRNT eenvoudiger uit te voeren zijn. 
We vonden dat de HI-test met behulp van gemodificeerde criteria gebruikt kon 
worden waarbij titers ≤80 overeenkomen met een primaire infectie terwijl titers 
> 640 als secundaire infecties moeten worden beschouwd. Titers tussen 160 en 
640 zijn moeilijker te interpreteren. Andere testen- zoals de IgG ELISA of PRNT - 
kunnen in deze gevallen gebruikt worden. 
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Afgezien van bovengenoemde indicatie, wordt de HI-test ook aanbevolen voor 
de bevestiging van de knokkelkoorts diagnose. Probleem is echter dat de test 
tamelijk omslachtig is en er kruisreacties kunnen zijn met andere Flavivirussen 
zoals Japanse encephalitis. Vaak levert deze test dus alleen een retrospectieve 
diagnose op.
Al met al is er dus een grote behoefte aan betere diagnostische testen om de 
diagnose knokkelkoorts in het veld te kunnen stellen. De gouden standaard 
viruskweek en isolatie analyse zijn technisch gezien moeilijk en tijdrovend. 
Bovendien zijn robuuste moleculaire tests zoals RT-PCR duur en kunnen ze 
alleen uitgevoerd worden in grote laboratoria of onderzoeksinstituten. Ten slotte 
zijn serologische tests, met name de snelle diagnostische tests, gemakkelijk uit 
te voeren. Echter, de specifieke Dengue IgM antilichamen zijn pas aantoonbaar 
vijf dagen na de eerste ziekte verschijnselen.
In secundaire gevallen zijn gepaarde IgG testen vaak vereist als IgM antilichamen 
niet kunnen worden aangetoond. Recentelijk zijn verschillende commerciële 
testen ontwikkeld die zich richten op het aantonen van het niet-structurele 
1 (NS1) proteïne van het knokkelkoortsvirus. NS1 wordt gecodeerd door het 
virusgenoom vervolgens uitgescheiden door geïnfecteerde cellen in een 
oplosbare vorm. NS1 is aantoonbaar in het bloed gedurende eerste dagen van 
de ziekte, voordat anti-dengue IgM-antistoffen waarneembaar zijn. De test is 
relatief goedkoop, gemakkelijk uit te voeren en snel. In hoofdstuk 6 wordt de 
diagnostische en voorspellende waarde van de NS1 antigeentest bij vroege 
diagnose van een dengue infectie besproken. We vonden een sensitiviteit van 
46.8%, wat de laagste was vergeleken studies uit andere landen. Desalniettemin 
was de sensitiviteit bij een primaire infectie 100%. De sensitiviteit varieerde 
tevens onder de verschillende serotypes, waarbij de hoogste sensitiviteit werd 
gevonden bij DENV-3 (47.1%), gevold door DENV1- (40.9%), DENV-2 (30%) en 
DENV-4 (27%). Verder vonden we dat NS1 minder frequent gedetecteerd werd 
bij patiënten met eerdere infecties met meer dan één serotype, terwijl NS1 vaker 
voorkwam bij vrouwen, ernstigere gevallen (denguekoorts met hemorragische 
verschijnselen en DHF) en patiënten met weinig trombocyten (<100.000/mm3).
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In de Hoofdstukken 7, 8, 9 en 10 bespreken we vier besmettelijke ziekten die 
onderdeel uitmaken van de differentiële diagnose van ongedifferentieerde 
koorts in West-Java. Hoofdstuk 7 gaat over chikungunya virus infecties bij 
volwassenen in Bandung. In tegenstelling tot eerdere studies waar gemeld wordt 
dat chikungunya als focale epidemie voorkomt, vond onze studie doorlopend 
chikungunya infecties. Bovendien bleek dat het aandeel van chikungunya 
infecties onder gevallen van acute febriele aandoening hoog is (7,1%), terwijl 
gewrichtspijn niet als een een prominent symptoom gerapporteerd wordt. We 
hebben ook het herhaalde malen voorkomen van chikungunya infecties bij drie 
patiënten aangetoond dat mogelijk is omdat ofwel chikungunya antibodies 
van vorige infecties niet levenslang immuniteit kunnen bieden kunnen en/of 
er mogelijk verschillende stammen in Bandung circuleren. Tot slotte bleek uit 
ons onderzoek dat IgM-antistoffen langdurig kunnen voorkomen hetgeen het 
stellen van de diagnose chikungunya compliceert. 
Hoofdstuk 8 gaat over influenza, inclusief de hoog pathogene influenza A/H5N1. 
Data werden verzameld uit een nationale influenza onderzoek - uitgevoerd van 
2003 tot 2007- waaronder gegevens van zes locaties van drie steden in West-
Java. Bij patiënten met influenza-achtige ziekte verschijnselen, kon bij 20,1% 
van de patiënten influenza worden aangetoond. In tegenstelling tot landen 
met een gematigd klimaat, circuleren in Indonesië gedurende het hele jaar 
influenzavirussen maar er is een piek in het regenseizoen van December tot Maart. 
Het is belangrijk om dengue en influenza van elkaar te onderscheiden: niet alleen 
omdat de behandeling anders is, maar ook omdat voorzorgsmaatregelen voor 
familie, school of werkplaats verschillend zijn. Dit onderscheid is vooral belangrijk 
met betrekking tot influenza A/H5N1, dat een sterftecijfer kan hebben dat kan 
oplopen tot 82%, maar waarvan de uitkomst gunstiger is wanneer Oseltamivir 
eerder word gegeven. Influenza A/H5N1 werd vaak niet overwogen bij patiënten 
met acute koorts omdat alternatieve diagnoses werden gemaakt (knokkelkoorts, 
tyfus, diarree ziekte, infectie van de luchtwegen). Aan de andere kant werd bij 
koortsende patiënten met kortademigheid, knokkelkoorts met longoedeem 
vaak ten onrechte gediagnosticeerd. Tijdens deze nationale surveillance studies 
bleek ook dat de antigenen van de circulerende virusstammen van influenza A 
en B veranderden.
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Hoofdstuk 9 worden middels klinische, serologische en epi zoölogische gegevens, 
de eerste Indonesische Seoul virusinfectie - die tot het geslacht hantavirus 
behoort, gedocumenteerd. Tekenen en symptomen, hoewel overeenkomend 
met hantavirus infectie - zoals koorts, spierpijn, bloedingsneiging, leukopenie, 
trombocytopenie, toegenomen serum transaminase- lijken vaak op ernstige een 
dengue infectie. Deze twee infectieziekten zijn daarom moeilijk te onderscheiden. 
Hantavirus infectie werd gediagnosticeerd door aantonen verhoogde hantavirus 
IgM en IgG antistoffen, terwijl de diagnose dengue-infectie verworpen kon 
worden. De diagnose van hantavirus infecties werd bovendien ook ondersteund 
doordat de prevalentie van hantavirus IgG antilichamen bij knaagdieren 
gevangen in de nabijheid van de patiënt zijn huis, hoger bleek te zijn dan bij 
knaagdieren uit een controlegebied (13,2% vs. 4,7%, p = 0.04). Bovendien werd 
het Seoul virus in 71 % van de seropositieve knaagdieren aangetoond.
In hoofdstuk 10 wordt voor de eerste keer het voorkomen van het West-Nijl virus 
(WNV) in Indonesië aangetoond. Het virus werd ontdekt in de gearchiveerde 
monsters van een studie uit 2004-2005 naar de oorzaken van acute koortsende 
ziekte bij gehospitaliseerde patiënten in Bandung, West-Java Indonesië. Het 
WNV positieve monster was afkomstig van een 15-jarige jongen opgenomen 
met epistaxis, gastro-intestinale symptomen, verhoogde serum transaminase, 
leukopenie en trombocytopenie. Er werden geen neurologische symptomen 
gemeld en de patiënt is volledig hersteld zonder restverschijnselen. 
Behalve knokkelkoorts virus en de andere virussen beschreven in de 
hoofdstukken 7 tot en met 10, moeten er nog vele andere micro-organismen 
meegenomen worden in de differentiële diagnose bij patiënten met koortsende 
ziektes in Indonesië. De ontwikkeling van “point of care testen” - die bacteriële van 
virale infecties van elkaar onderscheiden, kunnen daarom van groot belang zijn 
voor het rationeel voorschrijven van antimicrobiële geneesmiddelen en de zorg 
voor dergelijke patiënten. Aangezien knokkelkoorts een veel voorkomend ziekte 
is - met soms een gecompliceerde verloop- is een robuuste diagnostische point 
of care test voor het aantonen of het uitsluiten van denque dringend nodig. De 
ontwikkeling van een dengue vaccin wordt gecompliceerd doordat het vaccin 
bescherming moet bieden aan alle vier de serotypen zonder de gevaccineerde 
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personen bloot te stellen aan ADE. De enigste preventieve maatregelen die nu 
beschikbaar zijn richten zich op het elimineren van broedplaatsen van muggen, 
verbetering van bewustwording en kennis van knokkelkoorts in de algemene 
populatie over te nemen voorzorgsmaatregelen en de tekenen die wijzen op 
een gecompliceerd beloop zodat doorsturen van een patiënt naar het ziekenhuis 
aangewezen is. 
Hoofdstuk 11 onderzoekt of onderwijs en voorlichting de kennis over 
knokkelkoorts beïnvloedt in onze prospectieve dengue-studie. Onderwijs werd 
gegeven in de vorm van lezingen, posters en hand-outs waarin de tekenen 
en symptomen van dengue werden uitgelegd evenals de methoden van 
transmissie en hoe de ziekte voorkomen kan worden. Voor de interventie werd 
een mondelinge vragenlijst afgenomen door de studie artsen om deelnemers 
hun kennis met betrekking tot knokkelkoorts te kunnen vaststellen. De dezelfde 
vragenlijst werd 18 maanden later opnieuw afgenomen. Van de 2340 deelnemers 
die de beide tests voltooiden, scoorde slechts 0,3% van de deelnemers 
‘uitstekend’ op de eerste test waarbij echter 8,4% ‘uitstekend’ op de tweede 
test scoorde. Ook het aantal deelnemers dat ‘zeer slecht’ scoorde verbeterde 
(1,4% versus 4,0%). De gemiddelde ruwe scores voor de pre en post tests waren 
respectievelijk 7,8 en 10.1. Verbetering van individuele scores correleerde sterk 
met het opleidingsniveau. Deze bevindingen tonen aan dat onze prospectieve 
studie leidde tot kennisverbetering bij vrijwilligers over van dengue. 
Hoofdstuk 12 beschrijft een studie waar families van 53 gehospitaliseerde 
knokkelkoorts patiënten en hun naaste buren in het westen van Jakarta 
gedurende twee weken werden gevolgd. In totaal zijn 785 familieleden of 
nabije buren geobserveerd en werden 192 (24,5%) knokkelkoorts infecties 
gedocumenteerd, bestaande uit 175 (22,3%) gevallen optredend vóór of tijdens 
de inclusie in de studie en 17 (2,2%) ontwikkelde knokkelkoorts tijdens de 
twee weken observatie periode. Van deze 17 nieuw ontwikkelde knokkelkoorts 
gevallen, hadden 8 personen geen symptomen, 8 koorts en was er één DHF 
grade II infectie. Deze studie geeft aan dat voor elke ziekenhuis patiënt met 
knokkelkoorts er ongeveer 3,6 andere knokkelkoorts infecties voorkomen in 
de nabijheid van de geïndexeerde patiënt. Deze studie toont verder aan dat 
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asymptomatische gevallen ook aanzienlijke bijdragen kunnen leveren aan de 
verspreiding van dengue virus; aangezien viremia ontdekt werd in twee van de 
acht. 
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